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Summary 
Osteoarthritis is a slowly developing chronic joint disease mainly characterized by joint 
pain and nodes with no curative treatment available except for joint replacement. The 
etiology of osteoarthritis is not exactly known, but the hypothesis that osteoarthritis not 
only evolves from wear-and-tear but is also inherent to systemic components is widely 
accepted. Systemic inflammation as in obesity or dyslipidemia was shown to negatively 
influence osteoarthritis of non-weight bearing joints such as joints in the hands. Hand 
osteoarthritis develops frequently in postmenopausal women. Menopausal transition in 
women mainly occurs from age 45 to 54, involves changes in sex hormones, and is 
associated with vasomotor and genitourinary symptoms mainly treated with systemic and 
vaginal hormone replacement therapy, respectively. Further associated symptoms such as 
joint pain or osteoarthritis (symptomatically treated with painkillers) or increased lipid 
levels (mainly treated with statins to reduce the risk of a cardiovascular event) are less 
known to the general public but carry a high disease burden.  
By means of epidemiologic studies using women’s primary care health records in the 
United Kingdom, this thesis aimed to help find drugs potentially delaying hand 
osteoarthritis onset by describing and assessing drugs treating symptoms evolving in 
menopausal transition in association with hand osteoarthritis. Potential negative 
associations may result in a decreased burden of this incurable disease. 
In a first descriptive study, we described incidence rates of hand osteoarthritis and of 
hormone replacement therapy use in women aged 40 to 69 years. We observed that rates 
of hormone replacement therapy initiation and of new diagnoses of hand osteoarthritis 
behaved inversely over time and uniformly in 5-year age groups between 40 to 54 years 
but not in older age groups. Hormone replacement therapy initiation rates shaped in a 
skewed Gaussian curve with a tail in older age groups while onset of hand osteoarthritis 
plateaued from age 55. In a second nested case-control study, observing women from age 
45 longitudinally, we assessed the association between systemic hormone replacement 
therapy initiation and hand osteoarthritis overall and in women with recorded menopause 
only as recorded menopause was a major confounder. Most hand osteoarthritis cases 
Summary 
ii 
 
occurred shortly after menopause, therefore, we assessed the timing of hormone 
replacement therapy initiation relative to menopause in current users as well as of 
hormone replacement therapy cessation relative to hand osteoarthritis diagnoses in past 
users, compared to non-users. The association between hormone replacement therapy 
use and hand osteoarthritis yielded an increased risk of hand osteoarthritis of 32%. 
However, in women with recorded menopause, the risk of hand osteoarthritis in hormone 
replacement therapy users disappeared compared to non-users. Furthermore, we 
observed a 28% decreased risk of hand osteoarthritis if hormone replacement therapy was 
initiated around menopause and used continuously, compared to non-users. This 
potential beneficial effect diminished the later hormone replacement therapy was 
initiated. However, we also observed a statistically non-significant 25% increased risk of 
hand osteoarthritis shortly after therapy cessation. In a third cohort study, in women aged 
45 to 64 years, we assessed the association between statin initiation and hand 
osteoarthritis and between statin initiation and generalized osteoarthritis (i.e. multiple 
joints affected, hand osteoarthritis is usually part of generalized osteoarthritis), overall, 
stratified by age, and by pre-existing dyslipidemia. Furthermore, we used psoriasis and 
tinnitus as negative control outcomes to control for confounding by differential 
menopause onset (psoriasis) and healthcare seeking behavior (psoriasis, tinnitus). We 
observed that statin use was neither associated with hand osteoarthritis nor with 
generalized osteoarthritis irrespective of age or pre-existing dyslipidemia. The use of 
negative control outcomes corroborated this finding.  
Our results support the existing hypothesis that menopause is a risk factor of hand 
osteoarthritis. However, it is likely not the only risk factor for hand osteoarthritis because 
otherwise we would have expected hand osteoarthritis incidence rates to decline similarly 
to those of hormone replacement therapy use among older age groups. Furthermore, our 
results suggest that timely initiation of hormone replacement therapy relative to 
menopause may be crucial for a potential delay of hand osteoarthritis onset to at least 
after hormone replacement therapy cessation. Finally, our results suggest that the lipid 
lowering effect of statins does not seem to translate into a reduced risk of hand 
osteoarthritis in peri-to-postmenopausal women.
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Abbreviations 
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1 Introduction 
1.1 Hand osteoarthritis 
1.1.1 Disease manifestation 
Osteoarthritis (OA) is a slowly developing chronic joint disease that presents as a 
heterogeneous disorder.1 It can affect any joint in the body and several joints at the same 
time. If multiple joints are affected, the disease is called “generalized OA”, but the term lacks 
a standard definition.2 If the disease localizes in certain joints of the hand, it is referred to as 
hand OA. Typically, hand OA is also present in patients who are diagnosed with generalized 
OA.2 Hand OA neither has a uniform definition but can be considered an umbrella term of 
multiple types of OA that manifest in the hand: In “interphalangeal OA”, distal and proximal 
interphalangeal joints are affected. If nodes are present in distal or proximal interphalangeal 
joints, called Heberden and Bouchard nodes, respectively, the disease is also referred to as 
“nodal OA”.1 Furthermore, in “base of thumb OA” the carpometacarpal joint of the thumb is 
affected, also called first carpometacarpal joint.1 Figure 1 depicts affected joints. OA in 
metacarpal joints of the wrist is not considered part of hand OA, but is called wrist OA.  
 
 
 
 
 
 
 
 
Fig1. In hand osteoarthritis, distal and proximal interphalangeal joints as well 
as the first carpometacarpal joint may be affected 
Adapted from https://myhealth.alberta.ca/Health/pages/conditions.aspx?hwid=zm6124, accessed Jan 4, 2019 
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There may be clustering of affected joints in hand OA, which, if occurring, occurs primarily by 
row and symmetrically in both hands with patterns being similar among women and men.3,4 
In around one forth to one third of patients, multiple joint types of the hand are affected (i.e. 
distal/proximal interphalangeal joints, first carpometacarpal joint).3,5 Reported prevalence of 
affected joint types vary between studies but distal interphalangeal joints generally seem to 
be most frequently affected.3–5 In affected joints, patients may experience activity-related 
pain, stiffness, decreased grip strength, and, in later stages, impaired mobility, and eventually, 
disability.1 By means of imaging techniques, the following structural abnormalities may be 
seen in affected joints: osteophytes (bone spurs), joint space narrowing, subchondral sclerosis 
(increased bone density underneath the cartilage), loss of cartilage, bone cysts, and 
subluxation (incomplete joint dislocation).1,6,7 However, not all patients who have structural 
abnormalities (i.e. OA diagnosed by medical imaging, also referred to as “radiographic OA”) 
have OA symptoms (also referred to as “symptomatic OA” which is clinically relevant), and 
vice versa.8,9 The research community is divided over the course of the disease but it is 
generally suggested to progress with time.10 
1.1.2 Epidemiology 
OA is a highly prevalent disease. According to the “Osteoarthritis in General Practice” report 
of Arthritis Research UK, around one third of inhabitants of the United Kingdom (UK) aged 45 
years and older (around 8.8 million) have sought medical advice for OA between 2004 and 
2010.11 Thereof, around 1.56 million patients (corresponding to approximately 6% of UK 
inhabitants) have sought medical advice for hand or wrist OA.11 Women were almost three 
times more likely to seek medical advice for hand or wrist OA than men if aged 45-64 (8% and 
3%, respectively) and almost twice more likely if aged 65-74 (9% and 5%, respectively).11  
The rate of disease onset (incidence rate, IR) of hand OA was described to be 4.3 per 
1’000 person-years (py, age- and sex-standardized) in UK general practice in 2013.12 
Age-specific IRs of hand OA in women from the year 2000 in the UK show that disease onset 
peaks between age 55 and 60 at around 4/1’000 py and decreases slowly subsequently.12 IRs 
of hand OA were reported to be higher in women than in men until the age of 85 when both 
populations show similar rates at around 2/1’000 py (IR of hand OA in men have plateaued at 
this rate as of age 65).12 Once set on, hand OA cannot be cured and manifests as a moderately 
prevalent disease in postmenopausal women and the elderly.13 End-stage hand OA results in 
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high morbidity as it prevents people from performing everyday activities such as dressing, 
writing/typing, or preparing a meal.11 
Main risk factors for primary hand OA (idiopathic hand OA due to multifactorial/unknown 
causes) include postmenopausal age in women and older age in general,13,14 genetic 
predisposition (family history),14 metabolic syndrome,15 visceral fat (in men),16 obesity,14,16 
and to a lesser extent handedness and occupations associated with constant repetitive hand 
movements.17 
1.1.3 Etiology 
The exact etiology of primary hand OA is unknown. Mechanical pressure is of major influence 
for weight-bearing joints (e.g. knee, hip), but less applicable to non-weight bearing joints (e.g. 
finger, thumb).15 Hence, hand OA was suggested to be a systemic disease associated with 
systemic factors.9,18 On a biochemical level, it was reported that hand OA may be associated 
with cytokines such as tumor necrosis factor (TNF), interleukin (IL)-1, and IL-6 as part of 
concomitant inflammation of, for example, the metabolic syndrome15,19 or single diseases 
thereof (e.g. obesity20, hyperlipidemia21,22). OA development may therefore be due to “joint 
failure” referring to failing regular cartilage turnover in which the rebuilding process is 
hindered by the presence of cytokines. For example, presence of IL-1 in the synovial fluid 
inhibits the production of collagen, a major component of cartilage.23 Furthermore, TNF24 
(secreted by T cells, mediating cartilage loss25), IL-1, and IL-6 are supposed to play a similar 
role in OA as they play in the inflammatory and cartilage degeneration process (i.e. synovitis) 
of rheumatoid arthritis. However, IL-6 (present in the synovium, secreted by chondrocytes 
and macrophages) was shown to have an ambivalent role in OA stimulating both degradation 
and building of cartilage.26,27 Cartilage breakdown in OA was suggested to be carried out by 
enzymes called matrix metalloproteinases (MMP).28 Osteophyte formation was reported to 
be enhanced by transforming growth factor-beta.29 A scheme of involved factors and enzymes 
is depicted in Figure 2.  
Hand OA is called “secondary” if causative factors including birth abnormalities, previous 
trauma, articular hypermobility, or other inflammatory arthropathies (mainly rheumatoid 
arthritis) are present at diagnosis.1,7,30 However, the disease manifestation is the same as in 
primary hand OA. 
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1.1.4 Diagnostic methods 
According to the National Institute for Health and Care Excellence (NICE) guidance on 
“Osteoarthritis: care and management”, the diagnosis of hand OA is carried out without 
further investigations if a patient is aged 45 years or older, shows activity-related joint pain, 
and has morning joint stiffness for less than 30 minutes (or no morning joint stiffness).8 Other 
diagnostic methods include joint palpation to assess pain and tenderness, and imaging 
techniques such as radiographic assessment, ultrasonography, or magnet resonance imaging 
(MRI).1,7,31  
Differential diagnoses of hand OA include hemochromatosis, rheumatoid arthritis, psoriatic 
arthritis, gout, and pseudogout.32 
Fig2. Scheme of involved factors and enzymes in osteoarthritis  
TNF: tumor necrosis factor, IL: interleukin, MMP: matrix metalloproteinase,  
RANKL: receptor activator of nuclear factor κB ligand, TGF-β, transforming growth factor β. 
Reprinted from Chevalier et al. (2013) with permission of Springer Nature © 2019 Springer Nature Publishing AG, 
License No: 4507550681131 
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1.1.5 Therapeutic options 
NICE guidance on “Osteoarthritis: care and management” suggests a holistic approach of 
non-pharmacological and top-up pharmacological treatment to ease OA symptoms as, to 
date, OA cannot be cured except through joint replacement.8 Non-pharmacological treatment 
suggestions mainly target OA of large weight-bearing joints (i.e. hip, knee); suggestions include 
local muscle strengthening, weight loss, joint manipulation, and advice on appropriate 
footwear and walking aids.8 Recommendations of the European League against Rheumatism 
(EULAR) focuses on the management of hand OA.33 EULAR also recommends a combination 
of non-pharmacological and pharmacological treatment which should be individualized 
according to affected joints, presence of inflammation, and underlying structural 
abnormalities while education about joint protection and an exercise regimen are 
recommended for all hand OA patients.33 NICE and EULAR agree that local pharmacological 
treatments (topical non-steroidal anti-inflammatory drugs or capsaicin) are preferable over 
systemic treatments (oral non-steroidal anti-inflammatory drugs, cyclo-oxygenase2 inhibitors, 
or opioids).8,33 NICE and EULAR further agree that surgery such as joint replacement surgery 
should only be considered as a final treatment option when other treatments have failed.8,33 
EULAR recommends splints for base of thumb OA, but advises against general use of 
intra-articular corticosteroid injections in hand OA.33 EULAR further recommends short-term 
oral glucocorticoid use but advises against the use of biologic agents such as TNF blockers or 
IL-1 receptor antagonists due to lack of efficacy in hand OA.33 
1.2 Menopause 
Menopause is defined as the point in time when a woman has ceased menstrual cycles for 
one entire year.34,35 The menopausal transition period, also called perimenopause, starts with 
alterations of more than seven days from normal cycle length.34 Menopause results from near 
depletion of ovarian follicles and hence reduced estrogen production.36 This occurs either 
naturally during the 5th or 6th decade of a woman’s life (median at around 50 years of age)37,38 
or can be surgically induced through bilateral oophorectomy and/or hysterectomy.39 After 
menopause, a woman enters postmenopause.34,35 In postmenopausal women, ovaries have 
ceased to produce estrogen, but aromatases40 in non-gonadal sites throughout the body (e.g. 
adipose tissue, bone, brain, liver, blood vessels) continue to convert precursors into small 
quantities of estrogen.41,42 
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1.2.1 Postmenopausal symptoms 
Postmenopausal symptoms are manifold, reflecting the various different locations of estrogen 
receptors throughout the body such as the reproductive system, brain, bone, liver, heart 
muscle, coronary arteries, and adipose tissue.43,44 Principal symptoms include vasomotor 
symptoms (hot flushes, night sweats), which are most prevalent shortly after menopause, and 
genitourinary symptoms (vaginal atrophy, urinary tract infections), which were reported to be 
inversely associated with serum estrogen levels.34 Notably, vasomotor symptoms do not 
necessarily correlate with serum estrogen levels,34,45 which may be explained by altered local 
estrogen concentrations in the hypothalamus, for example, which regulates body 
temperature.42 Further symptoms in postmenopausal women include sleep disturbance,34 
mood changes,34,46 memory and concentration loss,46 altered sexual function,34,46 joint pain 
and OA,46,47 osteoporosis,34,46 and unfavorable changes in fat mass deposition (i.e. increase in 
central fat)48–52 and in circulating lipids (increasing total cholesterol [TC], low-density 
lipoprotein [LDL], triglycerides [TG], and lipoprotein(a))50,53,54. Postmenopausal symptoms 
occur in up to 75-85% of women of whom around one fourth are affected by severe 
symptoms.34,46,55 In the UK, around 40% of postmenopausal women were reported to seek 
medical advice because of postmenopausal symptoms.55 
1.2.2 Vasomotor and genitourinary symptom control 
NICE guidance on “Menopause: diagnosis and management” suggests the use of systemic 
hormone replacement therapy (HRT) to treat vasomotor symptoms during up to five years.46 
HRT consists of the synthetically produced hormones estrogen, progesterone, or derivatives 
thereof (e.g. tibolone). The mechanism of action of HRT is to replenish decreased estrogen 
and progesterone levels after menopause.56 If a woman prefers non-hormonal therapy, drugs 
acting in the central nervous system such as antidepressants and antiepileptics, may also be 
used to lower vasomotor symptoms, but are not recommended by NICE guidance as first-line 
treatment.46 
To alleviate genitourinary symptoms, NICE suggests the use of vaginal estrogen (if necessary 
on top of systemic formulations) as long as symptoms prevail.46 Given evidence of associated 
risks of cardiovascular disease (CVD),57,58 breast cancer,59 and venous thrombotic events,58 the 
choice of HRT formulation and dosage should depend on risk factors (e.g. age, lifestyle, family 
history of adverse events) and personal preferences after risk-benefit evaluations.46,60 
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1.2.3 Other symptom control 
Other symptoms associated with menopause acknowledged with a treatment proposal by 
NICE guidance on “Menopause: diagnosis and management” are low mood (suggested to treat 
with HRT or cognitive behavioral therapy) and sexual difficulties (suggested to treat with HRT 
or testosterone).46  
Joint pain and osteoarthritis 
The International Menopause Society and the North American Menopause Society suggest 
that muscle and joint pain or stiffness (typical features of OA) may improve with HRT.61–63 
However, to date, no clear association could be established between OA and HRT.62 Preclinical 
studies mainly assessed the effect of HRT on knee OA and yielded contradictory results.64 
Weight-bearing joints such as the knees are subject to mechanical pressure, a major risk factor 
of OA.15 Therefore, hand OA is considered a more suitable outcome to assess the relationship 
between OA and systemic exposures such as drugs. Small observational studies (n ≤1’000) 
investigating the effect of HRT on hand OA respective generalized OA also yielded 
contradictory results.65–69 In humans, HRT use was reported to reduce the concentration of a 
cartilage metabolite in the urine when compared to non-use,70 but the potential beneficial 
effect of estrogen on joint tissues is not completely understood.62 On a biochemical level, 
estrogen receptors are present in joint tissues71,72 and estrogen was found to inhibit IL-6 
resulting in chondrocyte proliferation26. Estrogen withdrawal was found to increase the 
production of TNF24 and MMPs73 involved in OA development and progression, and to 
increase the sensitivity of maturing osteoclasts to its activator ligand (RANKL, resulting in bone 
loss if secreted by osteoblasts, unknown activity if expressed in cartilage74).24 To date, a 
potential effect of progesterone alone or in combination with estrogen on articular cartilage 
remains unknown. Estrogen depletion is discussed as a potential trigger factor of OA 
progression.9,75 
Unfavorable changes in circulating lipids and fat mass deposition 
Unfavorable changes in circulating lipids and fat mass deposition carry an inherent risk of CVD. 
It was reported that increased fat mass itself contributed to elevated lipid levels.50 
Furthermore, in a longitudinal study, lipid levels (TC, TG, LDL, and high-density lipoprotein 
[HDL]) were not only higher among peri-to-postmenopausal women compared to 
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premenopausal women, but also among HRT users compared to peri-to-postmenopausal 
non-users.50 Other studies reported lower LDL and higher HDL levels in HRT users when 
compared to non-users53 and the return of deviating levels of TC, LDL, HDL, and lipoprotein(a) 
to premenopausal levels with HRT76. The International Menopause Society and the North 
American Menopause Society state beneficial effects of HRT on lipid levels62 and abdominal 
obesity63, respectively. According to NICE guidance on “Cardiovascular disease: risk 
assessment and reduction, including lipid modification”, statins (principal lipid lowering 
treatment) should be offered to patients for primary prevention of CVD after lifestyle changing 
engagement to tackle secondary causes of dyslipidemia (i.e. smoking, alcohol consumption, 
hypertension, obesity).77 However, menopause as a potential trigger factor of increased lipid 
levels is not mentioned in NICE guidance on “Cardiovascular disease: risk assessment and 
reduction, including lipid modification”. Hence, there is no treatment recommendation 
especially for postmenopausal women with increased lipid levels. 
1.3 Principles of clinical research 
Clinical research is performed to evaluate the safety and efficacy of medical interventions by 
means of clinical trials.78 Clinical trials evaluate safety and efficacy in animals first. If beneficial, 
then safety and efficacy is evaluated in humans. Concerning efficacy evaluations in humans, 
clinical trials measure the average treatment effect. This means that in a trial with beneficial 
results not every participant in the intervention group has responded equally well but that, on 
average, the intervention was more efficacious than the control. Usually, those trials are 
performed prospectively, yield causal associations through randomization of patients and 
provide highest evidence for clinical decision-making, if performed correctly.78,79 
Randomization implies that the study is free of confounding variables, which otherwise skew 
the result because they are related to both the intervention and the outcome and are 
unequally distributed between intervention and control group. Correctly performed 
randomized controlled clinical trials further yield unbiased treatment effects, i.e. they are free 
of systematic errors and therefore yield the true effect estimate.78 
It is not possible to answer all research questions in clinical trials due to infeasibility or ethical 
concerns. Infeasible research questions for example include rare diseases or diseases with a 
long lag time until they develop or progress (e.g. cancer, chronic diseases). Furthermore, trials 
are considered unethical if withholding lifesaving treatment or if they put patients at risk of 
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known adverse events in absence of equipoise with regard to the expected treatment effect 
(i.e. if adverse events are expected to outweigh the benefits).80 In cases of studies needed 
other than for market approval of a new drug, observational research may fill the gap through 
the conduction of epidemiologic studies using previously collected medical data (e.g. from 
registries, electronic health records, administrative claims, multipurpose cohorts).78  
1.3.1 Observational epidemiology at a glance 
Observational epidemiology is the study of the distribution and determinants of disease 
frequency in a population.81 There is descriptive research (describing the distribution of 
determinants and diseases, hypothesis generating studies) and analytical research (assessing 
the association between potential determinants and diseases, usually hypothesis testing 
studies).82  
In observational epidemiology, analytical studies measure the real world effectiveness and 
safety of an exposure. Their results are usually generalizable to a larger patient population 
than the results of restricted populations in clinical trials. Applied study designs and statistical 
methods are manifold and are continuously expanded to tackle bias and unmeasured 
confounders. Bias and confounding in observational epidemiology are mainly due to the 
circumstances that the data was previously collected for other purposes (e.g. some data 
needed may not be available) and that the reason why patients use a medication may be 
related to the outcome as well.82 What cannot be tackled through design and methods is data 
quality. Therefore, before data can be used for observational studies, it needs to be carefully 
cleaned and validated considering that the data quality is the foundation for any study that 
arises from the respective data source.82 Medical data in Europe often stem from longitudinal 
patient record databases collected at the point of care (e.g. Clinical Practice Research Datalink 
[CPRD] in the UK, SIDIAP in Catalonia, Spain, Intercontinental Marketing Service Disease 
Analyzer [now part of IQVIA] in various European countries).83 
1.3.2 Clinical Practice Research Datalink 
The CPRD is a UK primary care database containing – as of July 2013 – medical information on 
around 11.3 million patients in 674 practices across the UK, out of whom 4.4 million patients 
were active at the time (i.e. alive, registered, and have not opted out as of July 2013) which 
corresponds to around 7% of the UK population.84 Patients were representative of the UK 
Introduction  
   
12 
 
population concerning age, sex, and ethnicity when compared to the UK census in 2011, and 
representative of body mass index (BMI) when compared to the Health Survey for England 
(comparison performed up to 201085).84 However, CPRD practices are not representative of 
all practice in the UK with regards to geography and number of patients.84  
The CPRD as it is known today has originated as a general practice information system in the 
1980s. Taken over by a venture capital company named Value Added Medical Products Ltd 
(again taken over by Reuters in 1993), the company handed out computers to general 
practitioners (GPs) as incentives to participate and manage their patient files electronically as 
of 1987.83 Since 1994, the CPRD belongs to the UK Department of Health.86,87 The CPRD is 
unique in the way that the GP acts as a gate keeper within the UK National Health Service, can 
be consulted free of charge (98% of the UK population are registered with a GP), and receives 
feedback from secondary care.84 Thereby, the GP keeps near complete medical patient 
records. Practices have only been allowed to participate in CPRD if they collected routine data 
with sufficient scrutiny according to a pre-defined standard (data quality checks throughout 
their participation included).86 In participating practices, data is collected automatically as part 
of day-to-day medical care.86 Patients’ conditions (i.e. symptoms, diagnoses) are entered as 
so called Read codes.84 All entries are made in standard software and are transferred via 
specially designed software as de-identified patient data to the Office for National Statistics 
which maintains and runs the database on behalf of the UK Department of Health.86 Recorded 
data include demographics, prescriptions including dosage and quantity, symptoms, 
diagnoses, lifestyle measures (e.g. smoking status, BMI), results of laboratory tests, preventive 
care, immunization, death, specialist referrals, hospital admissions, and other feedback from 
secondary care (e.g. diagnoses, procedures, and admission and discharge dates for hospital 
visits).84 Notably, not all entries are subject to a face-to-face consultation84 and not all 
consultation are subject to an entry in the medical chart (e.g. if there is nothing to add in the 
patient record)86. The CPRD maintains a bibliography which counted over 2’000 publications 
in peer-reviewed journals as of December 2018.88 This is to no surprise as the CPRD is one of 
the largest databases of longitudinal records from primary care worldwide84 and its recorded 
diagnoses were repeatedly shown to be of high validity89,90. 
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2 Aims and Objectives 
It is known that hand OA in women mainly develops after menopause. Hypotheses about the 
pathophysiologic mechanism between menopause and hand OA are estrogen depletion and 
systemic inflammation through unfavorable changes in circulating lipids and fat mass 
deposition.  
Small observational studies investigating the effect of HRT (principal treatment of 
postmenopausal estrogen depletion) and hand OA yielded contradictory results. Prior 
evidence assessing the relationship between statins (principal lipid lowering treatment) and 
hand OA in peri-to-postmenopausal women did not exist.  
To help find drugs potentially delaying hand OA onset by describing and assessing drugs 
treating symptoms evolving in menopausal transition in association with hand OA, we 
performed the following epidemiologic studies:  
1) A descriptive study estimating IRs of HRT use and hand OA over time and by age group. 
2) A nested case-control analysis assessing the association between HRT use and hand 
OA overall, by timing of HRT use (current or past use), and in women with recorded 
menopause only. In a secondary analysis, we assessed the association between 
menopause and hand OA. Furthermore, in women with recorded menopause only, we 
assessed the timing of HRT initiation relative to menopause in current users and of HRT 
cessation relative to hand OA diagnoses in past users, compared to non-users.  
3) A cohort study assessing the association between incident statin use and new onset of 
hand OA in peri-to-postmenopausal women overall, by age group, absent or present 
dyslipidemia diagnosis, and by duration of follow-up. In a secondary analysis, we 
assessed the association between incident statin use and new onset of generalized OA. 
Through the use of psoriasis and tinnitus as negative control outcomes, we aimed to 
qualitatively assess our results for confounding by differential menopause onset and 
healthcare seeking behavior.  
A potential negative association between the respective drug initiation and hand OA onset 
may result in a decreased burden of this incurable disease.
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3 Methods, Results and Discussions 
3.1 Incidence rates of hormone replacement therapy use and of hand 
osteoarthritis: A descriptive study 
The subsequent work is based on data of the following publications: 
Burkard T, Moser M, Rauch M, Jick SS, Meier CR. Utilization pattern of hormone therapy in 
UK general practice between 1996 and 2015: A descriptive study Menopause. 
2019;26(7):000-000 (ahead of print) 
 
Please see Appendix 1. 
Burkard T, Rauch M, Spoendlin J, Prieto-Alhambra D, Jick SS, Meier CR. Risk of hand 
osteoarthritis in new users of hormone therapy: A nested case-control analysis Submitted to 
Maturitas  
 
Please see Appendix 2. 
The studies were approved by the Independent Scientific Advisory Committee for Medicines 
and Healthcare products Regulatory Agency database research with protocol 18_034R and 
18_089R, respectively. 
3.1.1 Methods 
Study design and data source 
We conducted a population-based descriptive study using data derived from the UK-based 
CPRD. A study is called population-based if it is performed among a major or representative 
sample of the underlying population (i.e. the study is large in size or has a non-restrictive study 
population).82 Descriptive studies usually describe how personal characteristics (e.g. age, sex, 
ethnicity, place of residence, socioeconomic status) relate to an underlying disease or trends 
in drug utilization.82 A further tool of descriptive studies is the description of temporal trends, 
which may generate new or underpin existing hypotheses.82 
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Study population 
We identified all women aged 40-69 years (based on their year of birth) between January 1996 
and December 2015 (study period) in the CPRD. From this study population, we selected two 
cohorts (a cohort comprises patients who have particular characteristics in common).  
1) For description of incidence rates of HRT use, we identified women who had no HRT 
prescriptions before age 40 (based on their year of birth), had ≥3 years of history in 
the database before their first HRT prescription, and who had ≥1 GP contact prior to 
their first HRT prescription.  
2) For description of incidence rates of hand OA, we identified women who had no hand 
OA diagnosis before age 40 (based on their year of birth), had ≥3 years of history in the 
database before their first hand OA diagnosis, and who had ≥1 GP contact prior to their 
first hand OA diagnosis. 
Outcomes 
HRT was defined as a recorded prescription for any unopposed or opposed HRT (includes 
separate estrogen and progestogen prescriptions prescribed within the same calendar year), 
or tibolone product, regardless of route of administration.  
Hand OA was defined as a first hand OA diagnosis (primary or secondary) or a diagnosis of 
hand pain if followed by an incident diagnosis of hand OA, OA, or generalized OA within 
365 days.  
Data analysis 
We divided the study period into twenty 1-year blocks and estimated annual IRs of HRT use 
and hand OA. Throughout the study period, we estimated IRs of HRT use and of hand OA 
stratified by age groups (40-44 years, 45-49 years, 50-54 years, 55-59 years, 60-64 years, 
65-69 years).  
In a post-hoc analysis to account for the strong time trend in HRT initiation, we divided the 
study period by two (1996-2002 and 2003-2015). In each study period, we estimated IRs of 
HRT use and of hand OA stratified by age groups (40-44 years, 45-49 years, 50-54 years, 55-59 
years, 60-64 years, 65-69 years).  
IRs of HRT use and hand OA 
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We calculated IRs of 1) new HRT use and of 2) hand OA by dividing the number of 1) new HRT 
prescriptions and 2) hand OA diagnoses by the respective accumulated pys at risk.  
3.1.2 Results 
From 1996 to 2015, we identified 229,104 new HRT users and 20,274 women with an incident 
diagnosis of hand OA among the study population. Figure 3 depicts annual IRs of HRT use and 
hand OA over time. Corresponding numeric values are displayed in Appendix 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
IRs of HRT use dropped from a maximum of 4.6/100 py in 1996 to a plateau of 3.6-3.8/100 py 
between 1998 and 2001, then halved to 2.0/100 py in 2003, followed by a slight decrease to 
a minimum of 1.6/100 py in 2005, and slowly increased up until 1.9/100 py in 2015.  
Hand OA IRs plateaued from 1996 until 2000 at around 1.0/1’000 py followed by an increase 
to a pleateau at around 1.8/1’000 py between 2004 and 2007. Thereafter, hand OA IRs 
Fig3. Annual incidence rates of hormone replacement therapy use and of hand osteoarthritis 
in women aged 45-69 from 1996 to 2015 
HRT: hormone replacement therapy, IR: incidence rate, py: person-years, OA: osteoarthritis 
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increased to another plateau at around 2.0/1’000 py until 2013 before slightly decreasing 
again. 
Figure 4 depicts IRs of HRT use and hand OA stratified by age group. Corresponding numeric 
values are displayed in Appendix 4.  
 
 
IRs of HRT use increased from 1.0/100 py in women aged 40-44 to 4.4/100 py in women aged 
50-54 before decreasing again to 1.3/100 py in women aged 65-69.  
Hand OA IRs increased with increasing age from age 40-44 at 0.5/1’000 py to 2.4/1’000 py in 
55-59 year old women, and plateaued thereafter. 
Figure 5 depicts IRs of HRT use stratified by age group and study period. Corresponding 
numeric values are displayed in Appendix 5.  
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Fig4. Incidence rates of hormone replacement therapy use and hand osteoarthritis in women 
stratified by age group 
HRT: hormone replacement therapy, IR: incidence rate, py: person-years, OA: osteoarthritis 
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IRs of HRT use in age groups before and as of 2003 followed a similar pattern. IRs of HRT use 
before 2003 yielded a stronger increase in women aged 45-49 years and a higher peak 
(7.6/100 py) in women aged 50-54 years, compared to a peak of 3.3/100 py in women of the 
same age group who initiated HRT as of 2003. After the peaks, IRs of HRT use before 2003 and 
as of 2003 declined and converged to 1.0/100 py and 1.6/100 py, respectively, in women aged 
65-69. 
Figure 6 depicts IRs of hand OA stratified by age group and study period. Corresponding 
numeric values are displayed in Appendix 6.  
 
 
  
Fig5. Incidence rates of hormone replacement therapy use in women stratified by age group 
and study period 
HRT: hormone replacement therapy, IR: incidence rate, py: person-years 
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IRs of hand OA in age groups before and as of 2003 increased similarly until 1.4/1’000 py and 
2.0/1’000 py, respectively, in women aged 50-54, when IRs of hand OA in age groups started 
to diverge. As of 2003, IRs of hand OA increased further until a peak in women aged 55-59 and 
a subsequent plateau at around 2.7/1’000 py, while, before 2003, IRs of hand OA increased 
only slightly until a peak in women aged 55-59 at 1.6/1’000 py and decreased slowly 
subsequently. 
3.1.3 Discussion 
In this descriptive study in the UK-based CPRD between 1996 and 2015, we described IRs of 
HRT use and of hand OA in women between 40 and 69 years of age. We observed that IRs of 
HRT use and of hand OA behaved inversely over time and uniformly in 5-year age groups of 
40 to 54 years but not in older age groups. 
IRs of HRT use dropped by around 20% from 1996 to a plateau between 1998 and 2001 as a 
likely consequence of increased breast cancer risks associated with HRT use reported 
continuously since the 1980s.91 It might have declined more rapidly if not for the common 
belief of a protective effect of HRT on CVD at the time.92–94 However, in 2002, an associated 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
40-44 45-49 50-54 55-59 60-64 65-69
age [years]
 Hand OA IR per 1'000 py before 2003
 Hand OA IR per 1'000 py as of 2003
Fig6. Incidence rates of hand osteoarthritis in women stratified by age group and study period 
OA: osteoarthritis, IR: incidence rate, py: person-years 
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increased risk of CVD was found by the well-known randomized controlled trial Women’s 
Health Initiative (WHI).58 As a likely consequence, IRs of HRT use almost halved until 2003. A 
study assessing reasons for HRT initiation pre-and post-WHI in the United States reported that 
provider advice, youth-preservation, and prevention of osteoporosis, CVD, and memory loss 
had decreased as reasons for HRT initiation post-WHI compared to pre-WHI.95 Furthermore, 
irrespective of duration of vasomotor symptoms, only around one third of women initiated 
HRT post-WHI compared to pre-WHI.95 The authors concluded that women with a low risk 
profile of CVD in their 50s may have forgone HRT for vasomotor symptom relief due to 
improper interpretation of associated risks post-WHI.95 In 2005, the turning point of IRs of HRT 
use was reached when IRs of HRT use started to slowly increase up again until 2015. In 2015, 
the HRT initiation level of 2003 was reached reflecting a potential ongoing underutilization in 
women suffering from postmenopausal symptoms with a positive risk-benefit profile when 
assuming similar reactions to WHI of UK women as of US women. 
Observed IRs of hand OA in women over time followed the same pattern as age standardized 
IRs of clinical hand OA (including hand pain) reported by Yu et al. in a population-based study 
using the same data source, but were around 50% lower.12 Yu et al. reported IRs in women to 
plateau at around 1.5-2/1’000 py from 1992 until 1996 before increasing to 5.25/1’000 py in 
2013.12 Increasing IRs of hand OA over time may be due to better understanding of the disease 
and therefore better diagnosing, and also potentially raised awareness and therefore more 
thorough coding. Yu et al. reported age-standardized IRs of hand OA in men, which were lower 
than those in women but followed the same pattern as those in women over time.12 
IRs of HRT use in age groups almost followed the Gaussian curve of natural menopause onset 
between age 40 to age 60 irrespective of the observation period.37 As of age 40, IRs of HRT 
use increased until a peak in women aged 50-54 years, however, did not decrease quite as 
strongly but showed a tail in age groups ≥60 years. With women and prescribers anxious about 
HRT use post-WHI,95 post-WHI HRT initiators were likely women with severe postmenopausal 
symptoms as HRT initiation rates were much lower, especially among women aged 45 to 
54 years, when compared to HRT initiation rates pre-WHI. However, in women aged ≥60 years, 
the difference in HRT initiation between pre- and post-WHI was small. This was likely due to 
women initiating HRT to treat genitourinary symptoms (mainly treated with vaginal HRT with 
IRs of HRT use and hand OA 
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no or low systemic uptake) in these age groups as these symptoms present rather late during 
postmenopausal age and were reported to increase in severity with age.96  
Observed IRs of hand OA in age groups also followed a similar course compared to those 
reported by Yu et al. (based on data from year 2000) but were also generally lower by around 
40%, and by around 30% when assessing IRs of hand OA before 2003.12 Yu et al. reported IRs 
of hand OA to peak at around 4/1’000 py in women aged 55 to 60 years old and to slowly 
decrease thereafter to around 2/1’000 py at age 85 with men not following this pattern.12  
Reasons for lower IRs of hand OA in our study compared to Yu et al. may be due to our 
requirement that a hand pain diagnosis had to be followed by a diagnosis of hand OA, OA, or 
generalized OA while Yu et al. accepted a hand pain diagnosis above the age of 45 as clinical 
hand OA. However, Yu et al. censored follow-up time in patients with differential diagnoses 
of hand OA potentially leading to lower IRs (when we took differential indications into 
account, IRs of hand OA lowered by around 5%, data not shown). Furthermore, Yu et al. used 
fewer Read codes for hand OA which should have also resulted in lower IRs. Both studies 
applied a 3-year run-in period while they used additional inclusion criteria concerning CPRD 
practices. Differences in magnitude of hand OA IRs remain unexplained but observed patterns 
of hand OA IRs were highly similar with those reported by Yu et al12. 
A major strength of this study is its very large patient population of >2 million women yielding 
informative results. Additionally, as CPRD prescriptions are issued electronically by the GP, we 
likely captured near complete patient prescription records, especially since HRT suggestions 
from specialists such as gynecologists and endocrinologists, who may treat women at high risk 
of adverse events, are issued by the GP for reasons of reimbursement.  
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3.2 Risk of hand osteoarthritis in new users of hormone replacement 
therapy: A nested case-control analysis 
The subsequent work is based on the following manuscript: 
Burkard T, Rauch M, Spoendlin J, Prieto-Alhambra D, Jick SS, Meier CR. Risk of hand 
osteoarthritis in new users of hormone therapy: A nested case-control analysis Submitted to 
Maturitas  
 
Please see Appendix 2.  
The study was approved by the Independent Scientific Advisory Committee for Medicines and 
Healthcare products Regulatory Agency database research with protocol 18_089R. 
3.2.1 Methods 
Study design and Data source  
We conducted a nested case-control study using data derived from the UK-based CPRD. We 
further used CPRD-linked patient level data on socio-economic status (index of multiple 
deprivation, IMD), which is available for patients living in England only.97,98  
A nested case-control study is a case-control study nested within a well-defined cohort,99 
meaning that controls are randomly sampled from the same cohort population in which cases 
are identified. In case-control studies, odds ratios (ORs) are estimated by dividing exposure 
odds of cases by exposure odds of controls. ORs transfer the information whether the 
exposure is a risk factor (OR >1) or a beneficial factor (OR <1) of the outcome.79 An OR is called 
“crude” if there is no adjustment for confounders in the statistical model (i.e. a simple division 
of exposure odds, also called simple logistic regression). If confounders are put into the 
statistical model (i.e. a multivariable logistic regression model), the OR is called “adjusted” for 
confounders and implies that the result is free of potential confounding by these variables, 
given that the variables were measured correctly. 
Study population 
We included all women on July 1st (cohort entry) of the year in which they turned 45 years old 
(based on their year of birth) between January 1998 and December 2017 in an inception 
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cohort. In contrast to a regular cohort, an inception cohort only comprises patients who have 
an incident common characteristic, here, age 45. 
We excluded all women with ≤1 year of active history and/or <1 GP visit on the database prior 
to cohort entry. We further excluded women with a history of hand OA and with diseases 
potentially linked to secondary OA or differential diagnoses of hand OA prior to cohort entry, 
namely hemarthrosis of the hand, malformation or misalignments of the fingers, 
hypermobility syndrome, hyperparathyroidism, acromegaly, previous finger injury (e.g. 
fracture, dislocation, tear of ligament), Stickler syndrome, Paget’s disease, disorder of iron 
metabolism (hemochromatosis), inflammatory polyarthropathies, and Wilson disease.14,100,101 
Women were not eligible if they had a recorded Read code for any cancer (except 
non-melanoma skin cancer), alcoholism, alcohol/ other substance abuse, or human 
immunodeficiency virus/ acquired immune deficiency syndrome (HIV/AIDS) at any time prior 
to cohort entry. Furthermore, women were excluded if they had a prescription of systemic 
HRT prior to cohort entry. 
Follow-up and Case definition 
We followed all women from cohort entry until they developed incident hand OA defined as 
1) a first-time Read code for hand OA or 2) a record of hand pain followed by an incident Read 
code of hand OA, OA, or generalized OA within 365 days thereafter (these women are further 
referred to as “cases” and the date of their first hand OA or hand pain diagnosis as the “index 
date”). Follow-up was censored at the first of the following: recorded exclusion criterion 
described above (except for first-time systemic HRT use), disenrollment from the CPRD, age 
65, or the end of the study period (December 2017). Read codes in CPRD do not differentiate 
between primary and secondary hand OA diagnoses. However, as we were interested in 
primary hand OA cases, we excluded women with causes of secondary hand OA and censored 
women when a diagnosis for a potential cause of secondary hand OA was recorded. 
Definition of Controls 
Each hand OA case was matched to four controls from the inception cohort who did not have 
a record of hand OA up to 180 days prior to the case index date (risk-set sampling102 with a lag 
period to account for gradual disease onset) on age, calendar date (index date of the case), 
GP practice, and years of history in the CPRD before the index date. 
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Risk-set sampling (also called incidence density sampling) implies that patients at risk of 
becoming a case are selected as controls from the study population each time a case is 
diagnosed.82,99 The patients who are “at risk” when a case is diagnosed are also called the 
“risk-set”.82,99 Risk-set sampling ensures that controls are selected in proportion to the time 
they contribute person-time at risk (i.e. a patient who is “at risk” longer is more likely to serve 
as a control or to serve as a control several times).99 Furthermore, when assessing incident 
cases, ORs are equal to rate ratios of cohort studies (explanation of rate ratios and cohort 
studies on page 41). This is because resulting risk estimates will be almost identical to 
estimates that would have been obtained in the underlying cohort, but with wider CIs.102 
Moreover, after risk-set sampling, resulting risk estimates are not biased by differential 
censoring.82,99  
Exposure 
We defined new HRT use as a first ever recorded prescription for any systemic unopposed or 
opposed HRT (includes separate estrogen and progestogen prescriptions prescribed within 
close proximity). Possible routes of administration were oral, transdermal (i.e. patch), topical 
(i.e. gel), nasal, implanted, or injected. We did not include vaginal HRT administrations due to 
their relatively low, variable systemic bioavailability.  
A woman was considered exposed from the day after the first HRT prescription, and was 
considered “currently exposed” for as long as each prescription was followed by a subsequent 
prescription within a grace period of 180 days after the alleged end of supply (Figure 7).  
 
 
 
 
 
 
 
 
 
 Fig7. Hormone replacement therapy exposure definition in the case-control analysis 
OA: osteoarthritis, HRT: hormone replacement therapy 
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Supply length was determined based on the number of prescribed products and dose 
instructions. In case of missing or improbable information on supply length, we used 
previously assessed default values of product quantities and dosing. A person was classified 
as having past exposure from day 181 after a current prescription supply ended (Figure 7). 
Past users were censored whenever a new systemic HRT prescription was recorded (i.e. past 
users could not become current users again).  
Covariates 
We assessed the following potential confounders of the association between HRT initiation 
and hand OA (selected a priori based on clinical knowledge) recorded at any time before the 
index date (if not specified otherwise): BMI ≥30 kg/m2 (Read code or measure for 
BMI),65,66,68,75,103,104 current smoking,66,68,69,104 heavy alcohol consumption >14 units/week,68 
osteoporosis (Read code or prescription for bone-modifying drug),65,75,104,105 diabetes (Read 
code or antidiabetic drug), thiazide prescriptions,66 dyslipidemia (Read code or laboratory 
value), a vaccination record (proxy for healthcare seeking behavior), and >5 GP contacts103 
within 1 year prior to cohort entry (proxy for healthcare seeking behavior; we assessed GP 
contacts prior to cohort entry because assessing GP contacts prior to the index date may lie 
on the causal pathway between HRT initiation and being diagnosed with hand OA). With 
dichotomization of lifestyle covariates, we assumed that women with a missing record of BMI 
(9.0%), smoking status (2.8%), or alcohol consumption (8.3%) were non-obese, non-smokers, 
or non-heavy drinkers. We further assessed any time vaginal HRT use and socio-economic 
status in quintiles of IMD (where quintile 1 represents least deprived and quintile 5 most 
deprived). Menopause (natural or surgically induced) was assessed between cohort entry and 
the index date.  
Statistical analysis 
We conducted multivariable conditional logistic regression analyses to estimate crude and 
adjusted odds ratios (OR) with 95% confidence intervals (CI) of the association between new 
HRT use compared to non-use and hand OA overall, and stratified by timing of HRT use 
(currently exposed, past exposed).  
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We performed the following sensitivity analyses (analyses to qualitatively analyze the level of 
certainty of results of the main analysis by being stricter with inclusion/exclusion criteria, the 
outcome or other features of the study):  
1) We further adjusted the analysis for vaginal HRT use as we neglected vaginal HRT use due 
to its rather low and variable systemic uptake.  
2) We further adjusted the analysis for socio-economic status in women with available 
information on IMD (ordinal variable) as socio-economic status is a potential confounder of 
the association between HRT use and hand OA.  
3) As hand OA is a diagnosis mainly made in primary care, we could not validate diagnoses 
using secondary care data. Nonetheless, we restricted cases to women with a diagnosis of 
incident hand OA that was preceded or followed by a specialist referral/ discharge 
(rheumatologist/ orthopedist/ radiologist), or diagnostic work up (MRI, X ray, 
ultrasonography) within 90 days before or after the diagnosis.  
4) Furthermore, to account for the slowly developing character of hand OA potentially leading 
to a delayed diagnosis, we re-analyzed the data with the index date shifted to 180 days before 
the hand OA diagnosis date or matched date in controls.  
To assess confounding by whether or not a woman had menopause recorded in the database, 
we calculated crude and adjusted ORs of hand OA in women with recorded menopause 
compared to women who had no menopause record (menopause records between cohort 
entry and the index date only, women with a menopause record before cohort entry were 
excluded in this analysis). Because we observed an association between the presence of 
recorded menopause and a diagnosis for hand OA, we restricted the remainder of analyses to 
women with recorded menopause. In these women, we estimated ORs of the association 
between hand OA and new HRT use, compared to non-use overall and stratified by timing of 
HRT use (currently exposed, past exposed). We further estimated ORs stratified by timing of 
HRT initiation relative to recorded menopause in current users compared to non-users 
(>3 months before menopause [range: 140-2811 days], ≤3 months before/after menopause, 
3-36 months after menopause, and >36 months after menopause [range: 1126 4474 days]). 
Furthermore, we estimated ORs stratified by timing of HRT cessation before the index date 
among past users, compared to non-users (≤18 months before the index date, >18-54 months 
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Fig8. Scheme of determining 1-year intervals after recorded menopause 
before the index date, and >54 months before the index date). Moreover, to describe the 
temporal trend of hand OA onset after menopause, we described the proportion of hand OA 
cases in women with recorded menopause after cohort entry in 1-year intervals after recorded 
menopause (Figure 8). Proportions were estimated by dividing the number of hand OA cases 
in each interval by the number of total hand OA cases at any time between cohort entry and 
index date. We performed all analyses using SAS statistical software version 9.4 (NC, USA). 
 
 
 
 
 
 
In a post-hoc analysis, we assessed whether potential residual confounding was strong enough 
to explain observed results in the stratum of women who initiated HRT ≤3 months 
before/after recorded menopause using the array approach as described by Schneeweiss106. 
The array approach was performed using a tool made available by the Division of 
Pharmacoepidemiology and Pharmacogenomics from Harvard University, Massachusetts, 
USA.107  
3.2.2 Results 
We identified 623,671 women who turned 45 years old during the study period. After 
application of exclusion criteria, 438,674 women entered the inception cohort (Figure 9).  
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Among the cohort, we identified 3440 hand OA cases and 13,760 matched controls. 
Characteristics of these women are displayed in Table 1. The mean age of cases and controls 
at the index date was 50.9 years (standard deviation: 4.1 years). Cases had more recorded 
diagnoses of osteoporosis, diabetes, dyslipidemia, and obesity, and also saw their GP more 
often in the year prior to cohort entry, than controls. 
Tab1. Patient characteristics of cases and matched controls before the index date  
Variables used for matching or covariate adjusting in 
logistic regression 
Cases 
(n=3440) 
Controls 
(n=13,760) 
Mean age at index date (SD) 50.9 (4.1) 50.9 (4.1) 
Mean number of years of history in the database (SD) 15.9 (5.6) 15.9 (5.6) 
>5 GP contacts ≤1 year prior to cohort entry* 2573 (74.8%) 8474 (61.6%) 
Osteoporosis (%) 63 (1.8%) 210 (1.5%) 
Smokers (%) 592 (17.2%) 2435 (17.7%) 
Heavy alcohol drinker (>14 units/week) [%] 100 (2.9%) 415 (3.0%) 
Diabetes diagnosis (%) 148 (4.3%) 502 (3.7%) 
Thiazide prescriptions (%) 454 (13.2%) 1405 (10.2%) 
Fig9. Flow chart of the study composition 
CPRD: Clinical Practice Research Datalink, GP: general practitioner, HRT: hormone replacement therapy 
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Dyslipidemia diagnosis or according laboratory value (%) 1174 (34.1%) 4018 (29.2%) 
Obesity diagnosis or BMI≥30 kg/m2 (%) 907 (26.4%) 3364 (24.5%) 
Vaccine use (%) 1619 (47.1%) 6086 (44.2%) 
Additional variables used in sensitivity/subgroup analyses 
Vaginal hormone replacement therapy use 218 (6.4%) 670 (4.9%) 
IMD quintile 1 (least deprived) 632 (18.4%) 2424 (17.6%) 
IMD quintile 2 498 (14.5%) 2024 (14.7%) 
IMD quintile 3 393 (11.4%) 1567 (11.4%) 
IMD quintile 4 321 (9.3%) 1348 (9.8%) 
IMD quintile 5 (most deprived) 229 (6.7%) 914 (6.6%) 
IMD unknown 1367 (39.7%) 5483 (39.9%) 
Recorded menopause after cohort entry 860 (25.0%) 2610 (19.0%) 
SD: standard deviation, GP: general practitioner, BMI: body mass index, IMD: index of multiple deprivation 
*number of GP contacts prior to the index date would lie on the causal pathway 
 
The adjusted OR of hand OA in current HRT users compared to non-users was 1.32 (95% CI 
1.17-1.48) [Table 2].  
Tab2. Odds ratios of hand osteoarthritis in association with hormone replacement therapy overall 
and stratified by timing of hormone replacement therapy use at the index date 
Overall Cases: 
3440 (%) 
Controls: 
13,760 (%) 
OR crude 
(95% CI) 
OR adjusted* 
(95% CI) 
No HRT use 2982 (86.7) 12,415 (90.2) 1.00 ref 1.00 ref 
Overall HRT use 458 (13.3) 1345 (9.8) 1.45 (1.29-1.63) 1.32 (1.17-1.48) 
Overall HRT use additionally adjusted for vaginal HRT use 1.31 (1.16-1.47) 
Current HRT use  189 (5.5) 627 (4.6) 1.27 (1.07-1.50) 1.11 (0.93-1.31) 
Past HRT use 269 (7.8) 718 (5.2) 1.62 (1.39-1.89) 1.52 (1.31-1.78) 
Women with information on 
IMD 
Cases: 
2073 (%) 
Controls: 
8277 (%) 
OR crude 
(95% CI) 
OR adjusted* 
(95% CI) 
No HRT use 1797 (86.7) 7480 (90.4) 1.00 ref 1.00 ref 
Overall HRT use additionally 
adjusted for IMD in quintiles 
276 (13.3) 797 (9.6) 1.47 (1.27-1.72) 1.34 (1.15-1.57) 
Index date shift to 180 days 
before the index date† 
Cases: 
3308 (%) 
Controls: 
13,154 (%) 
OR crude 
(95% CI) 
OR adjusted* 
(95% CI) 
No HRT use 2850 (86.2) 11,813 (89.8) 1.00 ref 1.00 ref 
Overall HRT use 458 (13.9) 1341 (10.2) 1.31 (1.19-1.45) 1.23 (1.11-1.36) 
Cases with a secondary care 
entry‡ 
Cases: 
660 (%) 
Controls: 
2640 (%) 
OR crude 
(95% CI) 
OR adjusted* 
(95% CI) 
No HRT use 572 (86.7) 2403 (91.0) 1.00 ref 1.00 ref 
Overall HRT use 88 (13.3) 237 (9.0) 1.62 (1.23-2.14) 1.43 (1.08-1.89) 
OR: odds ratio, CI: confidence interval, HRT: hormone replacement therapy, IMD: index of multiple deprivation 
* adjusted for osteoporosis, smoking, alcohol consumption, diabetes, thiazide prescriptions, dyslipidemia, 
obesity, vaccine use prior to index date and for number of GP contacts prior to cohort entry 
† cases with ≤180 days of follow-up and their matched controls as well as any control with ≤180 days of 
follow-up were excluded 
‡ hand osteoarthritis preceded or followed by a specialist referral/discharge (rheumatologist, orthopedist, or 
radiologist) or diagnostic work up (MRI, X ray, ultrasonography) within 90 days before or after the diagnosis. 
Other hand osteoarthritis cases and their matched controls were excluded  
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OR adjusted* with 95% CI 
A record of menopause (irrespective of HRT use) was associated with an increased adjusted 
OR of hand OA of 1.42 (95% CI 1.29-1.57) when compared to women without recorded 
menopause (Figure 10).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In women with recorded menopause, there was no association between HRT use and risk of 
hand OA:  adjusted OR 0.98 (95% CI 0.85-1.14) when compared to non-use. Current HRT users 
(versus non-users) had a statistically non-significantly decreased adjusted OR of hand OA of 
0.72 (95% CI 0.49-1.05), when HRT was initiated within 3 months before/after menopause 
with ORs increasing with later HRT initiation. Women with past HRT use had a statistically non-
Women with or without 
recorded menopause 
after cohort entry and 
before the index date 
Cases: 
3085 (%) 
Controls: 
12,681 (%) 
 
OR adjusted* 
(95% CI) 
No recorded menopause  2225 (72.1) 10,071 (79.4) 1.00 ref 
Recorded menopause  860 (27.9) 2610 (20.6) 1.42 (1.29-1.57) 
No HRT use 604 (19.6) 1821 (14.4) 1.00 ref 
Overall HRT use 256 (8.3) 789 (6.2) 0.98 (0.85-1.14) 
Current HRT use  106 (3.4) 378 (3.0) 0.85 (0.69-1.04) 
… HRT start >3 months 
before menopause 
8 (0.3) 21 (0.2) 1.04 (0.52-2.09) 
… HRT start ≤3 months 
before/after menopause 
55 (1.8) 238 (1.9) 0.72 (0.55-0.96) 
… HRT start 3-36 months 
after menopause 
33 (1.1) 98 (0.8) 0.97 (0.68-1.37) 
… HRT start >36 months  
after menopause 
10 (0.3) 21 (0.2) 1.30 (0.69-2.43) 
Past HRT use 150 (4.9) 411 (3.2) 1.10 (0.91-1.31) 
… HRT stop ≤18 months 
before the ID 
29 (0.6) 64 (0.3) 1.25 (0.86-1.81) 
… HRT stop >18-54 
months before the ID 
65 (2.4) 170 (1.6) 1.11 (0.86-1.43) 
… HRT stop >54 months 
before the ID 
56 (1.8) 177 (1.4) 1.01 (0.76-1.33) 
Fig10. Odds ratios of hand osteoarthritis in association with recorded menopause after cohort entry, 
and, in patients with recorded menopause after cohort entry, odds ratios of hand osteoarthritis in 
association with hormone replacement therapy and stratified by timing of hormone replacement 
therapy use (current/ past use) and by timing of hormone replacement therapy initiation relative to 
recorded menopause (in current users) and of hormone replacement therapy cessation before the index 
date (in past users) 
HRT: hormone replacement therapy, ID: index date, OR: odds ratio, CI: confidence interval 
* adjusted for osteoporosis, smoking, alcohol consumption, diabetes, thiazide prescriptions, dyslipidemia, obesity, 
vaccine use prior to index date, and adjusted for number of GP contacts prior to cohort entry.  
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Fig11. Proportion of newly diagnosed hand osteoarthritis cases in 1-year intervals after 
recorded menopause 
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significantly adjusted OR of hand OA of 1.25 (95% CI 0.86-1.81) if HRT was stopped ≤18 months 
before the index date, which decreased towards the null with increasing duration between 
HRT cessation and the index date (Figure 10). 
The proportion of women with hand OA diagnoses decreased with increasing number of 
1-year intervals after recorded menopause. A maximum proportion of 18.4% of women had 
hand OA recorded (158 of 860 cases) within 1 year after recorded menopause. Cumulatively 
of all women who developed hand OA after menopause, 54.9% and 79.9% of women did so 
within 4 years and 7 years, respectively (Figure 11).  
 
 
 
 
 
 
 
 
 
 
 
 
In all analyses, adjusted ORs of hand OA were lower in current and higher in past HRT users 
than when HRT was assessed overall (Table 2, Figure 10). When we further adjusted the overall 
analysis for vaginal HRT use and socioeconomic status (IMD available in 60.2% of women) in 
two sensitivity analyses, results remained unchanged (Table 2). In two further sensitivity 
analyses related to outcome validity, results remained largely unchanged as well (Table 2).  
In a post-hoc analysis, we assessed the extent of residual confounding needed to potentially 
explain the decreased adjusted OR of hand OA of 0.72 in HRT initiators ≤3 months before/after 
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recorded menopause who were still HRT users at the index date, compared to non-initiators. 
To increase the observed adjusted OR to 1.0, a potential unmeasured confounder would need 
to have, for example, a prevalence of 15% and 0% in non-users and HRT users, respectively, 
and to achieve a relative risk of hand OA of 3.0 (the lower the prevalence in non-users or the 
higher the prevalence in HRT users, the stronger the association between unmeasured 
confounder and hand OA would need to be) [Appendix 7]. 
3.2.3 Discussion 
In this nested case-control study in UK-based CPRD between 1998 and 2017, we observed 
women from age 45 longitudinally and assessed the association between systemic HRT and 
hand OA and between menopause and hand OA with both associations yielding increased risks 
of 32% and 42%, respectively. However, the increased risk of hand OA in HRT users compared 
to non-users disappeared in women with recorded menopause. The proportion of hand OA 
diagnoses decreased with increasing 1-year intervals after recorded menopause and, in 
women with a menopause record, when compared to non-users, we observed a 28% 
decreased risk of hand OA if HRT was initiated around menopause and used continuously.  
Due to heterogeneous methods, a comparison of our results to previous observational studies 
on the association of HRT initiation and the risk of hand OA is difficult.65–69 The authors of 
previous cross-sectional studies yielded contradictory results.65–69 They had detailed 
hospital-based hand OA diagnoses at hand but were unable to determine temporality of HRT 
use and hand OA as well as the timing of HRT use relative to menopause.65–69 Furthermore, 
data of HRT exposure was collected mainly through questionnaires and did not account for 
timing of HRT use. We observed a 32% increased risk of hand OA in HRT users when compared 
to non-users, which was supported by sensitivity analyses (taking into account socio-economic 
status, vaginal HRT use, potential lag time of diagnosis, and case validity). However, the risk 
disappeared after restriction to women with recorded menopause. Other observational 
studies assessing the association between menopause with or without HRT use and hand OA 
did not yield precise results mainly due to small sample sizes.103,104,108–111 Watt et al. 
performed a small study (n=82) describing the association between menopause or HRT 
cessation and onset of hand OA symptoms in women in a UK secondary care clinic.112 The 
authors reported a median duration between HRT cessation and onset of hand OA of 
6 months.112 We observed that, among women with recorded menopause who developed 
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hand OA, 55% of women did so within 4 years after menopause, the same proportion was 
reported by Watt et al.. 112  
Women who initiated HRT shortly before/after menopause were at a reduced risk of hand OA 
(around 28% lower risk for women with current HRT use at the index date). We hypothesize 
that women who use systemic HRT to alleviate vasomotor symptoms may profit from a 
delayed onset or progression of hand OA, when HRT is initiated around menopause and used 
continuously. Thus, our results support position statements of the International Menopause 
Society62 and the North American Menopause Society63, which postulate a potential benefit 
of HRT on joint/ muscle pain and joint stiffness based on evidence from the well-known WHI 
reporting reduced arthroplasty and joint pain among unopposed HRT users113,114, and reduced 
joint pain and stiffness among opposed HRT users115, compared to non-users. Our findings 
among current users are mainly based upon opposed HRT users (74.9% of women used 
opposed HRT for ≥12 months prior to the index date). To date, there is no information on the 
effect of progesterone alone or in conjunction with estrogen on articular cartilage. Our results 
also suggest that HRT cessation may slightly increase the risk of hand OA (25% risk increase 
≤18 months after cessation, based on small sample size), which may question the initial clinical 
benefit of HRT use. We hypothesize that hand OA onset likely expressed by hand pain is similar 
to spontaneous exacerbation of vasomotor symptoms after HRT cessation.63  
A strength of this study is its large population of more than 3’000 hand OA cases among 
women observed longitudinally from age 45 on. Furthermore, we applied a new user design, 
allowing us to assess temporality of HRT use and hand OA. Moreover, we likely captured near 
complete HRT prescription information, as CPRD prescriptions are issued electronically by the 
GP. We do not know if women filled their prescriptions at the pharmacy and if they adhered 
to the prescribed therapy. However, of women who had HRT prescribed during follow-up, 
77.4% had >1 HRT prescription recorded, suggesting that most women filled their 
prescriptions repeatedly, and thus likely took the medication.  
A major limitation of this study is the inconsistent recording of menopause in the CPRD. 
However, HRT use among women with recorded menopause in our study is consistent with 
numbers reported among the general UK female population (around 20-40% of women who 
have sought medical advice on menopause used HRT over time).55,116 
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Furthermore, as only around 30% of women with recorded menopause were prescribed HRT 
in our study, we hypothesize that women with a menopause record in the CPRD do not only 
represent women with severe (post)menopausal symptoms but also women who had mild 
symptoms or whose menopause was recorded by chance. Therefore, our results can likely be 
generalized to women in the UK in peri-to-post-menopause. However, sample size of some 
strata in our study population was small, and results have to be confirmed before drawing 
causal conclusions for clinical practice. However, the decreased risk of hand OA in the stratum 
of women initiating HRT within 3 months before or after menopause and who were still HRT 
users at the index date, when compared to non-users, is unlikely entirely explained by residual 
confounding as suggested by the results of the array approach.  
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3.3 Risk of hand osteoarthritis in female new users of statins of 
peri-to-postmenopausal age: A sequential cohort study 
The subsequent work is based on data of the following publication: 
Burkard T, Hügle T, Layton JB, Glynn RJ, Bloechliger M, Frey N, Jick SS, Meier CR, Spoendlin J. 
Risk of incident osteoarthritis of the hand in statin initiators: A sequential cohort study 
Arthritis Care Res (Hoboken). 2018;70(12):1795-1805. 
 
Please see Appendix 8.  
The study was approved by the Independent Scientific Advisory Committee for Medicines and 
Healthcare products Regulatory Agency database research with protocol 16_092R. 
3.3.1 Methods 
Study design and data source 
We conducted a propensity score (PS)-matched sequential cohort study using data from the 
UK-based CPRD. We further used CPRD-linked patient level data on socio-economic status 
through the use of IMD, which is available for patients living in England only.97,98  
The PS is a mathematical construct that was introduced by Rosenbaum and Rubin in 1983 to 
indicate probability of exposure with the treatment of interest.117 The PS can be used as a tool 
to balance covariates of exposed and unexposed patients in observational studies. The 
estimation of the PS is independent of the outcome as it is estimated using logistic regression 
(seldom machine learning algorithms) using the exposure as the dependent variable and with 
risk factors of the outcome and confounders as the independent variables.118 In a subsequent 
“outcome model” in which the risk of an outcome associated with a certain exposure is 
estimated, either exposed and unexposed patients were matched on their PS, or in case of  
weighting or adjusting, the PS may be the only covariate in the model. That means, when using 
PS, confounding control happens separately from risk assessment which shall yield causal 
effects given four assumptions: 1) consistency (i.e. we measure what we think we measure), 
2) exchangeability (i.e. there are no unmeasured confounders), 3) positivity (i.e. no patient 
has a zero chance to be treated or not treated), and 4) no misspecification of the PS model 
(i.e. the selected variables to estimate the PS yield the true probability of treatment).119 The 
PS method is mainly used in cohort studies.120  
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In cohort studies, patients are observed longitudinally from exposure or non-exposure until a 
certain outcome occurs or until the medical record ends.82 If all patients completed follow-up, 
a risk ratio is estimated by dividing cumulative incidence of exposed and unexposed.79 If 
confounder adjustment is needed, risk estimation is carried out with a multivariable logistic 
regression analysis.82 However, if patients are censored along the way, an incidence rate ratio 
is estimated which takes into account contributed person-time at risk of patients. Incidence 
rate ratios are estimated by dividing the IR of the outcome of exposed patients by the IR of 
the outcome of unexposed patients.79,99 If confounder adjusting is needed, risk estimations 
are carried out using Poisson regression.82,83 A different approach taking censoring of patients 
into account is to define the outcome as “time-to-event” and to estimate hazard ratios (HR, 
crude or adjusted) in Cox proportional hazard regression analysis121.82 
Study population 
We identified all women aged 45 to 64 years at any time between January 1996 and December 
2015 in the CPRD and extracted their statin initiation episodes (those with ≥1 new prescription 
for atorvastatin, fluvastatin, pravastatin, rosuvastatin, or simvastatin) after a statin-free 
period of ≥3 years. New user designs rule out the risk of prevalent user bias, which occurs 
when comparing patients who have been treated with a drug for a long time to patients newly 
starting a drug. When compared to a patient newly starting a drug, prevalent users may be 
less susceptible to side effects, and therefore more adherent to the drug still being prescribed 
as they have not yet developed any side effects. Therefore, prevalent and new users likely 
differ and their comparison would introduces bias into the study. 
We categorized women into one of ten 2-year entry blocks (EB) according to the date of the 
first prescription (referred to as cohort entry). Within each EB, we identified all women who 
had no statin prescriptions but had ≥3 years of recorded statin-free active history and ≥1 
recorded GP encounters during the respective EB to ensure database activity. These women 
were assigned a random entry date within the respective EB (cohort entry) [Figure 12]. 
Women could only contribute one episode (statin initiation or non-initiation) per EB, but they 
could contribute multiple episodes throughout the study period in different EBs if eligibility 
criteria were fulfilled (i.e. follow-up time was counted multiple times for some women). We 
subsequently refer to women as statin initiators or non-initiators (which do not refer to unique 
women but to statin initiation episodes and non-initiation episodes).  
Risk of hand OA in peri-to-postmenopausal statin initiators 
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We excluded women with a Read code for prior atherothrombotic events in favor of 
homogeneity of the study population (i.e. to focus on statin use for primary prevention), but 
also because atherothrombotic events are a clear indication to initiate a statin and patients 
who did not do so are likely a biased comparator group.122 Women with strong risk factors for 
hand OA, such as a pre-existing OA of any joint, a disease associated with secondary OA, or a 
differential diagnosis of hand OA were excluded to minimize outcome misclassification. We 
Fig12. A) Study overview. Each entry block (EB) represented one cohort. The cohorts contained all 
eligible statin initiators and their 1:1 propensity score‑matched non-initiators. We followed all statin 
initiators and non-initiators for a maximum of 6 years after their entry in an EB, respectively 5.5 years 
after completed run-in period until they had a record of hand osteoarthritis or they were censored.  
B) Entry block in detail. At least three years statin free history was required for both statin initiators and 
non-initiators to enter the cohort, non-initiators required additionally ≥1 general practitioner 
encounters during the respective EB. Matched statin initiators entered on the date of their first statin 
prescription; matched non-initiators entered on a random date. After a run-in period of 180 days, all 
statin initiators and non-initiators were followed-up for a maximum of 5.5 years until they had a record 
of hand osteoarthritis or they were censored 
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excluded women with alcoholism/ substance abuse, HIV/AIDS or a malignant cancer because 
these women are generally associated with a higher risk of bias and confounding in 
observational studies. Women with a previous prescription for cerivastatin (withdrawn from 
the market in 2001)123 were also excluded. 
PS matching  
We estimated a PS (probability of statin initiation) for each statin initiator and non-initiator 
using multivariable logistic regression. We included characteristics recorded at any time 
before cohort entry, either associated with the risk of developing hand OA only, or potential 
confounders of the association between statin initiation and hand OA (selected a priori based 
on clinical knowledge) [Table 3].124 Pre-matching enrolment duration in the CPRD prior to the 
index date was comparable in PS-matched statin initiators and non-initiators with a mean 
duration of 3.2 years (standard deviation: 2.1 years) in initiators and of 3.3 years (standard 
deviation: 1.9 years) in non-initiators. Covariates included comorbidities that may influence 
prescribing behavior (e.g. heart diseases, diabetes)125 and proxies for healthcare seeking 
behavior (e.g. number of GP encounters ≤1 year prior to cohort entry).126 To maximize 
comparability between matched pairs, we matched non-initiators to statin initiators within 
each of the ten EBs separately (accounting for time-related bias due to changing statin 
prescribing patterns).127 A greedy 5-1 digit matching algorithm without replacement was 
applied, excluding those who could not be matched.128  
In a sensitivity analysis, we trimmed our study population asymmetrically at the extreme ends 
of the PS tail (statin initiators below the 5th and non-initiators above the 95th percentile before 
matching) to exclude statin initiators and non-initiators treated contrary to prediction.129,130 
Follow-up  
Follow-up started on day 181 after cohort entry (Figure 12B) to allow statin initiators to reach 
maintenance dose and to account for the delay in diagnosis due to slow disease progression 
of hand OA (i.e. to reduce the probability of detecting prevalent hand OA cases during early 
follow-up). Exclusion of episodes of ≤180 days of follow-up also rule out inclusion of women 
with poor statin adherence; it has previously been shown that a large proportion of patients 
discontinue statin treatment shortly after the first prescription.130,131 We followed statin 
initiators and non-initiators in an “as-treated” approach until the first occurrence of a 
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diagnosis of hand OA or censoring due to: onset of an exclusion criterion described above, 
change of exposure status, disenrollment from the CPRD, December 2015, or maximum 
follow-up of 5.5 years after completed run-in period.  
In a sensitivity analysis, we started follow-up at day 1 after cohort entry.  
Exposure ascertainment 
We defined continuous statin exposure during follow-up based on the estimated duration of 
supply of each recorded statin prescription, accounting for the number of tablets and dose 
instructions. A statin initiator was considered continuously exposed if a subsequent 
prescription was recorded ≤180 days after the alleged end of supply; if not, censoring occurred 
at the last day of supply of the last prescription. Where prescription duration and/or dosing 
instructions were not recorded, we assumed a 28-day supply (mode for statin prescriptions) 
and a regimen of 1 tablet/day, respectively.  
Statins inhibit HMG-CoA-reductase, an enzyme in liver cells involved in cholesterol 
biosynthesis. The resulting decrease in cholesterol synthesis leads to an increase in LDL 
receptors on liver cells and therefore to an increased internalization of LDL and reduced serum 
LDL levels.132 Furthermore, certain statins were reported to inhibit IL-1 and MMPs involved in 
cartilage degradation in an articular cell culture.133 
Outcome 
We defined hand OA as the first recorded diagnosis of hand OA (base of thumb OA and hand 
pain were not considered).  
We performed a sensitivity analysis restricted to hand OA diagnoses that were preceded by 
diagnostic work up (MRI, radiography, ultrasonography) or a referral/discharge to/from a 
rheumatologist, orthopedist, or radiologist within 180 day before the first diagnosis. Other 
hand OA Read codes led to censoring on the date of the hand OA diagnosis.  
In a further sensitivity analysis, to account for heterogeneity by delayed hand OA diagnoses, 
we shifted the first hand OA diagnosis to 180 days prior to the first recorded diagnosis. 
Therefore, given the run-in period of 180 days, cases with less than 360 days of initial 
follow-up were disregarded. 
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To further assess the validity of our findings with respect to surveillance bias (differential 
healthcare seeking behavior) and the influence of unmeasured menopause onset, we defined 
two negative control outcomes (psoriasis and tinnitus). Negative control outcomes are not 
causally associated with the exposure, but should be subject to the same potential source of 
measured and unmeasured confounding as the original outcome.134 Therefore, if exposure 
and negative control outcome yield a positive or negative association, confounding is 
detected.135 If there is no association between exposure and negative control outcome, it 
supports the main study findings. However, it does not imply that the observed primary 
association is causal nor is it a test for complete absence of confounding or bias in the primary 
association.135 Psoriasis and tinnitus are more likely diagnosed in patients who show 
healthcare seeking behavior (patients who see their GP often for minor reasons). Psoriasis was 
reported to exacerbate with menopause yielding increased new onset proportions in women 
aged 45-55 years136 which is supposedly due to the effect of low estrogen levels on the 
adaptive immune system.137 Thereby, psoriasis as a negative control outcome may disclose 
differential distribution of menopause among statin initiators and non-initiators.  
In a secondary analysis, we assessed generalized OA as the study outcome. We did not assess 
generalized OA as a primary outcome due to limited capability to define generalized OA in 
CPRD data.2 
Statistical analysis 
After combining all sequential cohorts into one, we compared covariate distribution between 
treatment groups before and after PS-matching. We performed Cox proportional hazard 
analyses estimating HRs with 95% CI for the association of hand OA and generalized OA 
separately with statin initiation, compared to non-initiation. The proportional hazard 
assumption was tested using the martingale residual method138 (held true overall, if hazards 
are proportional over time, the overall risk estimate is true throughout follow-up). For 
comparative reasons, we also ran all analyses using multivariable Cox regression in the 
unmatched cohort, adjusting for all covariates included in the PS. We performed subgroup 
analyses by age (45–54 years, 55-64 years), and diagnosed pre-existing dyslipidemia (i.e. a 
Read code of dyslipidemia or corresponding laboratory values), for which we re-matched 
within subgroups. We further quantified time-specific HRs within intervals of follow-up 
(0-1 year, 2–3 years, 4–5.5 years), excluding those whose follow-up ended before the period 
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of interest. The association between statin initiation and negative control outcomes was 
assessed identically. We further estimated pre- and post-matching c-statistics using a logistic 
regression model including all covariates included in the PS. The c-statistic indicates the level 
of covariate balance between study groups where 0.5 indicates perfect balance and 1.0 
indicates maximal imbalance.139 To assess potential confounding by socio-economic status, 
we performed a sensitivity analysis in patients with information on IMD only (66.4%). Therein, 
we added IMD as an ordinal variable (where quintile 1 represents least deprived and quintile 
5 most deprived) into the PS estimation model (re-matched patient characteristics are 
displayed in Appendix 9). In the unmatched cohort, we added IMD as an ordinal variable into 
the Cox regression model. We performed all analyses using SAS statistical software version 
9.4 (NC, USA). 
3.3.2 Results 
We identified 80,697 statin initiators (78,634 unique women [97.4%]) and 
2,730,961 non-initiators (786,111 unique women [28.8%]); a total of 18,531 statin initiators 
(23.0%) and 160,530 non-initiators (5.9%) were further excluded due to ≤180 days of 
follow-up, resulting in 62,166 statin initiators and 2,570,431 non-initiators (PS distribution 
before PS-matching can be seen in Figure 13). Before PS-matching, the c-statistic was c=0.91.  
 
  
 
 
 
 
 
 
 
Fig13. Propensity score distribution of statin initiators and non-initiators before 
propensity score matching 
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Of the 62,166 statin initiators, 96.1% were matched to non-initiators, resulting in 
59,731 PS-matched pairs (59,241 unique women in statin initiators [99.2%] and 50,527 unique 
women in non-initiators [81.2%]). Before PS-matching, the average age of statin initiators was 
higher, and statin initiators had on average shorter follow-up (mainly due to differential 
censoring for change in exposure status) and were more frequently hospitalized, rather obese, 
and more frequently diagnosed with hypertension, type2 diabetes, or heart diseases (Table 3). 
After PS-matching, covariate balance was achieved across all included covariates with a 
post-matching c-statistic of c=0.54.  
Tab3. Baseline characteristics of statin initiators and non-initiators (follow-up >180 days) before 
and after propensity score-matching 
 Before PS-matching PS-matched 
 
Statin initiators 
(N=62,166) 
Non-initiators 
(N=2,570,431) 
Statin initiators 
(N=59,731) 
Non-initiators 
(N=59,731) 
Mean age in years (SD) 56.3 (5.3) 53.1 (5.6) 56.3 (5.3) 56.3 (5.3) 
Mean follow-up in years (SD) 3.2 (2.1) 3.8 (1.9) 3.2 (2.1) 3.3 (1.9) 
Mean number of GP contacts 
≤1 year before cohort entry* 
(SD) 
19.3 (12.1) 9.8 (9.6) 18.9 (11.9) 19.6 (14.1) 
Current smokers 14,780 (23.8%) 514,341 (20.0%) 14,238 (23.8%) 14,151 (23.7%) 
Average alcohol intake       
(>14 units/week) 
1915 (3.1%) 75,322 (2.9%) 1867 (3.1%) 2071 (3.5%) 
Comorbidities before cohort entry:    
Obesity (BMI>30kg/m2) 23,776 (38.3%) 502,313 (19.5%) 22,285 (37.3%) 22,735 (38.1%) 
Osteoporosis† 1688 (2.7%) 46,873 (1.8%) 1625 (2.7%) 1811 (3.0%) 
Dyslipidemia‡ 47,156 (75.9%) 453,181 (17.6%) 44,793 (75.0%) 46,418 (77.7%) 
Angina pectoris 3453 (5.6%) 18,371 (0.7%) 3066 (5.1%) 2641 (4.4%) 
Type2 diabetes 11,627 (18.7%) 24,018 (0.9%) 9710 (16.3%) 8330 (14.0%) 
Hypertension 29,074 (46.8%) 349,154 (13.6%) 27,574 (46.2%) 28,882 (48.4%) 
Ischemic heart disease 2418 (3.9%) 6850 (0.3%) 2093 (3.5%) 1653 (2.8%) 
Congestive heart failure 390 (0.6%) 2474 (0.1%) 346 (0.6%) 321 (0.5%) 
Hypothyroidism 6913 (11.1%) 152,437 (5.9%) 6582 (11.0%) 7163 (12.0%) 
Vascular disease 1612 (2.6%) 32,419 (1.3%) 1514 (2.5%) 1527 (2.6%) 
Chronic kidney disease 1579 (2.5%) 13,939 (0.5%) 1514 (2.5%) 1507 (2.5%) 
Hip fracture 176 (0.3%) 6858 (0.3%) 171 (0.3%) 182 (0.3%) 
Liver disease 438 (0.7%) 6206 (0.3%) 414 (0.7%) 417 (0.7%) 
COPD‡ 1397 (2.3%) 24,846 (1.0%) 1310 (2.2%) 1395 (2.3%) 
Deep vein thrombosis 969 (1.6%) 24,366 (1.0%) 928 (1.6%) 1054 (1.8%) 
Dysphagia 1029 (1.7%) 26,989 (1.1%) 989 (1.7%) 1079 (1.8%) 
≥1 hospitalization ≤1 year 
before cohort entry (SD) 
9991 (16.1%) 229,669 (8.9%) 9508 (15.9%) 9898 (16.6%) 
Incontinence 2123 (3.4%) 53,568 (2.1%) 2023 (3.4%) 2178 (3.7%) 
Pneumonia 1275 (2.1%) 49,178 (1.9%) 1221 (2.0%) 1341 (2.3%) 
Psychotherapy§ 3759 (6.1%) 116,496 (4.5%) 3612 (6.1%) 3896 (6.5%) 
Co-medication ≤180 days before cohort entry:    
Hormone replacement 
therapy 
10,800 (17.4%) 442,297 (17.1%) 10,437 (17.5%) 11,133 (18.6%) 
Oral corticosteroids 2530 (4.1%) 62,159 (2.4%) 2400 (4.0%) 2490 (4.2%) 
Opioids 4224 (6.8%) 84,542 (3.3%) 3989 (6.7%) 4217 (7.1%) 
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Benzodiazepines 4412 (7.1%) 114,511 (4.5%) 4215 (7.1%) 4617 (7.7%) 
COPD|| drugs 700 (1.1%) 12,156 (0.5%) 660 (1.1%) 679 (1.1%) 
Coronary vasodilators 3247 (5.2%) 7504 (0.3%) 2788 (4.7%) 2170 (3.6%) 
Histamin-2 antagonists 1616 (2.6%) 36,414 (1.4%) 1518 (2.5%) 1670 (2.8%) 
SSRIs 6263 (10.1%) 166,375 (6.5%) 6006 (10.1%) 6356 (10.6%) 
Other lipid lowering agents 1045 (1.7%) 4697 (0.2%) 976 (1.6%) 954 (1.6%) 
Number of CV drugs¶: 0 22,449 (36.1%) 2,175,920 (84.7%) 22,429 (37.6%) 22,909 (38.4%) 
Number of CV drugs¶: 1-3 33,659 (54.1%) 375,260 (14.6%) 32,193 (53.9%) 31,215 (52.3%) 
Number of CV drugs¶: 4-12 6058 (9.7%) 19,251 (0.8%) 5109 (8.6%) 5607 (9.4%) 
SD: standard deviation, GP: general practitioner, IMD: index of multiple deprivation, COPD: chronic obstructive pulmonary 
disease, SSRI: serotonin reuptake inhibitor, CV: cardiovascular PS: propensity score 
* only records on separate days  
† defined as an osteoporosis diagnose or intake of drugs affecting bone metabolism 
‡ defined as either an hyperlipidemia Read code, a laboratory value of low density lipoprotein ˃3 mmol/l, of high density 
lipoprotein ˂1 mmol/l, or of triglycerides ˃1.7 mmol/l 
§ as a proxy for psychiatric disease 
|| defined as xanthines, long-acting inhaled anticholinergics including combinations, indacaterol, or aclidinium including 
combinations 
¶ defined as ACE-inhibitors, ATII-inhibitors, beta-blockers, calcium-channel-blockers, diuretics, thrombocyte-aggregation-
inhibitors, vitamin K antagonists, acetylsalicylic acid, other lipid lowering agents, insulin, oral antidiabetics, or 
antiarrhythmics 
 
 
Censoring was comparable between statin initiators and non-initiators after PS-matching 
(Table 4). 
Tab4. Censoring reasons before and after propensity score-matching 
 Before PS-matching PS-matched 
Statin initiators 
(n=62,166) 
Non-initiators 
(n=2,570,431) 
Statin initiators 
(N=59,731) 
Non-initiators 
(N=59,731) 
Osteoarthritis 4059 (3.2%) 121,861 (4.7%) 3820 (6.4%) 3610 (6.0%) 
Rheumatoid arthritis,  
other arthritis 
955 (1.5%) 35,651 (1.4%) 893 (1.5%) 1047 (1.8%) 
Crystal arthropathies 7 (0.0%) 281 (0.0%) 6 (0.0%) 6 (0.0%) 
Disorders of iron metabolism 17 (0.0%) 711 (0.0%) 17 (0.0%) 21 (0.0%) 
Gout 516 (0.8%) 7638 (0.3%) 488 (0.8%) 419 (0.7%) 
Hem – or hydrarthoris 7 (0.0%) 180 (0.0%) 6 (0.0%) 5 (0.0%) 
Hyperparathyroidism 86 (0.1%) 1792 (0.1%) 80 (0.1%) 61 (0.1%) 
Wilson disease, acromegaly, or 
hypermobility syndrome 
9 (0.0%) 407 (0.0%) 9 (0.0%) 5 (0.0%) 
Previous finger injury 174 (0.3%) 8547 (0.3%) 167 (0.3%) 214 (0.4%) 
Finger 
malformation/misalignment 
534 (0.9%) 14,310 (0.6%) 497 (0.8%) 411 (0.7%) 
Amputation of at least wrist 
level 
3 (0.0%) 95 (0.0%) 3 (0.0%) 1 (0.0%) 
Cancer except non-melanoma 
skin cancer 
1854 (3.0%) 74,968 (2.9%) 1768 (3.0%) 2000 (3.4%) 
HIV/AIDS 0 (0.0%) 82 (0.0%) 0 (0.0%) 0 (0.0%) 
Alcohol/ other substance abuse 781 (1.3%) 29,647 (1.2%) 736 (1.2%) 724 (1.2%) 
Prescription of cerivastatin 101 (0.2%) 1613 (0.1%) 97 (0.2%) 79 (0.1%) 
Change of exposure status 15,135 (24.4%) 181,751 (7.0%) 14,649 (24.5%) 12,991 (21.8%) 
Loss to follow-up 16,643 (26.8%) 969,827 (37.7%) 16,317 (27.3%) 19,748 (33.1%) 
Completed follow-up, 
end of the study period 
20,756 (33.4%) 1,103,140 (42.9%) 19,680 (33.0%) 17,731 (29.7%) 
Death 214 (0.3%) 6506 (0.3%) 191 (0.3%) 363 (0.6%) 
PS: propensity score, HIV/AIDS: human immunodeficiency virus/ acquired immune deficiency syndrome 
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Overall, hand OA was not associated with statin initiators with a HR of 1.07 (95% CI 0.91-1.25) 
compared to non-initiators (Table 5).  
Tab5. Results of the association of statin initiation and incident hand osteoarthritis overall and in 
subgroups 
 Before PS-matching PS-matched 
 
Obs. time* 
in statin 
init. + 
non-init. 
Hand 
OA 
events 
HR 
crude 
(95% CI) 
HR 
adjusted† 
(95% CI) 
Obs. time* 
in statin 
init. + 
non-init. 
Hand 
OA 
events 
HR 
matched† 
(95% CI) 
Overall 201.2+ 
9783.5 
11,758 1.36 
(1.21-1.52) 
1.16 
(1.02-1.30) 
192.2+ 
198.0 
606 1.07 
(0.91-1.25) 
Age in years 
45-54 69.9+ 
6073.0 
6466 1.38  
(1.13-1.68) 
1.18  
(0.96-1.46) 
66.2+ 
71.7 
187 1.17  
(0.87-1.55) 
55-64 131.3+ 
3710.5 
5292 1.22  
(1.06-1.39) 
1.15  
(0.99-1.33) 
125.0+ 
125.3 
401 1.10  
(0.90-1.34) 
Indication for statin initiation 
Present 
dyslipidemia 
151.3+ 
1395.3 
2332 1.15  
(1.01-1.31) 
1.21  
(1.05-1.39) 
142.1+ 
143.7 
497 1.05  
(0.88-1.25) 
Absent dyslipidemia 49.9+ 
8388.1 
9426 1.03  
(0.79-1.34) 
1.00  
(0.76-1.30) 
49.5+ 
53.1 
123 0.90  
(0.63-1.28) 
Duration of follow-up     
0-1 years 54.5+ 
2412.6 
2566 1.30 
(1.03-1.64) 
1.04 
(0.81-1.33) 
52.3+ 
55.0 
152 0.92 
(0.67-1.27) 
2-3 years 80.1+ 
3917.9 
4494 1.53 
(1.29-1.81) 
1.29 
(1.07-1.55) 
76.5+ 
81.5 
238 1.33 
(1.03-1.71) 
4-5.5 years 66.6+ 
3453.0 
4698 1.22 
(1.01-1.48) 
1.10 
(0.89-1.35) 
63.4+ 
61.5 
216 0.93 
(0.72-1.22) 
Sensitivity analyses         
Outcome validity‡ 201.2+ 
9783.5 
1344 1.31 
(0.94-1.83) 
0.98 
(0.68-1.40) 
192.2+ 
198.0 
76 0.88 
(0.56-1.39) 
Trimmed 
population§ 
192.0+ 
9351.3 
11,071 1.39  
(1.24-1.56) 
1.13  
(1.00-1.29) 
75.4+ 
85.7 
282 0.96  
(0.76-1.21) 
Outcome shift|| 199.3+ 
9744.7 
10,462 1.36  
(1.20-1.53) 
1.17  
(1.03-1.33) 
189.7+ 
185.0 
523 1.03  
(0.87-1.22) 
No run-in period¶ 235.7+ 
11,090.8 
13,069 1.30 
(1.17-1.44) 
1.09 
(0.97-1.22) 
224.1+ 
277.3 
734 1.02 
(0.88-1.17) 
Additionally 
controlled for IMD# 
127.2+ 
6493.5 
7912 1.37  
(1.19-1.57) 
1.15  
(0.99-1.34) 
121.0+ 
125.4 
395 1.01  
(0.82-1.24) 
IMD: index of multiple deprivation, PS: propensity score, Obs.: observation, init.: initiators, non-init.: non-initiators, 
OA: osteoarthritis 
* Observation time in 1’000 person-years  
† Hazard ratio adjusted for/ PS estimation with all covariates (Table 3) 
‡ Only including hand osteoarthritis diagnoses that were preceded by diagnostic work up (MRI, radiography, 
ultrasonography) or a referral/discharge to/from a rheumatologist, orthopedist, or radiologist within 90 day before 
or after the first diagnosis 
§ Study population trimmed asymmetrically at the extreme ends of the propensity score (at the 5th percentile in 
exposed and at the 95th percentile in unexposed) 
|| hand osteoarthritis diagnoses shifted to 180 days before the initial record in the CPRD 
¶ follow-up started at day 1 instead of at day 181 
# in patients with information on index of multiple deprivation only (re-matched patient characteristics in 
Appendix 9). Index of multiple deprivation was used as an ordinal variable where quintile 1 represents least deprived 
and quintile 5 most deprived.  
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All sensitivity analyses also yielded overall null results (proportional hazard assumption did 
not hold in sensitivity analysis without run-in period as survivor functions crossed at around 
year 3 of follow-up). There was a slightly increased risk of hand OA in statin initiators with a 
follow-up of 2-3 years (1.33, 95% CI 1.03-1.71). Other subgroups (age and indication for statin 
initiation) yielded null results. Our results of the multivariable and PS-matched analyses were 
similar except in the stratum of present dyslipidemia (adjusted HR of 1.21, 1.05-1.39, matched 
HR of 1.05, 95% CI 0.88-1.25). 
The outcome generalized OA was not associated with statin initiation in the overall 
PS-matched cohort (HR 0.98, 95% CI 0.82-1.17) nor in any subgroup except for the subgroup 
of women aged 55-64 years (HR 1.31, 95% CI 1.05-1.62) [Table 6]. Results of the multivariable 
and PS-matched analyses were similar. 
Tab6. Results of the association of statin initiation and incident generalized osteoarthritis overall 
and in subgroups 
 Before PS-matching PS-matched 
 
Obs. time* 
in statin 
init. +   
non-init. 
Gener.
OA 
events  
HR  
crude  
(95% CI) 
HR  
adjusted† 
(95% CI) 
Obs. time* 
in statin 
init. +   
non-init. 
Gener.
OA 
events  
HR 
matched† 
(95% CI) 
Overall 212.5+ 
10,123.4 
6977 1.83  
(1.61-2.07) 
1.15  
(1.00-1.32) 
203.2+ 
208.1 
494 0.98 
(0.82-1.17) 
Age in years 
45-54 73.1+ 
6236.8 
3317 1.71 
(1.34-2.19) 
0.96 
(0.73-1.27) 
69.0+ 
74.7 
127 0.94 
(0.66-1.33) 
55-64 139.5+ 
3886.6 
3660 1.55  
(1.34-1.79) 
1.25  
(1.06-1.47) 
133.1+ 
132.9 
328 1.31  
(1.05-1.62) 
Indication for statin initiation 
Present 
dyslipidemia 
159.9+ 
1454.0 
1331 1.48  
(1.27-1.73) 
1.15  
(0.98-1.37) 
150.4+ 
150.6 
324 1.16  
(0.93-1.44) 
Absent 
dyslipidemia 
52.7+ 
8669.4 
5646 2.03 
(1.59-2.57) 
1.18 
(0.92-1.52) 
52.1+ 
56.0 
128 1.18 
(0.84-1.68) 
Duration of follow-up     
0-1 years 55.5+ 
2438.9 
1346 1.80  
(1.37-2.37) 
1.11 
(0.82-1.49) 
53.3+ 
56.0 
115 0.81  
(0.56-1.17) 
2-3 years 83.9+ 
4029.8 
2716 2.03  
(1.68-2.46) 
1.28 
(1.04-1.58) 
80.3+ 
85.1 
203 1.18  
(0.90-1.56) 
4-5.5 years 73.1+ 
3654.7 
2915 1.65 
(1.34-2.03) 
1.06 
(0.84-1.33) 
69.6+ 
67.1 
176 0.90  
(0.67-1.21) 
PS: propensity score, Obs.: observation, init.: initiators, non-init.: non-initiators, Gener.: generalized, OA: osteoarthritis 
* Observation time in 1’000 person-years  
† Hazard ratio adjusted for / PS estimation with all covariates (Table 3) 
 
 
The negative control outcomes psoriasis and tinnitus were neither associated with statin use 
overall nor in any subgroup (Table 7/8).  
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Tab7. Results of the association of statin initiation and incident psoriasis overall and in subgroups 
 Before PS-matching PS-matched 
 Obs. time* 
in statin 
init. +   
non-init. 
Psoria. 
events  
HR  
crude  
(95% CI) 
HR  
adjusted† 
(95% CI) 
Obs. time* 
in statin 
init. +   
non-init. 
Psoria. 
events  
HR 
matched† 
(95% CI) 
Overall 290.1+ 
11,920.7 
21,711 1.32 
(1.23-1.43) 
0.99 
(0.91-1.08) 
278.2+ 
282.9 
1270 1.04 
(0.93-1.16) 
Age in years 
45-54 90.8+ 
6954.7 
11,955 1.50 
(1.32-1.71) 
1.05 
(0.91-1.21) 
86.1+ 
92.5 
433 1.02 
(0.84-1.23) 
55-64 199.3+ 
4966.0 
9756 1.20 
(1.09-1.32) 
0.98 
(0.88-1.08) 
190.64+ 
189.1 
830 1.02 
(0.89-1.17) 
Indication for statin initiation 
Present 
dyslipidemia 
218.7+ 
1832.0 
4336 1.10 
(1.00-1.21) 
0.96 
(0.87-1.06) 
205.9+ 
204.4 
907 1.02 
(0.90-1.16) 
Absent 
dyslipidemia 
71.4+ 
10,088.8 
17,375 1.44  
(1.24-1.67) 
1.14 
(0.98-1.33) 
70.9+ 
75.3 
330 1.17 
(0.94-1.45) 
Duration of follow-up     
0-1 years 74.3+ 
2847.9 
5001 1.33 
(1.14-1.56) 
0.99 
(0.84-1.17) 
71.6+ 
75.2 
310 0.94  
(0.76-1.16) 
2-3 years 66.9+ 
2684.8 
8624 1.34  
(1.18-1.51) 
0.96  
(0.84-1.10) 
109.6+ 
115.6 
524 1.00  
(0.84-1.19) 
4-5.5 years 101.7+ 
4336.3 
8086 1.30 
(1.14-1.48) 
1.05 
(0.91-1.21) 
97.0+ 
92.1 
406 1.19 
(0.96-1.45) 
PS: propensity score, Obs.: observation, init.: initiators, non-init.: non-initiators, Psoria.: psoriasis 
* Observation time in 1’000 person-years  
† Hazard ratio adjusted for / PS estimation with all covariates (Table 3), except for hip fracture. Additionally adjusted 
for non-steroidal anti-inflammatory drugs, family history of psoriasis and history of organ transplantation 
 
 
 
 
 
 
 
Tab8. Results of the association of statin initiation and incident tinnitus overall and in subgroups 
 Before PS-matching PS-matched 
 
Obs. time* 
in statin 
init. +   
non-init. 
Tinnit. 
events  
HR  
crude  
(95% CI) 
HR  
adjusted† 
(95% CI) 
Obs. time* 
in statin 
init. +   
non-init. 
Tinnit. 
events  
HR 
matched† 
(95% CI) 
Overall 289.6+ 
11,881.1 
41,763 1.23 
(1.16-1.30) 
1.00 
(0.94-1.06) 
277.5+ 
281.8 
2351 0.97 
(0.90-1.06) 
Age in years 
45-54 91.5+ 
6969.5 
22,172 1.16 
(1.05-1.30) 
0.96 
(0.85-1.08) 
86.7+ 
92.6 
672 0.96 
(0.83-1.12) 
55-64 198.1+ 
4911.5 
19,591 1.16 
(1.09-1.24) 
1.02 
(0.95-1.10) 
189.1+ 
186.8 
1658 1.00 
(0.91-1.10) 
Indication for statin initiation 
Present 
dyslipidemia 
218.3+ 
1816.1 
8555 1.05 
(0.98-1.12) 
1.03 
(0.96-1.11) 
205.4+ 
203.6 
1798 1.02 
(0.93-1.12) 
Absent 
dyslipidemia 
71.3+ 
10,064.9 
33,208 1.07 
(0.94-1.21) 
0.95 
(0.84-1.08) 
70.7+ 
75.4 
525 0.94 
(0.79-1.12) 
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 Before PS-matching PS-matched 
 
Obs. time* 
in statin 
init. +   
non-init. 
Tinnit. 
events  
HR  
crude  
(95% CI) 
HR  
adjusted† 
(95% CI) 
Obs. time* 
in statin 
init. +   
non-init. 
Tinnit. 
events  
HR 
matched† 
(95% CI) 
Duration of follow-up     
0-1 years 74.4+ 
2847.1 
9427 1.29 
(1.15-1.44) 
1.02 
(0.90-1.15) 
71.6+ 
75.2 
601 1.00 
(0.85-1.17) 
2-3 years 114.1+ 
4724.3 
16,241 1.25 
(1.14-1.37) 
1.00 
(0.91-1.11) 
109.4+ 
115.3 
946 0.98 
(0.87-1.12) 
4-5.5 years 101.1+ 
4309.6 
16,095 1.16 
(1.06-1.28) 
0.99 
(0.89-1.10) 
96.4+ 
91.3 
804 0.94 
(0.82-1.08) 
PS: propensity score, Obs.: observation, init.: initiators, non-init.: non-initiators, Tinnit.: tinnitus 
* Observation time in 1’000 person-years  
† Hazard ratio adjusted for / PS estimation with all covariates (Table 3) except for hip fracture. Additionally adjusted 
for initiation of non-steroidal anti-inflammatory drugs and anti-depressant drugs 
3.3.3 Discussion 
In this cohort study in the UK-based CPRD between 1996 and 2015, in women aged 45 to 64, 
we assessed the association between statin initiation and hand OA and between statin 
initiation and generalized OA. We observed that statin use was neither associated with hand 
OA nor with generalized OA overall. However, compared to non-initiators, in the subgroups 
of follow-up of 2-3 years, statin initiators yielded a 33% increased risk of hand OA and in the 
subgroup of women aged 55 to 64, statin initiators yielded a 31% increased risk of generalized 
OA.  
Observed increased risks may be chance findings among the multitude of performed analyses, 
they may reflect true associations, or they may indicate residual confounding. The increased 
risks of hand OA among statin initiators with a 2-3 year follow-up was likely a chance finding 
because the proportional hazards assumption held true overall, which implies that hazards 
among statin initiators and non-initiators were sufficiently constant throughout follow-up. 
Moreover, the proportional hazard assumption in the sensitivity analysis without a run-in 
period did not hold true. The survivor functions showed a separation of hazards right at the 
start of follow-up with a lower hazard of hand OA among statin initiators and crossed in year 3 
of follow-up. The finding of this sensitivity analysis indicates that including women from day 1 
of follow-up may have introduced bias into the study as an immediate effect of statins on hand 
OA would be unlikely and early discontinuers of statins likely differ from those remaining on 
statin therapy in dyslipidemia severity for example. 
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The increased risk of generalized OA in women aged 55 to 64 years old likely indicates residual 
confounding as we observed consistently increased crude HRs for the association between 
statin initiation and generalized OA. The finding may be due to post-menopausal women 
rather having dyslipidemia than premenopausal (younger) women and that statin initiation 
may be a proxy for more severe dyslipidemia for which we could not adequately control. 
Dyslipidemia as a risk factor for hand OA may not have been either adequately controlled for 
in multivariable adjusted models yielding an increased HR of hand OA in statin initiators 
compared to non-initiators overall and with present dyslipidemia (the risk disappeared in the 
PS-matched cohort). Our results of the multivariable and PS-matched analyses were similar 
among all other subgroups and results of all sensitivity analyses supported the robustness of 
our methodology.  
It is known that the lack of a suitable active comparator group imposes several challenges 
when studying statins in large electronic databases, because non-initiators may inherently 
differ from statin initiators in ways that are not captured electronically. For example, 
maintenance of statin therapy positively correlates with increased healthcare utilization and 
positive health-related behaviour,126 whereas comorbidities predict decreased statin 
adherence.125 Furthermore, non-adherence is not possible in non-users, which can lead to 
differential censoring. To address these challenges, we introduced negative control outcomes 
to control for residual confounding by healthcare utilization (surveillance bias). Observed null 
results throughout the PS-matched cohort in both negative control outcome analyses suggest 
that surveillance bias did not play a major role in this study. Furthermore, menopause as a 
major risk factor for hand OA was likely adequately controlled for as use of HRT and SSRIs, 
osteoporosis (and hip fracture), incontinence, and dyslipidemia were balanced after 
PS-matching potentially indicating menopause. Moreover, the negative control outcome 
psoriasis did not disclose a potential differential distribution of menopause between statin 
initiators and non-initiators.  
We did not include a robust estimator in our model due to computational power restrictions, 
although women may have entered our cohort multiple times. However, inclusion of a robust 
variance estimator in overall analysis of hand OA in all statin initiators widened CIs by a 
maximum of 0.01. Pre- and post-matching c-statistics showed strongly increasing covariate 
balance with increasing levels of restriction of the study population with almost perfect 
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balance (of measured covariates) after PS-matching (c=0.54), supporting our decision to apply 
the chosen restrictions and PS matching. HRT use was already balanced among groups 
pre-matching and yielded a slightly higher percentage among non-initiators than among statin 
initiators post-matching. However, given potential confounding by menopause (statin 
initiators being more likely postmenopausal as dyslipidemia is more prevalent among 
postmenopausal women than among premenopausal women), the slight imbalance in HRT 
use would have introduced bias towards the null. Moreover, given the strict inclusion criteria 
and PS-matching applied in our study, our final study population is not population-based but 
highly restricted to maximize comparability between study groups.  
This is the first observational study evaluating the risk of hand OA in association with statin 
initiation among peri-to-postmenopausal women using a well-validated primary-care 
database and robust analytical methods. Our results suggest no effect of statins on the risk of 
hand OA in peri-to-postmenopausal women irrespective of age and pre-existing dyslipidemia. 
Additional analyses with negative control outcomes corroborate this finding.  
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4 Limitations, Conclusions, and Outlook 
4.1 Limitations 
Observational research in general is limited by the quality of the previously collected data. 
Especially information that was not previously collected can lead to unmeasured confounding 
and misclassifications which has to be considered carefully in observational epidemiology.  
When assessing HRT use, menopause, or statin use in association with hand OA, an important 
unmeasured confounder is a patient’s healthcare seeking behavior because hand OA as a 
non-emergency disease is more likely diagnosed in healthcare seekers. We tried to control for 
this confounder by controlling for the number of GP visits (prior to cohort entry), chronic 
diseases, or vaccine use (which are associated with healthy behavior). Additionally, we used 
negative control outcomes, which yielded null results throughout. A further important 
unmeasured confounder is socio-economic status which is measured as IMD. When 
controlling for quintiles of IMD in patients with information on IMD, results remained 
unchanged. Local estrogen concentrations in, for example, cartilage, bone, liver, and 
hypothalamus may be another major unmeasured confounder for which we could not control. 
However, their exact role in the etiology of postmenopausal symptoms and OA are not yet 
completely understood. Furthermore, it is unclear whether the risk factor genetic 
predisposition for hand OA (for which we could not control for either) is associated with 
postmenopausal symptoms and therefore a true confounder. Lifestyle factors as potential 
confounders such as smoking, BMI, or alcohol consumption were almost completely recorded 
among peri-to-postmenopausal women; however, stages in life such as menopause were 
inconsistently recorded. This is a limitation as menopause is a major risk factor of hand OA, is 
associated with HRT use and potentially associated with statin use. To control for menopause 
onset, we restricted large parts of the nested case-control analysis to women with recorded 
menopause. Furthermore, the CPRD contains no records of over-the-counter medicine 
including plant-based preparations frequently used to treat menopausal symptoms (e.g. black 
cohosh, red clover) or increased lipid levels (e.g. red yeast rice extract, artichoke leaf extract) 
or information on women’s diet or physical activity, which may be confounders of the 
association between HRT or statin use and hand OA. Taken together, residual confounding 
may remain but likely not to an extent that could explain our study results. 
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We see prescriptions in the CPRD (electronically issued), but we do not know if women filled 
them at the pharmacy. Therefore, we can only assume that - in case of repeated prescriptions 
- the woman filled the prescription and took the medication. Information on the prescribed 
drug quantity is recorded in the CPRD, but occasionally shows improbably low or high values. 
We imputed missing values and outliers as follows: for very low values, we assumed number 
of packages instead of drug quantity and for very high values which would allow for 
continuous drug exposure over several years by one single prescription, we put previously 
assessed default values of the most frequently prescribed supply (i.e. mode) for this drug 
product. We did the same for improbable dosages; improbably low or high values were 
replaced with the dosage mode of all prescriptions of this drug product in the CPRD. 
Furthermore, we can rarely see a woman’s full medical history in the CPRD, because they may 
not stay with a GP practice contributing data to the CPRD for their whole life. Therefore, when 
assessing first-time use of a drug, women may not have been true first-time users even though 
we required women to be present for at least 1-3 years prior to cohort entry. However, we 
presumed the number of misclassifications in drug use to be small as neither systemic HRT 
use nor statin use is often intermitted by several years. Taken together, repeated prescriptions 
likely reflect drug use and thus should have resulted only in little exposure misclassification. 
According to NICE guideline on “Osteoarthritis: care and management”, hand OA is a straight 
forward diagnosis mainly made in primary care without diagnostic testing or secondary care 
referrals. Therefore, we were not able to perform a formal validation of the hand OA outcome 
using diagnoses made in secondary care. Furthermore, feedback from secondary care into 
primary care records may be incomplete, as entries have to be entered manually, for which 
time may be sometimes lacking in a GP practice. However, results did not change meaningfully 
in sensitivity analyses with a stricter outcome definition including secondary care entries. 
Hand OA may be diagnosed early by chance or not until late when the disease has become 
debilitating. Therefore, we may have underestimated rates of incident hand OA diagnoses. 
However, a shift of the hand OA diagnosis by 180 days did not change results. Taken together, 
potential disease misclassification unlikely explains our results. 
Despite these limitations, results of conducted studies in this thesis remain meaningful and 
are an important fundament for future research concerning clinical practice in women’s 
mid-life health. 
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4.2 Conclusions 
Our aim was to identify drugs potentially delaying hand OA. Observed IRs of HRT use suggest 
that HRT initiation can be considered a proxy for menopause before age 60. We observed IRs 
of HRT use and of hand OA which both increased uniformly until age 54, the age when most 
women experienced menopause. We further observed a positive association between 
menopause and hand OA and that incident hand OA proportions were highest within the first 
year after recorded menopause and decreased with increasing time after recorded 
menopause. These results underpin the existing hypothesis that menopause is a risk factor of 
hand OA. However, IRs of hand OA only peaked in women aged 55-59 years and remained 
almost constant thereafter. This suggests that menopause is not the only risk factor for hand 
OA because otherwise we would have expected hand osteoarthritis incidence rates to decline 
similarly to incidence rates of hormone replacement therapy use among older age groups.  
Temporal trends of IRs of HRT use and hand OA could not confirm the hypothesis of a 
menopause-mediated association between HRT use and hand OA as IRs of hand OA in men 
also behaved inversely to IRs of HRT use over time. However, the decreased risk of hand OA 
in HRT users if HRT was initiated shortly before or after menopause and used continuously 
suggest that timely initiation of HRT around menopause may be crucial for a potential 
beneficial effect of HRT on hand OA. We observed consistently lower risks of hand OA in 
current HRT users than in past HRT users compared to non-users. Furthermore, we observed 
an increased risk of hand OA shortly after HRT cessation (however, statistically non-significant) 
which decreased with time between HRT cessation and hand OA which may be similar to a 
rebound effect of vasomotor symptoms after HRT cessation. These results underpin the 
hypothesis of a potential estrogen-mediated effect on joint tissue as estrogen receptors are 
present in joint tissues and estrogen was reported to inhibit TNF and MMPs involved in 
cartilage degradation. However, the existence of further potential mediators remains elusive. 
Nonetheless, HRT potentially delayed hand OA onset to after HRT cessation.  
On the other hand, given observed null results of statin use and hand OA, respectively 
generalized OA, we are not able to rule out a potential beneficial effect of statins on OA 
through lipid lowering or through direct inhibition of IL-1 and MMPs as suggested by 
preclinical studies. However, if such effects are present, they do not seem to translate into a 
clinically meaningful reduction of hand OA in peri-to-postmenopausal women. 
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4.3 Outlook 
There was a time when human life ended shortly after the reproductive period. Today, women 
live well beyond their reproductive age and are particularly affected by hormonal changes 
induced by the end of their reproductive period. Therefore, research in all aspects of this 
transition is needed, from vasomotor symptoms to mood changes, lipid level changes to 
changes in immune responses. There are few studies which have investigated serum 
concentrations of estrogen or progesterone in relation to postmenopausal symptoms. Yet, it 
is a difficult field to study because of the complex interplay between systemic factors. Notably, 
because local estrogen concentrations, dependent on estrogen receptor and aromatase 
expression, were reported to play an important role rendering serum concentrations 
meaningless. 
Observational data from medical records can be used to assess the association between HRT 
or menopause and certain outcomes. However, observational research is limited due to 
unmeasured confounding such as menopause onset, healthcare seeking behavior, and 
potentially local estrogen concentrations. Randomized controlled trials represent the gold 
standard in assessing effects of drugs but have become unethical in the field of HRT due to 
reported adverse events such as breast cancer and CVD. 
Large prospective cohorts observing women from age 40 or even earlier could contribute to 
the demystification of menopausal changes, their causes, influencing factors, and drug 
utilization and effectiveness aspects concerning postmenopausal symptoms relief. Thereby, 
hormone levels at various locations in the body as well as aromatase and estrogen receptor 
expressions could be regularly measured. Furthermore, core temperature, skin parameters, 
joint pain including imaging of affected joints, lipid levels, and serotonin levels could be 
measured, while comorbidities and drug intake could be observed as well. Smartphone 
applications could be used to collect self-reported patient information on daily symptoms, 
diet, mood, and physical activity for example. However, questions whether factors in young 
age play a role in the development of postmenopausal symptoms, or whether symptom 
severity is pre-determined by the genome through heredity remain. 
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Supplementary File 1. Detailed information on categorization of hormone therapy 
product’s estrogen dose strength 
 
Low dose (including ultra-low dose): ≤1 mg estradiol oral,1  ≤0.45 mg conjugated estrogen 
oral,1,2 ≤37.5 µg estradiol transdermal,1,2 ≤50 µg estradiol vaginal,3 ≤0.3 mg conjugated 
estrogens/≤0.5 g vaginal cream3 
Normal dose: all other than above mentioned ultra-low and low dose estrogen applications, 
injections, implants,4 and nasal applications 
1. O’Neill S, Eden J. The pathophysiology of menopausal symptoms. Obstet Gynaecol 
Reprod Med. 2014;24(12):349-356.  
2. Gynecologists TAC of O and. Practice bulletin: Clinical Management guidelines for 
obstetrician-gynecologists. Obstet Gynecol. 2014;123(1):202-216.  
3. Bachmann G, Santen RJ. Treatment of genitourinary syndrome of menopause 
(vulvovaginal atrophy). UpToDate. https://www.uptodate.com/contents/treatment-of-
genitourinary-syndrome-of-menopause-vulvovaginal-atrophy. Published 2017. 
4. Suhonen SP, Allonen HO, Lähteenmäki P. Sustained-release subdermal estradiol implants: 
A new alternative in estrogen replacement therapy. Am J Obstet Gynecol. 
1993;169(5):1248-1254.  
 
 
Supplementary File2. Numeric values corresponding to Figure1 of the main manuscript. 
Proportion of overall and new hormone therapy use in the general UK female population 
from 1996 to 2015 
 
Supplementary Table1. Annual proportion of overall and new hormone therapy use in women 
aged 40-79 years from 1996 to 2015  
Year Number of 
women with 
≥1 HT 
prescription 
Number of 
women with a 
first HT 
prescription 
Number of 
eligible 
women 
(denominator) 
Proportion of 
overall HT use [%] 
(95% CI) 
Proportion of 
new 
HT use [%] 
(95% CI) 
1996 142,712 17,349 866,426 16.5 (16.4-16.6) 2.00 (1.97-2.03) 
1997 156,954 16,378 920,447 17.1 (17.0-17.1) 1.78 (1.75-1.81) 
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1998 166,618 15,920 961,153 17.4  (17.3-17.4) 1.66 (1.63-1.68) 
1999 176,238 16,674 997,337 17.7 (17.6-17.7) 1.67 (1.65-1.70) 
2000 189,535 17,994 1,030,248 18.4 (18.3-18.5) 1.75 (1.72-1.77) 
2001 197,061 17,559 1,061,319 18.6 (18.5-18.6) 1.65 (1.63-1.68) 
2002 197,017 15,094 1,090,053 18.1 (18.0-18.1) 1.38 (1.36-1.41) 
2003 168,813 10,881 1,111,530 15.2 (15.1-15.3) 0.98 (0.96-1.00) 
2004 135,698 10,740 1,135,903 11.9 (11.9-12.0) 0.95 (0.93-0.96) 
2005 119,158 9536 1,153,660 10.3 (10.3-10.4) 0.83 (0.81-0.84) 
2006 110,535 10,056 1,170,919 9.4 (9.4-9.5) 0.86 (0.84-0.88) 
2007 105,387 10,377 1,178,555 8.9 (8.9-9.0) 0.88 (0.86-0.90) 
2008 100,254 10,728 1,173,476 8.5 (8.5-8.6) 0.91 (0.90-0.93) 
2009 96,596 10,817 1,168,740 8.3 (8.2-8.3) 0.93 (0.91-0.94) 
2010 92,779 11,135 1,149,867 8.1 (8.0-8.1) 0.97 (0.95-0.99) 
2011 88,258 11,123 1,122,420 7.9 (7.8-7.9) 0.99 (0.98-1.01) 
2012 84,319 10,992 1,091,857 7.7 (7.7-7.8) 1.01 (0.99-1.03) 
2013 80,194 10,465 1,051,561 7.6 (7.6-7.7) 1.00 (0.98-1.01) 
2014 73,767 9893 961,973 7.7 (7.6-7.7) 1.03 (1.01-1.05) 
2015 61,948 8335 821,080 7.5 (7.5-7.6) 1.02 (0.99-1.04) 
HT: hormone therapy, CI: confidence interval 
 
Supplementary File3. Proportion of new hormone therapy use in the general UK female 
population within 2-year blocks stratified by age groups  
 
 
 
Supplementary Table2. Proportion of new hormone therapy use in women aged 40-79 years in 
2-year blocks stratified by age groups 
Years Age group 
[years] 
Number of women with 
a first HT prescription 
Number of eligible 
women 
(denominator) 
Proportion of new 
HT use [%]   
(95% CI) 
1996/1997 40-49  13633 317,311 4.30 (4.23-4.38) 
 50-59  12363 246,725 5.01 (4.93-5.10) 
 60-69  4846 207,305 2.34 (2.27-2.40) 
 70-79  2885 187,456 1.54 (1.48-1.60) 
1998/1999 40-49  12482 338,418 3.69 (3.63-3.75) 
 50-59  12803 282,693 4.53 (4.45-4.61) 
 60-69  4301 221,352 1.94 (1.89-2.00) 
 70-79  3008 203,331 1.48 (1.43-1.53) 
2000/2001 40-49  13254 369,282 3.59 (3.53-3.65) 
 50-59  14948 310,893 4.81 (4.73-4.88) 
 60-69  4261 231,940 1.84 (1.78-1.89) 
 70-79  3090 207,381 1.49 (1.44-1.54) 
2002/2003 40-49  9888 399,048 2.48 (2.43-2.53) 
 50-59  10487 329,125 3.19 (3.13-3.25) 
 60-69  3168 241,123 1.31 (1.27-1.36) 
 70-79  2432 206,566 1.17 (1.13-1.22) 
2004/2005 40-49 7514 424,528 1.77 (1.73-1.81) 
 50-59  7955 335,495 2.37 (2.32-2.42) 
 60-69  2632 254,903 1.03 (0.99-1.07) 
 70-79  2175 204,582 1.06 (1.02-1.11) 
2006/2007 40-49  7454 442,125 1.69 (1.65-1.72) 
 50-59  8497 336,421 2.53 (2.47-2.58) 
 60-69  2442 269,653 0.91 (0.87-0.94) 
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 70-79  2040 205,029 1.00 (0.95-1.04) 
2008/2009 40-49  7265 439,834 1.65 (1.61-1.69) 
 50-59  9481 323,052 2.93 (2.88-2.99) 
 60-69  2619 280,409 0.93 (0.90-0.97) 
 70-79  2180 200,948 1.08 (1.04-1.13) 
2010/2011 40-49  7010 424,954 1.65 (1.61-1.69) 
 50-59  10186 316,770 3.22 (3.15-3.28) 
 60-69  3113 280,325 1.11 (1.07-1.15) 
 70-79  1949 193,760 1.01 (0.96-1.05) 
2012/2013 40-49  6537 391,104 1.67 (1.63-1.71) 
 50-59  10434 306,591 3.40 (3.34-3.47) 
 60-69  2734 268,016 1.02 (0.98-1.06) 
 70-79  1752 183,506 0.95 (0.91-1.00) 
2014/2015 40-49  5120 321,621 1.59 (1.55-1.64) 
 50-59  9334 275,982 3.38 (3.32-2.45) 
 60-69  2343 234,920 1.00 (0.96-1.04) 
 70-79  1431 169,694 0.84 (0.80-0.89) 
HT: hormone therapy, CI: confidence interval 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure1. Proportion of new hormone therapy use in women aged 40-79 years in 
2-year blocks stratified by age groups 
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Supplementary File 4. Index of multiple deprivation of hormone therapy users and 
non-users in quintiles from 1996/1997 to 2014/2015 
 
Supplementary Table3. Proportion of index of multiple deprivation (IMD) of hormone therapy users 
and non-users in quintiles over time where IMD=1 equals “least deprived” and IMD=5 equals “most 
deprived” 
Years Exposure 
status 
Number of 
women 
with 
IMD=1 
(%) 
Number of 
women 
with 
IMD=2 
(%) 
Number of 
women 
with 
IMD=3 
(%) 
Number of 
women 
with 
IMD=4 
(%) 
Number of 
women 
with 
IMD=5 
(%) 
Number of 
women with 
missing 
information 
on IMD (%) 
1996/ 
1997 
HT users 30,535 
(17.0) 
29,126 
(16.2) 
23,807 
(13.2) 
18,557 
(10.3) 
13,193 
(7.3) 
64,816 
(36.0) 
Non-users 109,201 
(14.0) 
116,281 
(14.9) 
101,181 
(13.0) 
89,163 
(11.5) 
69,092 
(8.9) 
293,845 
(37.7) 
1998/ 
1999 
HT users 34,328 
(16.9) 
32,978 
(16.2) 
27,238 
(13.4) 
21,122 
(10.4) 
14,971 
(7.4) 
72,822 
(35.8) 
Non-users 119,223 
(14.2) 
126,592 
(15.0) 
108,946 
(12.9) 
96,153 
(11.4) 
73.099 
(8.7) 
318,322 
(37.8) 
2000/ 
2001 
HT users 37,677 
(16.7) 
36,205 
(16.0) 
30,177 
(13.3) 
23,899 
(10.6) 
16,186 
(7.2) 
82,032 
(36.3) 
Non-users 127,601 
(14.3) 
133,919 
(15.0) 
113,860 
(12.8) 
101,157 
(11.3) 
75,664 
(8.5) 
341,119 
(38.2) 
2002/ 
2003 
HT users 35,646 
(16.3) 
35,264 
(16.1) 
29,053 
(13.3) 
23,200 
(10.6) 
15,474 
(7.1) 
80,245 
(36.7) 
Non-users 138,434 
(14.5) 
143,311 
(15.0) 
122,233 
(12.8) 
108,876 
(11.4) 
80,368 
(8.4) 
363,758 
(38.0) 
2004/ 
2005 
HT users 25,343 
(16.2) 
25,492 
(16.3) 
20,806 
(13.3) 
16,517 
(10.6) 
11,192 
(7.2) 
56,963 
(36.4) 
Non-users 156,999 
(14.8) 
161,155 
(15.2) 
137,139 
(12.9) 
121,454 
(11.4) 
88,727 
(8.4) 
397,630 
(37.4) 
2006/ 
2007 
HT users 22,135 
(16.7) 
22,164 
(16.7) 
17,946 
(13.5) 
13,914 
(10.5) 
9039 
(6.8) 
47,426 
(35.8) 
Non-users 167,970 
(15.0) 
171,561 
(15.3) 
145,437 
(13.0) 
128,139 
(11.4) 
93,847 
(8.4) 
413,650 
(36.9) 
2008/ 
2009 
HT users 20,719 
(17.2) 
20,757 
(17.2) 
16,294 
(13.5) 
12,549 
(10.4) 
8159 
(6.8) 
42,256 
(35.0) 
Non-users 172,410 
(15.4) 
173,733 
(15.5) 
146,961 
(13.1) 
130,838 
(11.7) 
96,526 
(8.6) 
403,041 
(35.9) 
2010/ 
2011 
HT users 20,185 
(17.9) 
19,495 
(17.3) 
15,197 
(13.5) 
11,435 
(10.2) 
7392 
(6.6) 
389,932 
(34.6) 
Non-users 174,372 
(15.8) 
170,780 
(15.5) 
143,214 
(13.0) 
127,124 
(11.5) 
94,081 
(8.5) 
393,602 
(35.7) 
2012/ 
2013 
HT users 18,008 
(17.5) 
17,004 
(16.5) 
13,623 
(13.3) 
10,144 
(9.9) 
6497 
(6.3) 
37,545 
(36.5) 
Non-users 162,427 
(15.5) 
155,261 
(14.8) 
134,053 
(12.8) 
120,324 
(11.5) 
88,633 
(8.5) 
385,698 
(36.9) 
2014/ 
2015 
HT users 15,167 
(17.4) 
13,263 
(15.2) 
10,314 
(11.8) 
7889 
(9.0) 
4733 
(5.4) 
36,047 
(41.2) 
Non-users 139,685 
(15.3) 
127,573 
(14.0) 
106,929 
(11.7) 
98,653 
(10.8) 
71,467 
(7.8) 
370,497 
(40.5) 
IMD: index of multiple deprivation, HT: hormone therapy 
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Supplementary Figure2. Prevalence of index of multiple deprivation (IMD) of hormone therapy users 
and non-users in fifths over time where IMD=1 equals “least deprived” and IMD=5 equals “most 
deprived”  
IMD: index of multiple deprivation, HT: hormone therapy 
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Supplementary File5. Graphs corresponding to Table1 of the main manuscript. Main 
patient characteristics of hormone therapy users and non-users from 1996/1997 to 
2014/2015 
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Supplementary Figure3. Mean age among hormone therapy users and 
non-users in the general UK female population from 1996/1997 to 
2014/2015 
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Supplementary Figure4. Mean number of general practitioners contacts 
among hormone therapy users and non-users in the general UK female 
population from 1996/1997 to 2014/2015 
HT: hormone therapy 
 
Appendix 1 
84 
 
0
2.5
5
7.5
10
P
re
va
le
n
ce
 [
%
]
Prev. of CVD among HT users
Prev. of CVD among non-users
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
1
2
3
4
5
P
re
va
le
n
ce
 [
%
]
 Prev. of breast cancer among HT users
 Prev. of breast cancer among non-users
Supplementary Figure5. Prevalence of breast cancer among hormone 
therapy users and in the general UK female population from 1996/1997 to 
2014/2015 
HT: hormone therapy 
 
Supplementary Figure6. Prevalence of cardiovascular disease among 
hormone therapy users and non-users in the general UK female population 
from 1996/1997 to 2014/2015 
CVD: cardiovascular disease, HT: hormone therapy 
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Supplementary File6. Descriptive analytics of characteristics comprised in the definition of 
cardiovascular disease and cardiovascular risk factors of hormone therapy users and non-
users from 1996/1997 to 2014/2015 
 
Supplementary Table4. Descriptive analytics of characteristics comprised in the definition of 
cardiovascular disease and cardiovascular risk factors of hormone therapy users and non-users from 
1996/1997 to 2014/2015 
Exp. 
Stat. 
Years No. of 
women 
MI (%) Isch.  
stroke 
(%) 
AP 
(%) 
Curr.  
Smok. 
(%) 
Obesitya 
(%) 
Hypertens. 
(%) 
Hyperlip. 
(%) 
Diab. 
(%) 
HT 
users 
96/97 180,034 2014 
(1.1) 
2466 
(1.4) 
6347 
(3.5) 
40,690 
(22.6) 
26,358 
(14.6) 
29,144 
(16.2) 
9285 
 (5.2) 
3798 
(2.1) 
 98/99 203,459 2420 
(1.2) 
3092 
(1.5) 
7375 
(3.6) 
47,022 
(23.1) 
31,606 
(15.5) 
36,683 
(18.0) 
11,360 
(5.6) 
4964 
(2.4) 
 00/01 226,176 2788 
(1.2) 
3850 
(1.7) 
8290 
(3.7) 
52,162 
(23.1) 
37,662 
(16.7) 
46,291 
(20.5) 
14,122 
(6.2) 
6630 
(2.9) 
 02/03 218,882 3003 
(1.4) 
4068 
(1.9) 
8279 
(3.8) 
49,305 
(22.5) 
39,712 
(18.1) 
51,524 
(23.5) 
17,223 
(7.9) 
7726 
(3.5) 
 04/05 156,313 2095 
(1.3) 
2868 
(1.8) 
5382 
(3.4) 
33,655 
(21.5) 
30,088 
(19.3) 
39,327 
(25.2) 
15,714 
(10.1) 
6207 
(4.0) 
 06/07 132,624 1711 
(1.3) 
2421 
(1.8) 
4117 
(3.1) 
25,432 
(19.2) 
27,305 
(20.6) 
33,657 
(25.4) 
15,727 
(11.8) 
5671 
(4.3) 
 08/09 120,734 1480 
(1.2) 
2336 
(1.9) 
3402 
(2.8) 
21,834 
(18.1) 
26,651 
(22.1) 
30,926 
(25.6) 
16,213 
(13.4) 
5510 
(4.6) 
 10/11 112,636 1377 
(1.2) 
2240 
(2.0) 
2833 
(2.5) 
18,985 
(16.9) 
25,730 
(22.8) 
28,522 
(25.3) 
16,013 
(14.2) 
5541 
(4.9) 
Supplementary Figure7. Prevalence of ≥1 cardiovascular risk factor among 
hormone therapy users and non-users in the general UK female population 
from 1996/1997 to 2014/2015 
Prev.: prevalence, CVD: cardiovascular disease, HT: hormone therapy 
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Supplementary Figure8. Prevalence of myocardial infarction among 
hormone therapy users and non-users in the general UK female 
population from 1996/1997 to 2014/2015 
Prev.: prevalence, HT: hormone therapy 
 
 12/13 102,821 1232 
(1.2) 
2188 
(2.1) 
2269 
(2.2) 
15,684 
(15.3) 
24,086 
(23.4) 
26,356 
(25.6) 
15,701 
(15.3) 
5377 
(5.2) 
 14/15 87,413 931 
(1.1) 
1859 
(2.1) 
1777 
(2.0) 
12,083 
(13.8) 
21,286 
(24.4) 
22,165 
(25.4) 
13,765 
(15.8) 
4878 
(5.6) 
Non-
users 
96/97 778,763 15,104 
(2.0) 
21,337 
(2.7) 
35,48
2 (4.6) 
139,110 
(17.9) 
112,697 
(14.5) 
146,515 
(18.8) 
32,603 
(4.2) 
30,047 
(3.9) 
 98/99 842,335 16,748 
(2.0) 
24,255 
(2.9) 
38,56
7 (4.6) 
155,7761 
(18.5) 
132,249 
(15.7) 
167,330 
(19.9) 
41,706 
(5.0) 
35,718 
(4.2) 
 00/01 893,320 17,772 
(2.0) 
25,930 
(2.9) 
40,54
8 (4.5) 
170,385 
(19.1) 
154,328 
(17.3) 
191,346 
(21.4) 
53,438 
(6.0) 
42,778 
(4.8) 
 02/03 956,980 18,621 
(2.0) 
27,374 
(2.9) 
41,28
8 (4.3) 
185,352 
(19.4) 
185,253 
(19.4) 
220,926 
(23.1) 
71,060 
(7.4) 
51,594 
(5.4) 
 04/05 1,063,195 19,959 
(1.9) 
29,493 
(2.8) 
41,10
5 (3.9) 
203,615 
(19.2) 
228,243 
(21.5) 
266,930 
(25.1) 
102,465 
(9.6) 
62,521 
(5.9) 
 06/07 1,120,604 20,081 
(1.8) 
30,067 
(2.7) 
38,72
1 (3.5) 
207,450 
(18.5) 
268,916 
(24.0) 
290,455 
(25.9) 
125,602 
(11.2) 
70,511 
(6.3) 
 08/09 1,123,509 19,136 
(1.7) 
29,613 
(2.6) 
34,48
2 (3.1) 
205,485 
(18.3) 
289,924 
(25.8) 
294,113 
(26.2) 
138,096 
(12.2) 
75,350 
(6.7) 
 10/11 1,103,173 17,842 
(1.6) 
28,964 
(2.6) 
29,70
6 (2.7) 
198,000 
(18.0) 
299,893 
(27.2) 
288,028 
(26.1) 
144,054 
(13.1) 
78,058 
(7.1) 
 12/13 1,046,396 16,278 
(1.6) 
27,574 
(2.6) 
25,08
9 (2.4) 
178,119 
(17.0) 
294,418 
(28.1) 
275,668 
(26.3) 
146,115 
(14.0) 
78,523 
(7.5) 
 14/15 914,804 13,879 
(1.5) 
24,582 
(2.7) 
20,06
0 (2.2) 
146,214 
(16.0) 
266,759 
(26.2) 
243,424 
(26.6) 
135,732 
(14.8) 
71,742 
(7.8) 
Exp.: exposure, Stat. : status, HT: hormone therapy, No. : number, MI: myocardial infarction, Isch.: ischemic,  
AP: angina pectoris, Curr.: current, smok.: smoking, hypertens.: hypertension, hyperlip.: hyperlipidemia,  
diab.: diabetes 
a Obesity was defined as BMI >30 kg/m2 or a Read Code for obesity 
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Supplementary Figure9. Prevalence of ischaemic stroke among 
hormone therapy users and non-users in the general UK female 
population from 1996/1997 to 2014/2015 
Prev.: prevalence, HT: hormone therapy 
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Supplementary Figure10. Prevalence of angina pectoris among 
hormone therapy users and non-users in the general UK female 
population from 1996/1997 to 2014/2015 
Prev.: prevalence, HT: hormone therapy 
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Supplementary Figure11. Prevalence of current smokers among 
hormone therapy users and non-users in the general UK female 
population from 1996/1997 to 2014/2015 
Prev.: prevalence, HT: hormone therapy 
 
Supplementary Figure12. Prevalence of obesity among hormone 
therapy users and non-users in the general UK female population 
from 1996/1997 to 2014/2015 
Prev.: prevalence, HT: hormone therapy 
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Supplementary Figure13. Prevalence of hypertension among 
hormone therapy users and non-users in the general UK female 
population from 1996/1997 to 2014/2015 
Prev.: prevalence, HT: hormone therapy 
 
Supplementary Figure14. Prevalence of hyperlipidemia among 
hormone therapy users and non-users in the general UK female 
population from 1996/1997 to 2014/2015 
Prev.: prevalence, HT: hormone therapy 
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Supplementary File7. Hormone therapy use in the general UK female population and 
sub-populations with breast cancer, cardiovascular disease, and cardiovascular disease risk 
factors 
 
Supplementary Table5. Hormone therapy use in UK general practice and sub-populations with 
breast cancer, cardiovascular disease, and cardiovascular risk factors 
Years HT users in the 
general UK female 
population (%) 
HT users in the 
breast cancer 
population (%) 
HT users in the 
CVD population 
(%) 
HT users in the 
population with  
≥1 cardiovascular 
risk factors (%) 
1996/1997 180,034 (18.8) 1633 (8.5) 9130 (13.3) 97,189 (20.2) 
1998/1999 203,459 (19.5) 1999 (8.7) 10,799 (14.1) 114,983 (20.9) 
2000/2001 226,176 (20.2) 2449 (9.1) 12,449 (15.3) 135,204 (21.6) 
2002/2003 218,882 (18.6) 2780 (9.1) 12,693 (15.2) 139,837 (20.0) 
2004/2005 156,313 (12.8) 2380 (6.8) 8591 (10.5) 105,207 (13.6) 
2006/2007 132,624 (10.6) 2289 (6.0) 6862 (8.6) 90,398 (11.0) 
2008/2009 120,734 (9.7) 2214 (5.5) 6050 (8.1) 82,955 (10.0) 
2010/2011 112,636 (9.3) 2102 (5.1) 5441 (7.9) 77,106 (9.4) 
2012/2013 102,821 (8.9) 2066 (5.0) 4852 (7.8) 70,899 (9.0) 
2014/2015 87,413 (8.7) 1651 (4.4) 3993 (7.4) 60,487 (8.7) 
HT: hormone therapy, CVD: cardiovascular disease 
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Supplementary Figure15. Prevalence of diabetes among hormone 
therapy users and non-users in the general UK female population 
from 1996/1997 to 2014/2015 
Prev.: prevalence, HT: hormone therapy 
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Supplementary File8. Numeric values corresponding to Figure2 of the main manuscript. 
Proportion of use of different hormone therapy drug types over time in A) the 
cardiovascular disease and breast cancer sub-populations and B) the general UK female 
population  
 
Supplementary Table6. Hormone therapy use in the general UK female population stratified by drug 
type from 1996/1997 to 2014/2015 
Years Number of ET 
users (%) 
Number of EPT 
users (%) 
Number of tibolone 
users (%) 
Number of mixed 
users (%) 
1996/1997 80,813 (8.4) 83,477 (8.7) 7857 (0.8) 7887 (0.8) 
1998/1999 90,758 (8.7) 94,338 (9.0) 9536 (0.9) 8827 (0.8) 
2000/2001 99,181 (8.9) 104,990 (9.4) 11,709 (1.1) 10,296 (0.9) 
2002/2003 99,269 (8.4) 95,701 (8.1) 13,166 (1.1) 10,746 (0.9) 
2004/2005 84,353 (6.9) 55,999 (4.6) 9434 (0.8) 6527 (0.5) 
2006/2007 77,315 (6.2) 42,908 (3.4) 6970 (0.6) 5431 (0.4) 
2008/2009 74,362 (6.0) 36,210 (2.9) 5482 (0.4) 4680 (0.4) 
2010/2011 71,780 (5.9) 31,979 (2.6) 4354 (0.4) 4523 (0.4) 
2012/2013 66,575 (5.8) 28,688 (2.5) 3482 (0.3) 4076 (0.4) 
2014/2015 56,290 (5.6) 25,015 (2.5) 2640 (0.3) 3468 (0.4) 
ET: estrogen therapy, EPT: estrogen plus progestogen therapy 
Supplementary Table7. Hormone therapy use in cardiovascular disease patients stratified by drug 
type from 1996/1997 to 2014/2015 
Years Number of ET 
users (%) 
Number of EPT 
users (%) 
Number of tibolone or 
mixed users (%) 
1996/1997 5541 (8.1) 2765 (4.0) 824 (1.2) 
1998/1999 6455 (8.5) 3359 (4.4) 985 (1.3) 
2000/2001 7342 (9.0) 3869 (4.8) 1238 (1.5) 
2002/2003 7585 (9.1) 3758 (4.5) 1350 (1.6) 
2004/2005 5913 (7.2) 1907 (2.3) 771 (0.9) 
2006/2007 5178 (6.5) 1175 (1.5) 509 (0.6) 
2008/2009 4847 (6.5) 856 (1.2) 347 (0.5) 
2010/2011 4474 (6.5) 695 (1.0) 272 (0.4) 
2012/2013 4055 (6.5) 603 (1.0) 194 (0.3) 
2014/2015 3285 (6.2) 474 (0.9) 174 (0.3) 
ET: estrogen therapy, EPT: estrogen plus progestogen therapy 
Supplementary Table8. Hormone therapy use in breast cancer patients stratified by drug type from 
1996/1997 to 2014/2015 
Years Number of ET 
users (%) 
Number of EPT 
users (%) 
Number of tibolone or 
mixed users (%) 
1996/1997 984 (5.1) 531 (2.8) 118 (0.6) 
1998/1999 1153 (5.0) 682 (3.0) 164 (0.7) 
2000/2001 1378 (5.1) 812 (3.0) 259 (1.0) 
2002/2003 1570 (5.1) 894 (2.9) 316 (1.0) 
2004/2005 1583 (4.6) 556 (1.6) 241 (0.7) 
2006/2007 1677 (4.4) 422 (1.1) 190 (0.5) 
2008/2009 1713 (4.3) 364 (0.9) 137 (0.3) 
2010/2011 1673 (4.0) 308 (0.7) 121 (0.3) 
2012/2013 1676 (4.1) 290 (0.7) 100 (0.2) 
2014/2015 1370 (3.6) 220 (0.6) 61 (0.2) 
ET: estrogen therapy, EPT: estrogen plus progestogen therapy 
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Supplementary File9. Numeric values corresponding to Figure3 of the main manuscript. 
Proportion of use of different hormone therapy administration routes over time in A) the 
cardiovascular disease breast cancer sub-populations and B) the general UK female 
population  
 
Supplementary Table9. Hormone therapy use in the general UK female population stratified by 
administration route from 1996/1997 to 2014/2015 
Years Number of oral 
HT users (%) 
Number of 
vaginal HT 
users (%) 
Number of 
transdermal HT 
users (%) 
Number of 
othera HT 
users (%) 
Number of 
mixed users 
(%) 
1996/1997 117,698 (12.3) 18,536 (1.9) 26,779 (2.8) 1397 (0.2) 15,624 (1.6) 
1998/1999 134,890 (12.9) 19,735 (1.9) 31,122 (3.0) 1586 (0.2) 16,126 (1.5) 
2000/2001 152,759 (13.7) 21,693 (1.9) 33,557 (3.0) 1447 (0.1) 16,720 (1.5) 
2002/2003 145,467 (12.4) 23,485 (2.0) 32,620 (2.8) 1379 (0.1) 15,931 (1.4) 
2004/2005 92,859 (7.6) 29,905 (2.5) 22,675 (1.9) 930 (0.1) 9944 (0.8) 
2006/2007 71,523 (5.7) 34,227 (2.7) 17,840 (1.4) 550 (0.0) 8484 (0.8) 
2008/2009 60,172 (4.8) 37,718 (3.0) 14,928 (1.2) 353 (0.0) 7563 (0.6) 
2010/2011 51,894 (4.3) 40,296 (3.3) 13,113 (1.1) 145 (0.0) 7188 (0.6) 
2012/2013 44,880 (3.9) 40,293 (3.5) 11,209 (1.0) N/Ab 6435 (0.6) 
2014/2015 37,242 (3.7) 34,998 (3.5) 9680 (1.0) N/Ab 5492 (0.6) 
HT: hormone therapy 
a other hormone therapy use includes injections, implants, and nasal administrations 
b N/A: not applicable as cell counts <5 are not reportable due to Medicines and Healthcare products Regulatory 
Agency (MHRA) regulations 
 
 
Supplementary Table10. Hormone therapy use in cardiovascular disease patients stratified by 
administration route from 1996/1997 to 2014/2015 
Years Number of 
oral HT users 
(%) 
Number of vaginal 
HT users (%) 
Number of 
transdermal HT users 
(%) 
Number of othera 
HT or mixed users 
(%) 
1996/1997 4820 (7.0) 2287 (3.3) 1262 (1.8) 761 (1.1) 
1998/1999 5930 (7.8) 2447 (3.2) 1591 (2.1) 831 (1.1) 
2000/2001 7135 (8.8) 2648 (3.3) 1813 (2.2) 853 (1.1) 
2002/2003 7314 (8.8) 2674 (3.2) 1869 (2.2) 836 (1.0) 
2004/2005 4148 (5.1) 2805 (3.4) 1173 (1.4) 465 (0.6) 
2006/2007 2664 (3.4) 3049 (3.8) 815 (1.0) 334 (0.4) 
2008/2009 1967 (2.6) 3176 (4.3) 623 (0.8) 284 (0.4) 
2010/2011 1552 (2.3) 3113 (4.5) 538 (0.8) 238 (0.3) 
2012/2013 1282 (2.1) 2956 (4.7) 421 (0.7) 193 (0.3) 
2014/2015 954 (1.8) 2457 (4.6) 345 (0.7) 177 (0.3) 
HT: hormone therapy 
a other hormone therapy use includes injections, implants, and nasal administrations 
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Supplementary Table11. Hormone therapy in breast cancer patients stratified by administration 
route from 1996/1997 to 2014/2015 
Years Number of 
oral HT users 
(%) 
Number of vaginal 
HT users (%) 
Number of 
transdermal HT users 
(%) 
Number of othera 
HT or mixed users 
(%) 
1996/1997 778 (4.0) 556 (2.9) 195 (1.0) 104 (0.5) 
1998/1999 970 (4.2) 671 (2.9) 233 (1.0) 125 (0.6) 
2000/2001 1247 (4.7) 808 (3.0) 270 (1.0) 124 (0.5) 
2002/2003 1408 (4.6) 940 (3.1) 294 (1.0) 138 (0.5) 
2004/2005 957 (2.8) 1110 (3.2) 226 (0.7) 87 (0.3) 
2006/2007 730 (1.9) 1284 (3.4) 193 (0.5) 82 (0.2) 
2008/2009 594 (1.5) 1381 (3.4) 172 (0.4) 67 (0.2) 
2010/2011 501 (1.2) 1404 (3.4) 138 (0.3) 59 (0.1) 
2012/2013 466 (1.1) 1379 (3.3) 152 (0.4) 69 (0.2) 
2014/2015 294 (0.8) 1175 (3.1) 135 (0.4) 47 (0.1) 
HT: hormone therapy 
a other hormone therapy use includes injections, implants, and nasal administrations 
 
 
 
Supplementary File10. Numeric values corresponding to Figure4 of the main manuscript. 
Proportion of use of different hormone therapy doses over time in A) the cardiovascular 
disease and breast cancer sub-populations and B) the general UK female population 
 
Supplementary Table12. Hormone therapy use in the general UK female population stratified by 
dose from 1996/1997 to 2014/2015 
Years Number of 
normal dose HT 
users (%) 
Number of 
low dose HT 
users (%) 
Number of 
mixed  dose 
users (%) 
1996/1997 149,909 (15.6) 11,786 (1.2) 18,339 (1.9) 
1998/1999 165,331 (15.8) 16,368 (1.6) 21,760 (2.1) 
2000/2001 176,053 (15.7) 22,729 (2.0) 27,394 (2.5) 
2002/2003 162,046 (13.8) 26,674 (2.3) 30,162 (2.6) 
2004/2005 104,445 (8.6) 27,655 (2.3) 24,213 (2.0) 
2006/2007 79,159 (6.3) 30,294 (2.4) 23,171 (1.9) 
2008/2009 69,728 (5.6) 32,455 (2.6) 18,551 (1.5) 
2010/2011 59,273 (4.9) 35,740 (2.9) 17,623 (1.5) 
2012/2013 51,602 (4.5) 35,795 (3.1) 15,424 (1.3) 
2014/2015 41,403 (4.1) 32,622 (3.3) 13,388 (1.3) 
HT: hormone therapy 
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Supplementary Table13. Hormone therapy in cardiovascular disease patients stratified by dose from 
1996/1997 to 2014/2015 
Years Number of 
normal dose HT 
users (%) 
Number of 
low dose HT 
users (%) 
Number of 
mixed  dose 
users (%) 
1996/1997 7458 (10.8) 683 (1.0) 989 (1.4) 
1998/1999 8724 (11.4) 928 (1.2) 1147 (1.5) 
2000/2001 9777 (12.0) 1216 (1.5) 1456 (1.8) 
2002/2003 9584 (11.5) 1479 (1.8) 1630 (2.0) 
2004/2005 5938 (7.2) 1415 (1.7) 1238 (1.5) 
2006/2007 4334 (5.5) 1516 (1.9) 1012 (1.3) 
2008/2009 3702 (5.0) 1623 (2.2) 725 (1.0) 
2010/2011 2937 (4.3) 1757 (2.5) 747 (1.1) 
2012/2013 2465 (3.9) 1765 (2.8) 622 (1.0) 
2014/2015 1891 (3.5) 1551 (2.9) 491 (0.9) 
HT: hormone therapy 
Supplementary Table14. Hormone therapy in breast cancer patients stratified by dose from 
1996/1997 to 2014/2015 
Years Number of 
normal dose HT 
users (%) 
Number of 
low dose HT 
users (%) 
Number of 
mixed  dose 
users (%) 
1996/1997 1329 (6.9) 149 (0.8) 155 (0.8) 
1998/1999 1617 (7.1) 209 (0.9) 173 (0.8) 
2000/2001 1837 (6.9) 337 (1.3) 275 (1.0) 
2002/2003 2002 (6.5) 436 (1.4) 342 (1.1) 
2004/2005 1563 (4.5) 483 (1.4) 334 (1.0) 
2006/2007 1383 (3.6) 593 (1.6) 313 (0.8) 
2008/2009 1271 (3.2) 690 (1.7) 253 (0.6) 
2010/2011 1079 (2.6) 783 (1.9) 240 (0.6) 
2012/2013 1030 (2.5) 806 (2.0) 230 (0.6) 
2014/2015 754 (2.0) 721 (1.9) 176 (0.5) 
HT: hormone therapy 
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Supplementary File11. Proportion of hormone therapy use stratified by drug type, 
administration route and dose in the breast cancer sub-population  
 
Supplementary Table15. Hormone therapy use stratified by drug type, administration route and 
dose in the breast cancer sub-population from 1996/1997 to 2014/2015 
   Number of women (%) 
Drug 
type 
Adm. 
route 
Dose 96/97 98/99 00/01 02/03 04/05 06/07 08/09 10/11 12/13 14/15 
EPT Oral Low 23 (0.12) 29 (0.13) 45 (0.17) 62 (0.20) 52 (0.15) 51 (0.13) 62 (0.15) 62 (0.15) 55 (0.13) 41 (0.11) 
Norm. 426 
(2.21) 
556 
(2.43) 
656 
(2.45) 
709 
(2.31) 
420  
(1.21) 
281 
(0.74) 
232 
(0.58) 
189 
(0.46) 
176 
(0.43) 
124 
(0.33) 
Mixed 20 (0.10) 14 (0.06) 27 (0.10) 24 (0.08) 24 (0.07) 41 (0.11) 28 (0.07) 18 (0.04) 21 (0.05) 16 (0.04) 
Trans Low N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 
Norm. 43 (0.22) 59 (0.26) 61 (0.23) 81 (0.26) 54 (0.16) 38 (0.10) 36 (0.09) 38 (0.09) 36 (0.09) 32 (0.08) 
Mixed N/Ab N/Ab N/Ab N/Ab N/Ab 5 (0.01) N/Ab N/Ab N/Ab N/Ab 
Vag. Low N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 
Norm. N/Ab 5 (0.02) 6 (0.02) 5 (0.02) N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 
Mixed N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 
Other
a/ 
mixed 
use 
Low N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 5 (0.01) 
Norm. 36 (0.19) 47 (0.21) 45 (0.17) 45 (0.15) 18 (0.05) 18 (0.05) 13 (0.03) 11 (0.03) 13 (0.03) 9 (0.02) 
Mixed 17 (0.09) 12 (0.05) 14 (0.05) 16 (0.05) 9 (0.03) 21 (0.05) 14 (0.03) 16 (0.04) 18 (0.04) 9 (0.02) 
ET Oral Low 25 (0.13) 30 (0.13) 58 (0.22) 64 (0.21) 58 (0.13) 49 (0.13) 49 (0.12) 56 (0.14) 62 (0.15) 33 (0.09) 
Norm. 203  
(1.06) 
231  
(1.01) 
265 
(0.99) 
301 
(0.98) 
191  
(0.38) 
145 
(0.38) 
113 
(0.28) 
86  
(0.21) 
86  
(0.21) 
36 
 (0.10) 
Mixed 6 (0.03) 6 (0.03) 6 (0.02) 9 (0.03) 14 (0.04) 17 (0.04) 8 (0.02) 6 (0.01) 8 (0.02) 11 (0.03) 
Trans Low 21 (0.11) 20 (0.09) 24 (0.09) 33 (0.11) 25 (0.07) 30 (0.08) 28 (0.07) 26 (0.06) 31 (0.08) 22 (0.06) 
Norm. 120 
(0.62) 
142  
(0.62) 
169 
(0.63) 
166 
(0.54) 
126  
(0.36) 
111 
(0.29) 
98  
(0.24) 
68  
(0.16) 
75  
(0.18) 
72  
(0.19) 
Mixed 10 (0.05) 10 (0.05) 13 (0.05) 12 (0.04) 19 (0.05) 9 (0.02) 7 (0.02) 6 (0.01) 10 (0.02) 6 (0.02) 
Vag. Low 79  
(0.41) 
125  
(0.55) 
200 
(0.75) 
264 
(0.86) 
338  
(0.97) 
457 
(1.20) 
538 
(1.34) 
634  
(1.53) 
644  
(1.56) 
612  
(1.62) 
Norm. 448 
(2.33) 
518  
(2.26) 
563 
(2.10) 
618 
(2.01) 
712  
(2.05) 
762 
(1.99) 
756 
(1.88) 
671 
 (1.62) 
632  
(1.53) 
470 
 (1.24) 
Mixed 28 (0.15) 23 (2.26) 37 (0.14) 50 (0.16) 55 (0.16) 62 (0.16) 86 (0.21) 97 (0.23) 102 
(0.25) 
90 (0.24) 
Other
a/ 
mixed 
use 
Low N/Ab N/Ab N/Ab N/Ab 5 (0.01) N/Ab 5 (0.01) N/Ab N/Ab N/Ab 
Norm. 32 (0.17) 31 (0.14) 29 (0.11) 31 (0.10) 20 (0.06) 14 (0.04) 13 (0.03) 8 (0.02) 9 (0.02) 7 (0.02) 
Mixed 12 (0.06) 14 (0.06) 13 (0.05) 21 (0.07) 20 (0.06) 20 (0.05) 12 (0.03) 13 (0.03) 14 (0.03) 8 (0.02) 
Tib. 
and 
mixed 
use 
Oral Low N/Ab N/Ab 5 (0.02) 5 (0.02) N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 
Norm. 14 (0.07) 13 (0.06) 26 (0.10) 31 (0.10) 10 (0.03) 8 (0.02) 7 (0.02) N/Ab N/Ab N/Ab 
Mixed 61 
 (0.32) 
90  
(0.39) 
159 
(0.59) 
203 
(0.66) 
187  
(0.54) 
136 
(0.36) 
94  
(0.23) 
81  
(0.20) 
56 
 (0.14 ) 
31  
(0.08) 
Trans Low N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 
Norm. N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 
Mixed N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 
Vag. Low N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 
Norm. N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 
Mixed N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 
Other
a/ 
mixed 
use 
Low N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 7 (0.02) N/Ab 
Norm. 6 (0.03) 15 (0.07) 17 (0.06) 15 (0.05) 9 (0.03) N/Ab N/Ab N/Ab N/Ab N/Ab 
Mixed N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab N/Ab 
EPT: estrogen plus progestogen therapy, ET: estrogen therapy, Tib.: tibolone, Adm.: administration, Trans.: transdermal, Vag.: vaginal, Norm.: normal 
a other HT: other hormone therapy use includes includes injections, implants, and nasal administrations 
b N/A: not applicable as cell counts <5 are not reportable due to Medicines and Healthcare products Regulatory Agency (MHRA) regulations 
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Supplementary File12. Hormone therapy use in the sub-population with ≥1 cardiovascular 
risk factor stratified by type, administration route and dose from 1996/1997 to 2014/2015 
 
Supplementary Table16. Hormone therapy use in a population with ≥1 cardiovascular risk factors 
stratified by drug type from 1996/1997 to 2014/2015 
Years Number of ET 
users (%) 
Number of EPT 
users (%) 
Number of tibolone or 
mixed users (%) 
1996/1997 44,184 (9.2) 44,417 (9.2) 8588 (1.8) 
1998/1999 52,129 (9.5) 52,494 (9.5) 10,360 (1.9) 
2000/2001 60,614 (9.7) 61,518 (9.8) 13,072 (2.1) 
2002/2003 64,405 (9.2) 60,339 (8.6) 15,093 (2.2) 
2004/2005 56,933 (7.4) 37,593 (4.9) 10,681 (1.4) 
2006/2007 53,121 (6.5) 28,931 (3.5) 8346 (1.0) 
2008/2009 51,489 (6.2) 24,684 (3.0) 6782 (0.8) 
2010/2011 49,479 (6.0) 21,706 (2.7) 5921 (0.7) 
2012/2013 46,350 (5.9) 19,452 (2.5) 5097 (0.7) 
2014/2015 39,430 (5.7) 16,970 (2.5) 4087 (0.6) 
ET: estrogen therapy, EPT: estrogen plus progestogen therapy 
 
Supplementary Figure17. Selected proportions of hormone therapy use stratified by drug type, 
administration route and dose in the breast cancer sub-population 
aEPT: estrogen plus progestogen therapy 
bET: estrogen therapy 
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Supplementary Table17. Hormone therapy use in a population with ≥1 cardiovascular risk factors 
stratified by administration route from 1996/1997 to 2014/2015 
Years Number of 
oral HT users 
(%) 
Number of 
vaginal HT 
users (%) 
Number of 
transdermal HT  
users (%) 
Number of 
othera HT or 
mixed users 
(%) 
1996/1997 63,733 (13.2) 9888 (2.1) 14,303 (3.0) 9265 (1.9) 
1998/1999 76,912 (14.0) 11,015 (2.0) 17,166 (3.1) 9890 (1.8) 
2000/2001 92,218 (14.8) 12,722 (2.0) 19,671 (3.2) 10,543 (1.7) 
2002/2003 94,525 (13.5) 14,246 (2.0) 20,471 (2.9) 10,595 (1.5) 
2004/2005 64,282 (8.3) 18,880 (2.4) 15,071 (2.0) 6974 (0.9) 
2006/2007 50,119 (6.1) 22,332 (2.7) 12,044 (1.5) 5903 (0.7) 
2008/2009 42,574 (5.1) 25,054 (3.0) 10,192 (1.2) 5135 (0.6) 
2010/2011 36,707 (4.5) 26,708 (3.3) 8951 (1.1) 4740 (0.6) 
2012/2013 31,894 (4.1) 27,220 (3.5) 7601 (1.0) 4184 (0.5) 
2014/2015 26,528 (3.8) 23,818 (3.4) 6588 (1.0) 3553 (0.5) 
HT: hormone therapy 
a other hormone therapy use includes injections, implants, and nasal administrations 
 
 
 
 
Supplementary Figure18. Proportion of use of different hormone therapy doses over time in A) 
a sub-population with ≥1 cardiovascular risk factor and B) the general UK female population  
aET: estrogen therapy 
bCVD: cardiovascular disease 
cRF: risk factor 
dEPT: estrogen plus progestogen therapy 
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Supplementary Table18. Hormone therapy use in a population with ≥1 cardiovascular risk factors 
stratified by dose from 1996/1997 to 2014/2015 
Years Normal HT dose 
use (%) 
Low HT dose 
use (%) 
Mixed dose use 
(%) 
1996/1997 81,108 (16.8) 6139 (1.3) 9942 (2.1) 
1998/1999 93,894 (17.0) 8739 (1.6) 12,350 (2.2) 
2000/2001 105,926 (16.9) 13,003 (2.1) 16,275 (2.6) 
2002/2003 104,328 (14.9) 16,326 (2.3) 19,183 (2.7) 
2004/2005 71,201 (9.2) 17,816 (2.3) 16,190 (2.1) 
2006/2007 54,756 (6.7) 19,928 (2.4) 15,714 (1.9) 
2008/2009 48,720 (5.9) 21,643 (2.6) 12,592 (1.5) 
2010/2011 41,425 (5.1) 23,692 (2.9) 11,989 (1.5) 
2012/2013 36,233 (4.6) 24,080 (3.1) 10,586 (1.4) 
2014/2015 29,186 (4.2) 22,093 (3.2) 9208 (1.3) 
HT: hormone therapy 
 
 
 
 
 
Supplementary Figure19. Proportion of use of different hormone therapy administration routes 
over time in A) a sub-population with ≥1 cardiovascular risk factor and B) the general UK female 
population 
aHT: hormone therapy 
bCVD: cardiovascular disease 
cRF: risk factor 
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Supplementary File13. Numeric values corresponding to Figure5 of the main manuscript. 
Proportion of use of different hormone therapy administration routes in a sub-population 
with ≥1 cardiovascular risk factor stratified by number of risk factors 
 
Supplementary Table19. Hormone therapy use in a population with ≥1 cardiovascular risk factors 
stratified by administration route and number of risk factors from 1996/1997 to 2014/2015 
Over.: overall, Trans.: trandsdermal, Vag.: vaginal, RF: risk factor 
a other: hormone therapy use includes injections, implants, and nasal administrations
 Number of women (%) 
96/97 98/99 00/01 02/03 04/05 06/07 08/09 10/11 12/13 14/15 
Over. 0-1 
RF 
153,701 
(18.8) 
169,593  
(19.5) 
182,488  
(20.2) 
56,502 
(18.5) 
46,966  
(12.8) 
43,976 
 (10.7) 
42,672  
(9.8) 
42,644 
(9.5) 
40,050 
(9.2) 
34,309 
(9.0) 
2-3 
RFs 
25,527 
(18.7) 
32,595  
(19.6) 
41,603  
(20.5) 
47,078 
(19.3) 
37,565  
(13.1) 
33,229  
(10.5) 
31,557  
(9.6) 
29,829 
(9.0) 
28,077 
(8.7) 
24,314 
(8.4) 
4-5 
RFs 
806 
(16.5) 
1271 
(16.8) 
2085 
(17.1) 
2854 
(15.5) 
2714 
(10.2) 
2684 
(8.1) 
2716 
(7.4) 
2672 
(7.0) 
2530 
(6.6) 
2283 
(6.5) 
Oral HT 0-1 
RF 
101,205 
(12.4) 
112,964  
(13.0) 
123,720  
(13.7) 
112,44
8 (12.3) 
69,068 
(7.6) 
52,735  
(5.8) 
43,789  
(5.0) 
37,491 
(4.4) 
32,164 
(4.1) 
26,507 
(3.9) 
2-3 
RFs 
16,056 
(11.7) 
21,148  
(12.7) 
27,777  
(13.7) 
31,251 
(12.8) 
22,305 
(7.8) 
17,487  
(5.5) 
15,183  
(4.6) 
13,353 
(4.0) 
11,845 
(3.7) 
9997  
(3.5) 
4-5 
RFs 
437 
(8.9) 
778  
(10.3) 
1262 
(10.3) 
1768 
(9.6) 
1486 
(5.6) 
1301 
(3.9) 
1200 
(3.3) 
1050 
(2.7) 
871 
(2.3) 
738 
(2.1) 
Trans 
HT 
0-1 
RF 
22,849 
(2.8) 
26,052 
 (3.0) 
27,183  
(3.0) 
25,142 
(2.8) 
16,870 
(1.9) 
13,030  
(1.4) 
10,721  
(1.2) 
9405  
(1.1) 
7972  
(1.0) 
6898  
(1.0) 
2-3 
RFs 
3772 
(2.8) 
4857  
(2.9) 
6026  
(3.0) 
7008 
(2.9) 
5388 
(1.9) 
4476 
(1.4) 
3913 
(1.2) 
3430 
(1.0) 
2986 
(0.9) 
2559 
(0.9) 
4-5 
RFs 
158 
(3.2) 
213  
(2.8) 
348  
(2.9) 
470 
(2.6) 
417 
(1.6) 
334 
(1.0) 
294 
(0.8) 
278 
(0.7) 
251 
(0.7) 
223 
(0.6) 
Vag. HT 0-1 
RF 
15,151 
(1.9) 
15,762 
(1.8) 
16,676 
 (1.8) 
17,556 
(1.9) 
21,678 
(2.4) 
24,047  
(2.7) 
25,967  
(3.0) 
27,717 
(3.3) 
27,249 
(3.5) 
23,322  
(3.4) 
2-3 
RFs 
3247 
(2.4) 
3795  
(2.3) 
4703 
 (2.3) 
5511 
(2.3) 
7566 
(2.6) 
9253 
(2.9) 
10,653 
(3.2) 
11,349 
(3.4) 
11,728 
(3.6) 
10,451 
(3.6) 
4-5 
RFs 
138 
(2.8) 
178  
(2.4) 
314 
 (2.6) 
418 
(2.3) 
661 
(2.5) 
927 
(2.8) 
1098 
(3.0) 
1230 
(3.2) 
1316 
(3.4) 
1225 
(3.5) 
Othera/ 
mixed 
use 
0-1 
RF 
14,496 
(1.8) 
14,815 
(1.7) 
14,909  
(1.7) 
13,804 
(1.5) 
8418 
 (0.9) 
6899  
(0.8) 
5984 
 (0.7) 
5522 
 (0.7) 
4829  
(0.6) 
4089  
(0.6) 
2-3 
RFs 
2452 
(1.8) 
2795 
 (1.7) 
3097  
(1.5) 
3308 
(1.4) 
2306 
(0.8) 
2013 
(0.6) 
1808 
(0.6) 
1697 
(0.5) 
1518 
(0.5) 
1307 
(0.5) 
4-5 
RFs 
73  
(1.5) 
102  
(1.4) 
161  
(1.3) 
198 
(1.1) 
150 
(0.6) 
122 
(0.4) 
124 
(0.3) 
114 
(0.3) 
92  
(0.2) 
97  
(0.3) 
Supplementary Figure20. Proportion of use of different hormone therapy doses over time in A) 
a sub-population with ≥1 cardiovascular risk factors and B) the general UK female population 
aHT: hormone therapy, bCVD: cardiovascular disease, cRF: risk factor 
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8.2 Appendix 2 
Risk of hand osteoarthritis in new users of hormone replacement therapy:   
A nested case-control analysis 
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Objective: To estimate the risk of hand osteoarthritis (HOA) associated with hormone 
replacement therapy (HRT). 
Methods: We conducted a nested case-control study using data from the UK-based Clinical 
Practice Research Datalink (1998-2017). In women entering at age 45 (inception cohort), we 
matched women with incident HOA during follow-up (cases) 1:4 to osteoarthritis-free controls 
on age and calendar date (index date, ID). We applied conditional logistic regression to 
calculate odds ratios (OR) with 95% confidence intervals (CI) of HOA associated with new HRT 
use compared to non-use overall and in women with recorded menopause, in whom, we 
calculated separate ORs subdivided by time between menopause and HRT initiation (current 
users), and by time between HRT cessation and the ID (past users), versus non-users. 
Results: Among 3440 cases and 13,760 controls (mean age: 50.9±4.1 years), we observed an 
adjusted OR (aOR) of HOA of 1.32 (95% CI 1.17-1.48) in HRT users (versus non-users), which 
attenuated to 0.98 (95% CI 0.85-1.14) in women with recorded menopause. Current users 
(versus non-users), who initiated HRT within 3 months before/after menopause, had an aOR 
of 0.72 (95% CI 0.55-0.96), while aORs increased with later HRT initiation. Among past users 
(versus non-users), we observed an aOR of 1.25 (95% CI 0.86-1.81) when HRT use was stopped 
≤18 months before the ID, approaching the null with increasing duration between HRT 
cessation and the ID. 
Conclusion: Current HRT use was associated with a decreased risk of HOA if initiated around 
menopause, but the risk reduction disappeared after HRT cessation. 
Keywords: hormone replacement therapy; hand osteoarthritis; menopause; epidemiology 
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INTRODUCTION  
Hand osteoarthritis is a degenerative disease characterised by joint pain and bony 
enlargements/ swellings, occurring most frequently in postmenopausal women and the 
elderly.[1,2] To date, no disease-modifying treatment is available.[3] The exact etiology of 
osteoarthritis is unknown, but the increase in incidence of hand osteoarthritis in 
postmenopausal women and the presence of estrogen receptors in cartilage suggest that 
hormone replacement therapy (HRT) may help preventing the development of 
osteoarthritis.[4]  
Preclinical studies mainly assessed the effect of HRT on knee osteoarthritis and yielded 
contradictory results.[5] Mechanical stress is a major risk factor for osteoarthritis of 
weight-bearing joints (i.e. knee, hip)[6], which is often not adequately controlled for. Hand 
osteoarthritis is minimally affected by mechanical factors and thus a more suitable outcome to 
assess the association between osteoarthritis and systemic exposures. However, small cross-
sectional studies investigating the association between HRT and hand osteoarthritis or 
generalized osteoarthritis (≥3 joints affected, usually includes hand osteoarthritis) also yielded 
contradictory results.[7-11] A descriptive study reported that 55% of women who developed 
hand osteoarthritis after menopause developed it within 4 years after menopause.[12] Thus, 
timing of HRT use relative to menopause and/or hand osteoarthritis may play an important role 
in the association between HRT use and hand osteoarthritis, but has not been studied yet. 
In this nested case-control analysis we investigated the association of new HRT use on the risk 
of incident hand osteoarthritis overall and stratified by timing of HRT use. Furthermore, we 
assessed the timing of HRT initiation and cessation relative to recorded menopause and 
diagnoses of hand osteoarthritis, respectively. 
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PATIENTS AND METHODS  
Study design and Data source  
We conducted a nested case-control study using data derived from Clinical Practice Research 
Datalink (CPRD) GOLD which comprises de-identified primary care data of more than 11.3 
million patients.[13] General practitioners (GP) act as gatekeepers within the National Health 
Service (NHS) and electronically record information on diagnoses, prescriptions, medical 
symptoms, laboratory values, referrals to secondary care, demographics, and lifestyle factors 
(e.g. body mass index [BMI], smoking status).[14] Prescriptions are (nearly) completely 
recorded and diagnoses have been repeatedly shown to be of high validity.[15] We further 
used CPRD-linked patient level data on socio-economic status (index of multiple deprivation, 
IMD), which is available for patients living in England only.[16,17] The interpretation and 
conclusions contained in this study are those of the authors alone. 
Study population 
We included all women on July 1st (cohort entry) of the year in which they turned 45 years old 
(based on their year of birth) between January 1998 and December 2017 in an inception 
cohort. We excluded all women with ≤1 year of active history and/or <1 GP visit on the 
database prior to cohort entry. We further excluded women with a history of hand 
osteoarthritis and with diseases potentially linked to secondary osteoarthritis or differential 
diagnoses of hand osteoarthritis prior to cohort entry, namely hemarthrosis of the hand, 
malformation or misalignments of the fingers, hypermobility syndrome, hyperparathyroidism, 
acromegaly, previous finger injury (e.g. fracture, dislocation, tear of ligament), Stickler 
syndrome, Paget’s disease, disorder of iron metabolism (hemochromatosis), inflammatory 
polyarthropathies, and Wilson disease.[18,19] Women were not eligible if they had a recorded 
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Read code[13] for any cancer (except non-melanoma skin cancer), alcoholism, alcohol/ other 
substance abuse, or HIV/ AIDS at any time prior to cohort entry. Furthermore, women were 
excluded if they used systemic HRT prior to cohort entry.  
Follow-up and case definition/ validity 
We followed all women from cohort entry until they developed incident symptomatic hand 
osteoarthritis (cases) defined as 1) a first-time Read code of hand osteoarthritis or 2) a Read 
code of hand pain if followed by an incident Read code of hand osteoarthritis, osteoarthritis, 
or generalized osteoarthritis (Read codes in Supplemental File 1) within 365 days thereafter. 
The case index date was defined as the first record of either first-time hand osteoarthritis or 
hand pain. Follow-up was censored at the first of the following: recorded exclusion criterion 
described above (except for first-time systemic HRT use), disenrollment from the CPRD, age 
65, or the end of the study period (December 2017). 
As hand osteoarthritis is a diagnosis mainly made in primary care, we could not validate 
diagnoses using secondary care data. Nonetheless, in a sensitivity analysis, we restricted cases 
to women with a diagnosis of incident hand osteoarthritis that was preceded or followed by a 
specialist referral/ discharge (rheumatologist/ orthopaedist/ radiologist), or diagnostic work 
up (MRI, X-ray, ultrasonography) within 90 days before or after the diagnosis (19.1% of cases). 
In a further sensitivity analysis, to account for the slowly developing character of hand 
osteoarthritis potentially leading to a delayed diagnosis, we reanalysed the data with the index 
date shifted to 180 days before the hand osteoarthritis diagnosis date or matched date in 
controls. Women with ≤180 days of follow-up were excluded from this analysis.  
Definition of controls 
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Each hand osteoarthritis case was matched to four controls from the study population who 
did not have a record of hand osteoarthritis up to 180 days prior to the case index date (risk-set 
sampling with a lag period to account for gradual disease onset) on age, calendar date (case 
index date), GP practice, and years of history in the CPRD before the index date. 
Exposure   
We defined new HRT use as a first ever recorded prescription for any systemic opposed or 
unopposed HRT. We included systemic formulations (i.e. oral, transdermal, topical, nasally 
administered, implanted, or injected formulations), but not vaginal formulations due to their 
relatively low, variable systemic bioavailability.  
A woman was considered exposed from the day after the first HRT prescription, and was 
considered “currently exposed” for as long as each prescription was followed by a subsequent 
prescription within a grace period of 180 days after the alleged end of supply (Figure 1). Supply 
length was determined based on the number of prescribed products and dose instructions. In 
case of missing or improbable information on supply length, we used previously assessed 
default values of product quantities and dosing (Supplemental File 2). A person was classified 
as having past exposure from day 181 after a current prescription supply ended (Figure 1). 
Past users were censored whenever a new systemic HRT prescription was recorded (i.e. past 
users could not become current users again).  
Covariates 
We captured the following potential confounders of the association between HRT initiation 
and hand osteoarthritis (selected a priori based on clinical knowledge) recorded at any time 
before the index date (if not specified otherwise): BMI ≥30 kg/m2 (Read code or measure for 
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BMI),[7,8,10,20,21] current smoking,[8,10,11] heavy alcohol consumption 
>14 units/week,[10] osteoporosis (Read code or prescription for bone-modifying drug),[7,20] 
diabetes (Read code or antidiabetic drug), thiazide prescriptions,[8] dyslipidemia (Read code 
or laboratory value), a vaccination record (proxy for health care seeking behavior), and >5 GP 
contacts[21] within the year prior to cohort entry (proxy for health care seeking behavior; we 
assessed GP contacts prior to cohort entry because assessing GP contacts prior to the index 
date would lie on the causal pathway between HRT initiation and hand osteoarthritis). With 
dichotomization of lifestyle covariates, we assumed that women with a missing record of BMI 
(9.0%), smoking status (2.8%), or alcohol consumption (8.3%) were non-obese, non-smokers, 
or non-heavy drinkers.  
Statistical analysis  
We conducted multivariable conditional logistic regression analyses to estimate crude and 
adjusted odds ratios (OR, adjusted for all covariates listed under 2.6 Covariates) with 95% 
confidence intervals (CI) of the association between new HRT use compared to non-use and 
hand osteoarthritis overall, and stratified by timing of HRT use (currently exposed, past 
exposed). In additional analyses, we further adjusted for anytime vaginal HRT use (yes/no), 
and separately for socio-economic status in 60.2% of women with available information on 
IMD (in quintiles). 
To assess confounding by whether or not a woman had menopause recorded in the database, 
we calculated crude and adjusted ORs of hand osteoarthritis in women with recorded 
menopause compared to women who had no menopause record (menopause records were 
assessed between cohort entry and the index date only, women with a menopause record 
before cohort entry were excluded). Because we observed an association between the 
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presence of recorded menopause and a diagnosis for hand osteoarthritis, we restricted the 
remainder of analyses to women with recorded menopause. In these women, we estimated 
ORs of the association between hand osteoarthritis and new HRT use, compared to non-use 
overall and stratified by timing of HRT use (currently exposed, past exposed). We further 
estimated ORs stratified by timing of HRT initiation relative to recorded menopause in current 
users compared to non-users (>3 months before menopause [range: 140-2811 days], 
≤3 months before/after menopause, 3-36 months after menopause, and >36 months after 
menopause [range: 1126-4474 days]). Furthermore, we estimated ORs stratified by timing of 
HRT cessation before the index date among past users, compared to non-users (≤18 months 
before the index date, >18-54 months before the index date, and >54 months before the index 
date).  
Moreover, to describe the temporal trend of hand osteoarthritis onset after menopause, we 
described the proportion of hand osteoarthritis cases in women with recorded menopause 
after cohort entry in 1-year intervals after recorded menopause. Proportions were estimated 
by dividing the number of hand osteoarthritis cases in each interval by the number of total 
hand osteoarthritis cases at any time between cohort entry and index date. We performed all 
analyses using SAS statistical software version 9.4 (NC, USA). 
RESULTS  
We identified 623,671 women who turned 45 years old during the study period. After 
application of exclusion criteria, we included 438,674 women in the inception cohort 
(Figure 2). Among this cohort, we identified 3440 hand osteoarthritis cases and 13,760 
matched controls. Characteristics of cases and controls are displayed in Table 1. The mean age 
of cases and controls at the index date was 50.9 years (standard deviation: 4.1 years). Cases 
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had more recorded diagnoses of osteoporosis, diabetes, dyslipidemia, and obesity before the 
index date, and also saw their GP more often in the year prior to cohort entry, than controls.  
The adjusted OR of hand osteoarthritis in HRT users compared to non-users was 1.32 (95% CI 
1.17-1.48) [Table 2]. A record of menopause (irrespective of HRT use) was associated with an 
increased adjusted OR of hand osteoarthritis of 1.42 (95% CI 1.29-1.57) when compared to 
women without recorded menopause (Figure 3, crude ORs in Supplemental File 3). In women 
with recorded menopause, there was no association between HRT use and risk of hand 
osteoarthritis: adjusted OR 0.98 (95% CI 0.85-1.14) when compared to non-use (Figure 3, 
crude ORs in Supplemental File 3). Current HRT users, versus non-users, had a decreased 
adjusted OR of hand osteoarthritis of 0.72 (95% CI 0.55-0.96), when HRT was initiated within 
3 months before/after menopause with ORs increasing with later HRT initiation. Of all current 
users 68% of women used oral EPT within 12 months prior to the index date. Women with 
past HRT use had a statistically non-significantly adjusted OR of hand osteoarthritis of 1.25 
(95% CI 0.86-1.81) if HRT was stopped ≤18 months before the index date, which decreased 
towards the null with increasing duration between HRT cessation and the index date (Figure 3, 
crude ORs in Supplemental File 3). 
The proportion of women with hand osteoarthritis diagnoses decreased with increasing 
number of 1-year intervals after recorded menopause. A maximum proportion of 18.4% of 
women had hand osteoarthritis recorded (158 of 860 cases) within 1 year after recorded 
menopause. Cumulatively, 54.9% and 79.9% of women had hand osteoarthritis recorded 
within 4 years and 7 years, respectively (Figure 4, Supplemental File 4). 
In all analyses, adjusted ORs of hand osteoarthritis were lower in current and higher in past 
HRT users than when HRT was assessed overall (Table 2, Figure 3). When we further adjusted 
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the overall analysis for vaginal HRT use and socioeconomic status, results remained 
unchanged (Table 2). In sensitivity analyses related to outcome validity, results remained 
largely unchanged as well (Table 2).  
DISCUSSION  
In this nested case-control study embedded in an inception cohort of women aged 45 at entry, 
we assessed the risk of hand osteoarthritis in HRT users compared to non-users overall, 
stratified by timing of HRT, and in women with recorded menopause only. In women with 
recorded menopause only, we further investigated separate ORs subdivided by time between 
menopause and HRT initiation (current users), and by time between HRT cessation and the 
index date (past users), compared to non-users.  
Previous small observational studies investigating the association between HRT and hand 
osteoarthritis, or generalized osteoarthritis, yielded contradictory results.[7-11] Though 
authors had access to hospital-based information on diagnosis, the cross-sectional study 
design prevented them from assessing temporality of HRT use in relation to hand 
osteoarthritis or menopausal status.[7-11] We observed a 32% increased risk of hand 
osteoarthritis in all HRT users when compared to non-users which attenuated to a null result 
after restriction to women with recorded menopause. We assumed that HRT use is a proxy 
for menopause onset in women without recoded menopause and therefore abstained from 
analyses in women without recorded menopause. Our results suggest that menopause is a 
risk factor for incident hand osteoarthritis (42% increased risk in our study). Other 
observational studies assessing the association between menopause with or without HRT use 
and hand osteoarthritis did not yield precise results mainly due to small sample sizes.[22] Watt 
et al. performed a small study (n=82) describing the association between menopause or HRT 
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cessation and onset of hand osteoarthritis symptoms in women in a UK secondary care 
clinic.[12] The authors reported a median duration between HRT cessation and onset of hand 
osteoarthritis of 6 months. We observed that, among women with recorded menopause who 
developed hand osteoarthritis, 55% of women did so within 4 years after menopause, the 
same proportion was reported by Watt et al.. 
Women who initiated HRT shortly before/after menopause were at a reduced risk of hand 
osteoarthritis (around 28% lower risk for women with current HRT use at the index date). We 
hypothesize that women who use systemic HRT to alleviate vasomotor symptoms may profit 
from a delayed onset or progression of hand osteoarthritis, when HRT is initiated around 
menopause and used continuously. Thus, our results support position statements of the North 
American Menopause Society[23] and International Menopause Society[24], which postulate 
a potential benefit of HRT on joint/ muscle pain and joint stiffness based on evidence from the 
well-known Women’s Health Initiative reporting reduced arthroplasty and joint pain among 
unopposed oral HRT users[25,26], and reduced joint pain and stiffness among opposed oral 
HRT users[27], compared to non-users. To date, there is no information on the effect of 
progesterone alone or in conjunction with estrogen on articular cartilage. Our results also 
suggest that HRT cessation may slightly increase the risk of hand osteoarthritis (25% risk 
increase ≤18 months after cessation, based on small sample size), which may question the 
initial clinical benefit of HRT use. We hypothesize that hand osteoarthritis onset likely 
expressed by hand pain is similar to spontaneous exacerbation of vasomotor symptoms after 
HRT cessation.[23]  
A strength of this study is its large population of more than 3’000 hand osteoarthritis cases 
among women observed longitudinally from age 45. Furthermore, we applied a new user 
design, allowing us to assess temporality of HRT use and hand osteoarthritis. Moreover, we 
Appendix 2 
111 
 
likely captured near complete HRT prescription information, as CPRD prescriptions are issued 
electronically by the GP. We do not know if women took all prescriptions. However, of women 
who had HRT prescribed during follow-up, 77.4% had >1 HRT prescription recorded, 
suggesting that most women filled their prescriptions repeatedly, and thus likely took the 
medication.  
A major limitation of this study is the inconsistent recording of menopause in the CPRD. 
However, HRT use among women with recorded menopause in our study is consistent with 
numbers reported among the general UK female population (around 20-40% of women who 
have sought medical advice on menopause used HRT over time)[28,29]. Furthermore, as only 
around 30% of women with recorded menopause were prescribed HRT in our study, we 
hypothesize that women with a menopause record in the CPRD do not only represent women 
with severe postmenopausal symptoms but also women who had mild symptoms or whose 
menopause was recorded by chance. In our cohort, we suspect under recording of hand 
osteoarthritis (prevalence of 0.8%) because GPs may frequently lack to specify joint 
localization of osteoarthritis. However, by only including specific records of hand 
osteoarthritis we achieve a high specificity which is relevant for reliable risk estimation in 
comparative analyses. Yet, sample size of some strata in our study population was small and 
results have to be confirmed before drawing causal conclusions for clinical practice.  
CONCLUSION 
This nested case-control study yielded an increased risk of hand osteoarthritis in HRT users 
compared to non-users. This result was likely confounded by menopausal status, as the risk 
was attenuated after restriction to women with recorded menopause. Moreover, we 
observed a decreased risk of hand osteoarthritis in current HRT users who initiated HRT 
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around the time of the first menopause record. However, HRT cessation was temporarily 
associated with a slight risk increase of hand osteoarthritis. 
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SUPPLEMENTAL FILES  
Supplemental File 1. Utilized Read codes for hand osteoarthritis diagnoses 
Hand osteoarthritis diagnosis 
N050100   Generalised osteoarthritis of the hand 
N051400   Localised; primary osteoarthritis of the hand 
N053400   Localised osteoarthritis; unspecified; of the hand 
N054400   Oligoarticular osteoarthritis; unspecified; of hand 
N05z400   Osteoarthritis NOS; of the hand 
N05zF00   Osteoarthritis NOS; of MCP joint 
N05zG00   Osteoarthritis NOS; of PIP joint of finger 
N05zH00   Osteoarthritis NOS; of DIP joint of finger 
N05z411   Finger osteoarthritis NOS 
N052400   Localised; secondary osteoarthritis of the hand 
2G26.00   O/E - hands - Heberden's nodes 
N050111   Heberdens' nodes 
N050700   Heberden's nodes with arthropathy 
N050112   Bouchards' nodes 
N050300   Bouchard's nodes with arthropathy 
N05z412   Thumb osteoarthritis NOS 
7K6ZG00   Injection of steroid into carpometacarpal joint of thumb 
N051C00   Primary arthrosis of first carpometacarpal joints; bilateral 
N052B00   Post-traumatic arthrosis of first carpometacarpal jt bilat 
N053900   449 Arthrosis of first carpometacarpal joint; unspecified 
Nyu2900   [X]Other primary arthrosis of first carpometacarpal joint 
Nyu2A00   [X]Other post-traumatic arthrosis/1st carpometacarpal joint 
Nyu2B00   [X]Other 2ndry arthrosis/1st carpometacarpal joints;bilaterl 
Nyu2C00   [X]Other secondary arthrosis of first carpometacarpal joint 
N03x600   Arthritis associated with other disease; MCP joint 
N03x700   Arthritis associated with other disease; PIP joint of finger 
N03x800   Arthritis associated with other disease; DIP joint of finger 
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N06z411   Hand arthritis NOS 
N066400   Unspecified monoarthritis of the hand 
N063400   Climacteric arthritis of the hand 
 
Record of hand pain if followed by incident Read code of hand osteoarthritis (see above), 
osteoarthritis or generalized osteoarthritis (see below) 
N245012  Finger pain 
N245.14   Hand pain 
N245000  Hand pain 
N094400  Arthralgia of the hand 
N094H00  Arthralgia of PIP joint of finger 
N094J00   Arthralgia of DIP joint of finger 
N245011  Thumb pain 
 
(Generalized) Osteoarthritis diagnosis 
N050400   Primary generalized osteoarthrosis 
N050500   Secondary multiple arthrosis 
N050600   Erosive osteoarthrosis 
Nyu2000   [X]Other polyarthrosis 
N050.00   Generalised osteoarthritis - OA 
N050000   Generalised osteoarthritis of unspecified site 
N050100   Generalised osteoarthritis of the hand 
N050200   Generalised osteoarthritis of multiple sites 
N050400   Primary generalized osteoarthrosis 
N050z00   Generalised osteoarthritis NOS 
N051.00   Localised; primary osteoarthritis 
N051000   Localised; primary osteoarthritis of unspecified site 
N051z00   Localised; primary osteoarthritis NOS 
N052.00   Localised; secondary osteoarthritis 
N052000   Localised; secondary osteoarthritis of unspecified site 
N052z00   Localised; secondary osteoarthritis NOS 
N053.00   Localised osteoarthritis; unspecified 
N053000   Localised osteoarthritis; unspecified; of unspecified site 
N053800   Localised osteoarthritis; unspecified; of other spec site 
N053z00   Localised osteoarthritis; unspecified; NOS 
N054.00   Oligoarticular osteoarthritis; unspecified 
N054000   Oligoarticular osteoarthritis; unspec; of unspecified sites 
N054400   Oligoarticular osteoarthritis; unspecified; of hand 
N054800   Oligoarticular osteoarthritis; unspecified; other spec sites 
N054900   Oligoarticular osteoarthritis; unspecified; multiple sites 
N054z00   Osteoarthritis of more than one site; unspecified; NOS 
N05z000   Osteoarthritis NOS; of unspecified site 
N05z800   Osteoarthritis NOS; other specified site 
N050500   Secondary multiple arthrosis 
N050600   Erosive osteoarthrosis 
Nyu2000   [X]Other polyarthrosis 
N065A00   Generalised arthritis 
Nyu2.00   [X]Arthrosis 
Nyu2D00   [X]Other specified arthrosis 
Nyu2F00   [X]Post-traumatic arthrosis of other joints 
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N05..00   Osteoarthritis and allied disorders 
N05..11   Osteoarthritis 
N050.00   Generalised osteoarthritis - OA 
N05z.00   Osteoarthritis NOS 
N05zz00   Osteoarthritis NOS 
N06z.11   Arthritis 
N063.00   Climacteric arthritis 
N063.11   Menopausal arthritis 
N094.00   Pain in joint - arthralgia 
N094000   Arthralgia of unspecified site 
N094800   Arthralgia of other specified site 
N094900   Arthralgia of multiple joints 
N094z00   Arthralgia NOS 
 
Supplemental File 2. Exposure duration estimation and utilized (default) values in case of 
missing or improbable prescription quantities and/ or dosing instructions 
 
In case of missing dosing instructions for hormone therapy (HT) products, we carried the last 
available value within the same patient of the same product code forward. If not available, we 
used the dosage of the last HT prescription within the patient if of the same administration 
type. If there was no previous information available, we used the following default values: 
- Oral: 1 tablet per day  
- Transdermal: 2 patches per week  
- Topical gel in tube: 2 squirts of 1.25 grams of topical gel application per day  
- Topical gel in sachets: 1 sachet of topical gel per day  
- Nasal: 1 inhalation per nostril per day  
- Injection: 1 injection per month  
- Implant: An implant of 25 mg estrogen lasts 3 months, of 50 mg lasts 6 months, and of 
100 mg lasts 10 months  
 
Furthermore, we defined certain ranges and cut-offs of exposure lengths to correct potential 
typing/ spelling errors in the database. 
Dose: 
- Oral: if daily dose >6, we used the default value of 1 tablet per day 
- Transdermal: if the daily dose was “biweekly” we used the default value of 2 patches per 
week (i.e. twice weekly)  
 
In the CPRD, the variable of quantity (package size) is sometimes misused as number of 
packages. Therefore, we introduced ranges and cut-offs as follows: 
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- Oral: “1-3” = number of packages, “4-12” = number of 1-month packages (à 28 tablets),  
“13-364” = number of tablets, “>364”, we used the default value of 84 tablets per 
package 
- Transdermal:  “≤6” = number of 1-month packages (à 8 patches), “7-52” = number of 
patches, “>52”, we used the default value of 24 patches per package 
- Topical gel in a tube: “≤8” = number of packages, “8-999” = weight in gram, “≥1000”, 
we divided the number by 100 and treated is as grams (these high numbers were likely 
due to a comma mistake) 
- Topical gel in sachets:  “≤3” = number of packages, “4-364” = number of sachets, 
“>364”, we used the default value of 28 sachets per package  
- Nasal: “≤3” = number of packages, “4-7” = number of 1-month packages (à 60 nasal 
inhalations), “˃7”, we used the default value of 180 nasal inhalations per package 
- Injections: “≤1” = number of packages  
- Implants: “≤1” = number of packages 
 
If there were overlapping periods of HT prescriptions with the same product code the new 
current days were added at the end of the first period. If the overlapping periods were longer 
than 180 days the new period was added after this 180 days and everything that was left from 
the previous period was deleted. If there were overlapping periods with another product 
code, we followed them in parallel.  
Supplemental File 3. Crude odds ratios corresponding to adjusted odds ratios of 
manuscript Figure 3 
 
Supplementary Table1. Crude odds ratios of hand osteoarthritis in association with recorded 
menopause after cohort entry, and, in patients with recorded menopause after cohort entry, 
odds ratios of hand osteoarthritis in association with hormone therapy and stratified by timing 
of hormone therapy use (current/past use) and by timing of hormone therapy initiation 
relative to recorded menopause (in current users) and of hormone therapy cessation before 
the index date (in past users). 
Patients with or without 
recorded menopause 
after cohort entry and 
before the index date 
Cases: 
3085 (%) 
Controls:  
12,681 (%) 
OR crude 
(95% CI) 
 
OR adjusted* 
(95% CI) 
No recorded menopause  2225 (72.1) 10,071 (79.4) 1.00 ref 1.00 ref 
Recorded menopause  860 (27.9) 2610 (20.6) 1.56 (1.42-1.72) 1.42 (1.29-1.57) 
No HT use 604 (19.6) 1821 (14.4) 1.00 ref 1.00 ref 
Overall HT use 256 (8.3) 789 (6.2) 0.97 (0.84-1.13) 0.98 (0.85-1.14) 
Current HT use  106 (3.4) 378 (3.0) 0.88 (0.72-1.08) 0.85 (0.69-1.04) 
… HT start >3 months 
before menopause 
8 (0.3) 21 (0.2) 1.11 (0.55-2.23) 1.04 (0.52-2.09) 
… HT start ≤3 months 
before/after menopause 
55 (1.8) 238 (1.9) 0.75 (0.57-0.99) 0.72 (0.55-0.96) 
… HT start 3-36 months 
after menopause 
33 (1.1) 98 (0.8) 1.01 (0.71-1.44) 0.97 (0.68-1.37) 
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… HT start >36 months  
after menopause 
10 (0.3) 21 (0.2) 1.30 (0.69-2.42) 1.30 (0.69-2.43) 
Past HT use 150 (4.9) 411 (3.2) 1.07 (0.90-1.28) 1.10 (0.91-1.31) 
… HT stop ≤18 months 
before the index date 
29 (0.6) 64 (0.3) 1.25 (0.86-1.82) 1.25 (0.86-1.81) 
… HT stop >18-54 months 
before the index date 
65 (2.4) 170 (1.6) 1.11 (0.86-1.43) 1.11 (0.86-1.43) 
… HT stop >54 months 
before the index date 
56 (1.8) 177 (1.4) 0.97 (0.73-1.27) 1.01 (0.76-1.33) 
OR: odds ratio, CI: confidence interval, HT: hormone therapy 
*adjusted for osteoporosis, smoking, alcohol consumption, diabetes, thiazide prescriptions, 
dyslipidemia, obesity, vaccine use prior to index date and for number of GP contacts prior to 
cohort entry 
 
Supplemental File 4. Numeric values corresponding to manuscript Figure 4 
Supplementary Table2. Numeric values corresponding to manuscript Fig4. Proportion of hand 
osteoarthritis cases in 1-year intervals after recorded menopause 
1-year intervals after 
recorded menopause 
Number of  
hand osteoarthritis cases 
(total 860 cases) 
Proportion of hand osteoarthritis cases  
in percentage terms 
(95% confidence interval) 
1 158 18.4 (15.9-21.1) 
2 114 13.3 (11.2-15.7) 
3 101 11.7 (9.8-14.1) 
4 99 11.5 (9.5-13.8) 
5 86 10.0 (8.2-12.2) 
6 77 9.0 (7.2-11.0) 
7 52 6.1 (4.6-7.8) 
8 51 5.9 (4.5-7.7) 
9 32 3.7 (2.6-5.2) 
10 30 3.5 (2.5-4.9) 
11 17 2.0 (1.2-3.1) 
12 15 1.7 (1.1-2.9) 
13 12 1.4 (0.8-2.4) 
14 11 1.3 (0.7-2.3) 
15 2 0.2 (0.1-0.8) 
16 2 0.2 (0.1-0.8) 
17 0 0.0  
18 1 0.1 (0.0-0.7) 
19 0 0.0 
20 0 0.0 
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8.3 Appendix 3 
Appendix Table1. Numeric values corresponding to Fig3. Annual incidence rates of hormone 
replacement therapy use and hand osteoarthritis from 1996 to 2015 
Year No. of 
women 
with a 
first HRT 
prescr. 
Obs. time 
in  
100 py 
Incidence rate 
of HRT use per 
100 py 
(95% CI) 
No. of 
women 
with a first 
hand OA 
diagnosis 
Obs. time 
in  
1’000 py 
Incidence rate of 
hand OA per  
1’000 py 
(95% CI) 
1996 15910 3464.6 4.59 (4.52-4.66) 579 587.0 0.99 (0.91-1.07) 
1997 14932 3688.6 4.05 (3.98-4.11) 664 629.9 1.05 (0.97-1.13) 
1998 14443 3914.7 3.69 (3.63-3.75) 652 665.0 0.98 (0.91-1.06) 
1999 15143 4139.5 3.66 (3.60-3.72) 663 695.5 0.95 (0.88-1.03) 
2000 16442 4349.9 3.78 (3.72-3.84) 722 729.5 0.99 (0.92-1.06) 
2001 16021 4495.9 3.56 (3.51-3.62) 945 757.0 1.25 (1.17-1.33) 
2002 13753 4625.3 2.97 (2.92-3.02) 1044 784.3 1.33 (1.25-1.41) 
2003 9790 4837.2 2.02 (1.98-2.06) 1286 807.0 1.59 (1.51-1.68) 
2004 9625 5085.2 1.89 (1.85-1.93) 1466 830.7 1.76 (1.67-1.85) 
2005 8476 5297.4 1.60 (1.57-1.63) 1531 848.5 1.80 (1.71-1.89) 
2006 9047 5483.4 1.65 (1.62-1.68) 1520 859.7 1.77 (1.68-1.86) 
2007 9346 5625.8 1.66 (1.63-1.69) 1569 867.6 1.81 (1.72-1.90) 
2008 9630 5763.3 1.67 (1.64-1.70) 1706 872.7 1.95 (1.86-2.05) 
2009 9735 5824.8 1.67 (1.64-1.70) 1728 866.1 2.00 (1.90-2.09) 
2010 10133 5844.8 1.73 (1.70-1.77) 1692 850.1 1.99 (1.90-2.09) 
2011 10176 5819.0 1.75 (1.71-1.78) 1611 830.6 1.94 (1.84-2.03) 
2012 10095 5737.7 1.76 (1.73-1.79) 1585 814.0 1.95 (1.85-2.04) 
2013 9610 5394.4 1.78 (1.75-1.82) 1490 766.8 1.94 (1.84-2.04) 
2014 9117 4788.0 1.90 (1.87-1.94) 1280 681.9 1.88 (1.77-1.98) 
2015 7680 3941.2 1.95 (1.91-1.99) 1049 567.5 1.85 (1.74-1.96) 
No.: number, HRT: hormone replacement therapy, prescr.: prescription, Obs.: observation, py: person-years,  
CI: confidence interval, OA: osteoarthritis 
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8.4 Appendix 4 
Appendix Table2. Numeric values corresponding to Fig4. Incidence rates of hormone replacement 
therapy use and of hand osteoarthritis stratified by age group 
Age 
group 
[years] 
No. of 
women 
with a first 
HRT prescr. 
Obs. time 
in  
100 py 
Incidence rate 
of HRT use per 
100 py 
(95% CI) 
No. of 
women 
with a first 
hand OA 
diagnosis 
Obs. time 
in 
1’000 py 
Incidence rate 
of hand OA per 
1’000 py 
(95% CI) 
40-44 25,871 25,711.1 1.01 (0.99-1.02) 1556 3098.4 0.50 (0.48-0.53) 
45-49 64,286 22,413.7 2.87 (2.85-2.89) 2961 2956.7 1.00 (0.97-1.04) 
50-54 73,067 16,475.1 4.43 (4.40-4.47) 4963 2762.6 1.80 (1.75-1.85) 
55-59 33,421 11,983.8 2.79 (2.76-2.82) 5958 2457.3 2.42 (2.36-2.49) 
60-64 18,792 10,609.5 1.77 (1.75-1.80) 5169 2163.3 2.39 (2.32-2.46) 
65-69 13,667 10,927.2 1.25 (1.23-1.27) 4175 1872.7 2.23 (2.16-2.30) 
No.: number, HRT: hormone replacement therapy, prescr.: prescription, Obs.: observation, py: person-years,  
CI: confidence interval, OA: osteoarthritis 
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8.5 Appendix 5 
 
Appendix Table3. Numeric values corresponding to Fig5. Incidence rates of hormone replacement 
therapy use in women stratified by age group and study period 
Study 
period 
Age group 
[years] 
No. of women with a 
first HRT prescription 
Obs. time in  
100 py 
Incidence rate of 
HRT use per 100 py 
(95% CI) 
1996-2002 40-44 13,177 7502.8 1.76 (1.73-1.78) 
 45-49 31,883 5933.7 5.37 (5.31-5.43) 
 50-54 32,795 4316.6 7.60 (7.51-7.68) 
 55-59 13,523 3245.4 4.17 (4.10-4.24) 
 60-64 8403 3489.1 2.41 (2.36-2.46) 
 65-69 6863 4190.9 1.64 (1.60-1.68) 
2003-2015 40-44 12,694 18,208.3 0.70 (0.69-0.71) 
 45-49 32,403 16,471.0 1.97 (1.94-1.99) 
 50-54 40,272 12,158.5 3.31 (3.28-3.34) 
 55-59 19,898 8738.4 2.28 (2.25-2.31) 
 60-64 10,389 7120.4 1.46 (1.43-1.49) 
 65-69 6804 6736.3 1.01 (0.99-1.03) 
No.: number, HRT: hormone replacement therapy, Obs.: observation, py: person-years,  
CI: confidence interval, OA: osteoarthritis 
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8.6 Appendix 6  
 
Appendix Table4. Numeric values corresponding to Fig6. Incidence rates of hand osteoarthritis in 
women stratified by age group and study period 
Study 
period 
Age group 
[years] 
No. of women with a 
first hand OA 
diagnosis 
Obs. time in 
1’000 py 
Incidence rate of hand 
OA per 1’000 py 
(95% CI) 
1996-2002 40-44 377 983.5 0.38 (0.34-0.42) 
 45-49 698 935.6 0.75 (0.69-0.80) 
 50-54 1273 934.5 1.36 (1.29-1.44) 
 55-59 1210 751.8 1.61 (1.52-1.70) 
 60-64 927 643.7 1.44 (1.35-1.53) 
 65-69 784 599.1 1.31 (1.22-1.44) 
2003-2015 40-44 1179 2114.9 0.56 (0.53-0.59) 
 45-49 2263 2021.2 1.12 (1.07-1.17) 
 50-54 3690 1828.2 2.02 (1.95-2.08) 
 55-59 4748 1705.5 2.78 (2.70-2.86) 
 60-64 4242 1519.6 2.79 (2.71-2.88) 
 65-69 3391 1273.7 2.66 (2.57-2.75) 
No.: number, OA: osteoarthritis, Obs.: observation, py: person-years,  
CI: confidence interval 
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8.7 Appendix 7 
Appendix Table5. Array approach assessing residual confounding needed to increase the observed 
adjusted odds ratio (=relative risk) of 0.72 to 1.0 in hormone replacement initiators ≤3 months 
before/after recorded menopause who were still hormone replacement users at the index date 
Observed 
adjusted 
RR* 
Unmeasured 
confounder 
strength (RR)† 
Unmeasured 
confounder 
prevalence in 
HRT users 
Unmeasured 
confounder 
prevalence in 
non-users 
RR additionally 
adjusted for 
unmeasured 
confounder  % Bias 
0.72 1.0 0.00 0.15 0.7 0.00 
0.72 1.5 0.00 0.15 0.8 -9.09 
0.72 2.0 0.00 0.15 0.9 -16.67 
0.72 2.5 0.00 0.15 0.9 -23.08 
0.72 3.0 0.00 0.15 1.0 -28.57 
0.72 3.5 0.00 0.15 1.1 -33.33 
0.72 4.0 0.00 0.15 1.2 -37.50 
0.72 4.5 0.00 0.15 1.2 -41.18 
0.72 5.0 0.00 0.15 1.3 -44.44 
0.72 5.5 0.00 0.15 1.4 -47.37 
0.72 1.0 0.05 0.15 0.7 0.00 
0.72 1.5 0.05 0.15 0.8 -6.82 
0.72 2.0 0.05 0.15 0.8 -12.50 
0.72 2.5 0.05 0.15 0.9 -17.31 
0.72 3.0 0.05 0.15 0.9 -21.43 
0.72 3.5 0.05 0.15 1.0 -25.00 
0.72 4.0 0.05 0.15 1.0 -28.13 
0.72 4.5 0.05 0.15 1.0 -30.88 
0.72 5.0 0.05 0.15 1.1 -33.33 
0.72 5.5 0.05 0.15 1.1 -35.53 
0.72 1.0 0.10 0.15 0.7 0.00 
0.72 1.5 0.10 0.15 0.8 -4.55 
0.72 2.0 0.10 0.15 0.8 -8.33 
0.72 2.5 0.10 0.15 0.8 -11.54 
0.72 3.0 0.10 0.15 0.8 -14.29 
0.72 3.5 0.10 0.15 0.9 -16.67 
0.72 4.0 0.10 0.15 0.9 -18.75 
0.72 4.5 0.10 0.15 0.9 -20.59 
0.72 5.0 0.10 0.15 0.9 -22.22 
0.72 5.5 0.10 0.15 0.9 -23.68 
OR: odds ratio, RR: relative risk (or rate ratio), HRT: hormone replacement therapy  
* relative risk of hand osteoarthritis of hormone replacement therapy initiators ≤3 months before/after 
recorded menopause who were still hormone replacement therapy users at the index date, compared to 
non-initiators, adjusted for osteoporosis, smoking, alcohol consumption, diabetes, thiazide prescriptions, 
dyslipidemia, obesity, vaccine use prior to index date and for number of GP contacts prior to cohort entry 
† relative risk of hand osteoarthritis and unmeasured confounder compared to no unmeasured confounder 
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Supp1. Exclusion criteria: conditions associated with secondary osteoarthritis or differential 
diagnosis of HOA any time before cohort entry1,2,3 
- a record of a previous finger injury (e.g. fracture, dislocation, tear of ligament, or 
finger amputation) 
- a recorded finger malformation/misalignment 
- hypermobility syndrome 
- hyperparathyroidism 
- acromegaly 
- disorder of iron metabolism (haemochromatosis) 
- inflammatory polyarthropathies (rheumatoid arthritis, Psoriatic and enteropathic 
arthropathies, Juvenile arthritis, gout, crystal arthropathies, other 
arthropathies/arthritis) 
- haem – or hydrarthrosis 
- Wilson disease  
References 
1. Leung GJ, Rainsford KD, Kean WF. Osteoarthritis of the hand I: Aetiology and 
pathogenesis, risk factors, investigation and diagnosis. J Pharm Pharmacol. 
2014;66(3):339-346. 
2. Creamer P, Hochberg MC. Osteoarthritis. Lancet. 1997;350:503-508.  
3. Altman RD. Pharmacological therapies for osteoarthritis of the hand: A review of the 
evidence. Drugs and Aging. 2010;27(9):729-745.  
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Supp2. Topical glaucoma therapy – exposure definition 
 
Topical glaucoma therapy contained sympathomimetics, parasympathomimetics, carbonic anhydrase 
inhibitors, betablockers, prostaglandine-analogues and others such as guanethidine and dapiprazole. 
 
Supp3. Read code list of the primary outcome HOA 
N050100   Generalised osteoarthritis of the hand 
N051400   Localised; primary osteoarthritis of the hand 
N053400   Localised osteoarthritis; unspecified; of the hand 
N054400   Oligoarticular osteoarthritis; unspecified; of hand 
N05z400   Osteoarthritis NOS; of the hand 
N05zF00   Osteoarthritis NOS; of MCP joint 
N05zG00   Osteoarthritis NOS; of PIP joint of finger 
N05zH00   Osteoarthritis NOS; of DIP joint of finger 
N05z411   Finger osteoarthritis NOS 
N052400   Localised; secondary osteoarthritis of the hand 
2G26.00    O/E - hands - Heberden's nodes 
N050111   Heberdens' nodes 
N050700   Heberden's nodes with arthropathy 
N050112   Bouchards' nodes 
N050300   Bouchard's nodes with arthropathy 
 
Supp4. Read code list of the secondary outcome GOA 
N050.00    Generalised osteoarthritis - OA 
N050000   Generalised osteoarthritis of unspecified site 
N050200   Generalised osteoarthritis of multiple sites 
N050400   Primary generalized osteoarthrosis 
N050z00   Generalised osteoarthritis NOS 
 
Supp5. Characteristics of statin initiators and non-initiators before the application of exclusion 
criteria 
 Statin init (N=1,044,573) Non-init. (N=33,219,405) 
Mean age in years (SD*) 63.6 (12.7) 36.8 (22.5) 
Mean no. of GP contacts ≤1 yr before 
cohort entry‡ (SD*) 
18.7 (14.5) 8.8 (10.5) 
Female 482,687 (46.2%) 17,909,707 (46.2%) 
Current smoker 224,329 (21.5%) 6,898,976 (20.1%) 
Average alcohol intake (>14 
units/week) 
118,087 (11.3%) 2,086,987 (6.3%) 
Comorbidities before cohort entry:  
Obesity (BMI>30kg/m2) 307,828 (29.5%) 4,200,729 (12.7%) 
Osteoporosis** 47,117 (4.5%) 471,877 (1.4%) 
Dyslipidaemiaⱡ 654,631 (62.7%) 3,282,731 (9.9%) 
Angina pectoris 124,133 (11.9%) 379,347 (1.1%) 
Type2 diabetes 180,060 (17.2%) 356,089 (1.1%) 
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Hypertension 495,921 (47.5%) 3,034,683 (9.1%) 
Chronic ischaemic heart dis. 136,485 (13.1%) 347,494 (1.1%) 
Congestive heart failure 35,565 (3.4%) 209,641 (0.6%)  
Hypothyroidism 73,316 (7.0%) 785,717 (2.4%) 
Vascular disease 51,412 (4.9%) 340,834 (1.0%) 
Chronic kidney disease (stage≥3) 73,417 (7.0%) 405,352 (1.2%) 
Hip fracture 13,683 (1.3%) 218,880 (0.7%) 
Liver disease 9209 (0.9%) 93,812 (0.3%) 
Macular degeneration 14,478 (1.4%) 133,037 (0.4%) 
COPD 45,325 (4.3%) 356,886 (1.1%) 
Anaemia 68,910 (6.6%) 1,439.924 (4.3%) 
Pressure ulcer/decubitus 11,523 (1.1%) 142,160 (0.4%) 
Deep vein thrombosis 23,267 (2.2%) 239,356 (0.7%) 
Dysphagia 19,109 (1.8%) 230,343 (0.7%) 
≥1 hospitalization ≤1 year before the 
cohort entry 
205,741 (19.7%) 3,615,894 (10.9%) 
Incontinence 28,337 (2.7%) 430,366 (1.3%) 
Pneumonia 33,144 (3.2%) 632,333 (1.9%) 
PsychotherapyⱠ 51,093 (4.9%) 1,285,608 (3.9%) 
Delusional disorders 9659 (0.9%) 171,661 (0.5%) 
Co-medication ≤180 days before cohort entry:  
Hormone replacement therapy 45,027 (4.3%) 995,901 (3.0%) 
Oral corticosteroids 46,501 (4.5%) 693,165 (2.1%) 
Opioids 77,210 (7.4%) 973,679 (2.9%) 
Fluoroquinolone antibiotics 12,842 (1.2%) 205,056 (0.6%) 
Benzodiazepines 71,542 (6.9%) 1,113,104 (3.4%) 
COPD drugsⱵ 15,201 (1.5%) 142,232 (0.4%) 
Coronary vasodilators 90,411 (8.7%) 238,074 (0.7%) 
Histamin-2 antagonists 31,925 (3.1%) 430,164 (1.3%) 
SSRIs 62,338 (6.0%) 1,336,583 (4.0%) 
Other lipid-lowering agents 19,369 (1.9%) 65,683 (0.2%) 
Number of CV drugs†: 0 386,471 (37.0%) 29,299,671 (88.2%) 
Number of CV drugs†: 1-3 500,555 (47.9%) 3,372,725 (10.2%) 
Number of CV drugs†: 4-12 157,547 (15.1%) 547,009 (1.7%) 
Supplementary Tab1. Characteristics of statin initiators and non-initiators before the application of exclusion criteria  
*SD: standard deviation 
**defined as an osteoporosis diagnose or intake of drugs affecting bone metabolism 
‡only records on separate days 
ⱡdefined as either an hyperlipidaemia Read code, a laboratory value of low density lipoprotein ˃3 mmol/l, of high density lipoprotein 
˂1 mmol/l, or of triglycerides ˃1.7 mmol/l 
Ⱡas a proxy for psychiatric disease 
Ⱶdefined as xanthines, long-acting inhaled anticholinergics including combinations, indacaterol, or aclidinium including combinations 
†defined as ACE-inhibitors, ATII-inhibitors, beta-blockers, calcium-channel-blockers, diuretics, thrombocyte-aggregation-inhibitors, vitamin 
K antagonists, acetylsalicylic acid, other lipid-lowering agents, insulin, oral antidiabetics, or antiarrhythmics 
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Supp7. Characteristics of statin initiators before application of exclusion criteria and after 
exclusion criteria were applied (both before PS-matching) 
 
Statin init after exclusion 
criteria (N=237,864) 
Statin init before exclusion 
criteria (N=1,044,573) 
Mean age in years (SD*) 62.7 (9.4%) 63.6 (12.7) 
Mean no. of GP contacts ≤1 yr 
before cohort entry‡ (SD*) 
18.6 (11.9%) 18.7 (14.5) 
Female 116,938 (49.2%) 482,687 (46.2%) 
Current smoker 47,940 (20.2%) 224,329 (21.5%) 
Average alcohol intake (>14 
units/week) 
24,347 (10.2%) 118,087 (11.3%) 
Comorbidities before cohort entry:  
Obesity (BMI>30kg/m2) 69,683 (29.3%) 307,828 (29.5%) 
Osteoporosis** 7567 (3.2%) 47,117 (4.5%) 
Dyslipidaemiaⱡ 173,648 (73.0%) 654,631 (62.7%) 
Angina pectoris 20,416 (8.6%) 124,133 (11.9%) 
Type2 diabetes 42,980 (18.1%) 180,060 (17.2%) 
Hypertension 119,142 (50.1%) 495,921 (47.5%) 
Chronic ischaemic heart dis. 17,219 (7.2%) 136,485 (13.1%) 
Congestive heart failure 3981 (1.7%) 35,565 (3.4%) 
Hypothyroidism 16,480 (6.9%) 73,316 (7.0%) 
Vascular disease 9139 (3.8%) 51,412 (4.9%) 
Chronic kidney disease (stage≥3) 11,696 (4.9%) 73,417 (7.0%) 
Hip fracture 1629 (0.7%) 13,683 (1.3%) 
Liver disease 1218 (0.5%) 9209 (0.9%) 
Macular degeneration 1870 (0.8%) 14,478 (1.4%) 
COPD 7900 (3.3%) 45,325 (4.3%) 
Anaemia 12,614 (5.3%) 68,910 (6.6%) 
Pressure ulcer/decubitus 1902 (0.8%) 11,523 (1.1%) 
Deep vein thrombosis 3680 (1.6%) 23,267 (2.2%) 
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Dysphagia 3607 (1.5%) 19,109 (1.8%) 
≥1 hospitalization ≤1 year before the 
cohort entry 
37,127 (15.6%) 205,741 (19.7%) 
Incontinence 4934 (2.1%) 28,337 (2.7%) 
Pneumonia 5930 (2.5%) 33,144 (3.2%) 
PsychotherapyⱠ 10,288 (4.3%) 51,093 (4.9%) 
Delusional disorders 2069 (0.9%) 9659 (0.9%) 
Co-medication ≤180 days before cohort entry:  
Hormone replacement therapy 14,660 (6.2%) 45,027 (4.3%) 
Oral corticosteroids 8695 (3.7%) 46,501 (4.5%) 
Opioids 12,756 (5.4%) 77,210 (7.4%) 
Fluoroquinolone antibiotics 2648 (1.1%) 12,842 (1.2%) 
Benzodiazepines 13,676 (5.8%) 71,542 (6.9%) 
COPD drugsⱵ 3156 (1.3%) 15,201 (1.5%) 
Coronary vasodilators 17,928 (7.5%) 90,411 (8.7%) 
Histamin-2 antagonists 6527 (2.7%) 31,925 (3.1%) 
SSRIs 13,751 (5.8%) 62,338 (6.0%) 
Other lipid-lowering agents 4408 (1.9%) 19,369 (1.9%) 
Number of CV drugs†: 0 76,455 (32.1%) 386,471 (37.0%) 
Number of CV drugs†: 1-3 127,690 (53.7%) 500,555 (47.9%) 
Number of CV drugs†: 4-12 33,719 (14.2%) 157,547 (15.1%) 
Supplementary Tab2. Characteristics of statin initiators before application of exclusion criteria and after exclusion criteria 
were applied (both before PS-matching) 
*SD: standard deviation 
**defined as an osteoporosis diagnose or intake of drugs affecting bone metabolism 
‡only records on separate days 
ⱡdefined as either an hyperlipidaemia Read code, a laboratory value of low density lipoprotein ˃3 mmol/l, of high density 
lipoprotein ˂1 mmol/l, or of triglycerides ˃1.7 mmol/l 
Ⱡas a proxy for psychiatric disease 
Ⱶdefined as xanthines, long-acting inhaled anticholinergics including combinations, indacaterol, or aclidinium including 
combinations 
†defined as ACE-inhibitors, ATII-inhibitors, beta-blockers, calcium-channel-blockers, diuretics, thrombocyte-aggregation-
inhibitors, vitamin K antagonists, acetylsalicylic acid, other lipid-lowering agen 
 
 
Supp8. Censoring reasons before and after PS-matching 
 Before PS-matching PS-matched 
Statin init. Non-init. Statin init. Non-init. 
Osteoarthritis 14,285 (6.0%) 286,867 (4.8%) 13,924 (6.0%) 13,216 (5.7%) 
Rheumatoid arthritis,  
other arthropathies/arthritis 
2825 (1.2%) 70,962 (1.2%) 2761 (1.2%) 2754 (1.2%) 
Crystal arthropathies 72 (0.0%) 1245 (0.0%) 71 (0.0%) 67 (0.0%) 
Disorders of iron metabolism 67 (0.0%) 1715 (0.0%) 66 (0.0%) 90 (0.0%) 
Gout 4076 (1.7%) 53,946 (0.9%) 3973 (1.7%) 3648 (1.6%) 
Haem – or hydrarthoris 36 (0.0%) 727 (0.0%) 35 (0.0%) 34 (0.0%) 
Hyperparathyroidism 267 (0.1%) 3720 (0.1%) 262 (0.1%) 221 (0.1%) 
Wilson disease, acromegaly 
or hypermobility syndrome 
17 (0.0%) 520 (0.0%) 17 (0.0%) 13 (0.0%) 
Previous finger injury 663 (0.3%) 20,629 (0.3%) 651 (0.3%) 623 (0.3%) 
Finger malformation/misalignment 1768 (0.7%) 31,869 (0.5%) 1711 (0.7%) 1401 (0.6%) 
Amputation of at least wrist level 34 (0.0%) 610 (0.0%) 34 (0.0%) 18 (0.0%) 
Cancer except non-melanoma skin 
cancer 
10,436 (4.4%) 220,305 (3.7%) 10,182 (4.4%) 10,613 (4.5%) 
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HIV/AIDS 8 (0.0%) 393 (0.0%) 8 (0.0%) 7 (0.0%) 
Alcoholism / substance abuse 4764 (2.0%) 89,733 (1.5%) 4671 (2.0%) 3738 (1.6%) 
Prescription for cerivastatin 341 (0.1%) 5370 (0.1%) 339 (0.2%) 312 (0.1%) 
Change of exposure status 53,887 (22.7%) 608,577 (10.1%) 53,032 (22.7%) 57,035 (24.4%) 
Loss to follow-up 63,984 (26.9%) 2,192,617 (36.4%) 63,455 (27.2%) 75,098 (32.2%) 
Completed follow-up, 
end of the study period 
77,190 (32.5%) 2,352,102 (39.1%) 75,371 (32.3%) 59,758 (25.6%) 
Death 2412 (1.0%) 60,056 (1.0%) 2324 (1.0%) 4251 (1.8%) 
Supplementary Tab3. Censoring criteria frequencies before and after PS-matching 
 
Supp9. Results of the association of dose-dependent statin initiation (>20mg simvastatin 
equivalent initiation [medium or high-dose] versus ≤20 mg simvastatin equivalent initiation 
[low-dose]) and incident HOA overall and in subgroups 
 Before PS-matching PS-matched 
 Obs.-time* in 
medium/high-dose 
init. + low-dose init. 
HOA 
Events  
HR  
crude  
(95% CI) 
HR  
adjusted† 
(95% CI) 
Obs.-time* in 
medium/high-dose 
init. + low-dose init. 
HOA 
Events  
HR 
matched† 
(95% CI) 
Overall 301.3+ 
467.1 
734 1.17 
(1.01-1.35) 
1.16 
(1.00-1.35) 
240.1+ 
236.9 
498 1.02 
(0.85-1.21) 
Sex 
Men 163.9+ 
228.1 
225 1.03 
(0.79-1.35) 
1.01 
(0.77-1.32) 
121.6+ 
120.4 
145 0.95 
(0.69-1.32) 
Women 137.4+ 
239.1 
509 1.32 
(1.11-1.57) 
1.24 
(1.04-1.48) 
117.4+ 
115.8 
343 1.06 
(0.86-1.31) 
Age in years 
45-64 190.1+ 
256.7 
452 1.17 
(0.97-1.41) 
1.20 
(0.99-1.45) 
143.7+ 
140.1 
320 1.09 
(0.88-1.36) 
65-84 111.3+ 
210.4 
282 1.13 
(0.88-1.43) 
1.09 
(0.85-1.39) 
95.8+ 
95.5 
180 1.02 
(0.76-1.36) 
Agent        
Atorvastatin 60.1+ 
116.2 
150 1.26 
(0.91-1.75) 
1.25 
(0.89-1.74) 
53.5+ 
52.3 
89 1.05 
(0.69-1.59) 
Simvastatin 228.2+ 
303.0 
533 1.12 
(0.94-1.33) 
1.13 
(0.95-1.34) 
167.4+ 
167.5 
361 1.05 
(0.86-1.29) 
other 13.0+ 
47.9 
51 1.13 
(0.59-2.16) 
1.10 
(0.57-2.14) 
10.4+ 
9.7 
14 1.24 
(0.43-3.57) 
Indication for statin initiation     
Present dyslip.     555.5+ 
    3638.3 
4328 1.02 
(0.93-1.11) 
1.10 
(1.00-1.20) 
536.9+ 
513.5 
1106 1.01 
(0.89-1.13) 
Absent dyslip.      69.0+ 
     144.1 
150 1.16 
(0.83-1.62) 
1.14 
(0.81-1.61) 
54.4+ 
53.9 
78 1.16 
(0.74-1.80) 
Duration of follow-up      
0–1 year 87.0+ 
122.4 
178 1.07 
(0.80-1.44) 
1.04 
(0.77-1.40) 
66.7+ 
66.2 
117 0.79 
(0.55-1.14) 
2–3 years 123.0+ 
184.8 
288 1.27 
(1.01-1.60) 
1.29 
(1.02-1.63) 
97.0+ 
94.8 
207 1.13 
(0.86-1.49) 
4–5.5 years 91.3+ 
160.0 
268 1.21 
(0.88-1.43) 
1.12 
(0.87-1.43) 
76.4+ 
75.9 
174 1.06 
(0.79-1.43) 
Supplementary Tab4. Results of the association of dose-dependent statin initiation and incident HOA overall and in 
subgroups 
*Observation-time in 1000 person-years 
†Adjusted for / PS-matched with all covariates (table1), except for hip fracture and fluoroquinolone antibiotics. Additionally 
adjusted for non-steroidal anti-inflammatory drugs, non-melanoma skin cancer, and family history of cataract 
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Supp10. Results of the association of statin initiation and incident GOA overall and in 
subgroups 
 Before PS-matching PS-matched 
 Obs.-time* in 
statin init. +   
non-init. 
GOA 
events  
HR  
crude  
(95% CI) 
HR  
adjusted† 
(95% CI) 
Obs.-time* in 
statin init. +   
non-init. 
GOA 
events  
HR 
matched† 
(95% CI) 
Overall 807.7+ 
22,838.9 
15,377 1.56 
(1.46-1.68) 
1.15 
(1.07-1.25) 
791.2+ 
763.0 
1471 1.10 
(0.99-1.21) 
Sex 
Men 407.0+ 
9337.5 
3734 1.57 
(1.38-1.79) 
1.09 
(0.94-1.25) 
399.8+ 
376.6 
418 1.18 
(0.98-1.44) 
Women 400.7+ 
13,501.4 
11,643 1.72 
(1.58-1.88) 
1.18 
(1.08-1.29) 
388.5+ 
385.5 
1036 1.11 
(0.98-1.25) 
Age in years 
45-64 466.2+ 
17,340.2 
9189 1.61 
(1.45-1.78) 
1.14 
(1.02-1.28) 
452.3+ 
448.1 
698 1.08 
(0.93-1.26) 
65-84 341.5+ 
5498.7 
6188 1.19 
(1.08-1.31) 
1.18 
(1.06-1.31) 
333.7+ 
312.0 
790 1.02 
(0.88-1.17) 
Daily dose in simvastatin equivalents 
≤20mg 492.1+ 
22,838.9 
15,075 1.59 
(1.46-1.74) 
1.14 
(1.04-1.26) 
489.9+ 
462.2 
941 1.06 
(0.94-1.21) 
>20mg 315.5+ 
22,838.9 
14,876 1.52 
(1.35-1.70) 
1.16 
(1.03-1.30) 
315.3+ 
310.9 
569 1.11 
(0.94-1.31) 
Agent        
Atorvastatin 186.2+ 
22,838.9 
14,792 1.84 
(1.61-2.10) 
1.34 
(1.17-1.54) 
186.0+ 
171.4 
393 1.14 
(0.94-1.40) 
Simvastatin 557.1+ 
22,838.9 
15,079 1.43 
(1.31-1.56) 
1.05 
(0.96-1.16) 
555.2+ 
540.3 
989 1.00 
(0.88-1.13) 
other 64.4+ 
22,838.9 
14,654 1.95 
(1.56-2.43) 
1.37 
(1.10-1.71) 
64.3+ 
61.5 
147 1.14 
(0.82-1.58) 
Indication for statin initiation 
Present dyslip.      584.3+ 
3780.6 
3157 1.39 
(1.26-1.52) 
1.15 
(1.05-1.27) 
564.9+ 
535.2 
1027 1.06 
(0.94-1.20) 
Absent dyslip. 223.4+ 
19,058.4 
12,220 1.73 
(1.53-1.97) 
1.17 
(1.03-1.34) 
223.1+ 
222.7 
468 1.06 
(0.88-1.27) 
Duration of follow-up   
0–1 year 212.9+ 
5678.8 
3262 1.74 
(1.51-2.01) 
1.20 
(1.03-1.40) 
209.0+ 
216.1 
382 1.05 
(0.86-1.28) 
2–3 years 321.3+ 
9163.8 
5999 1.58 
(1.41-1.77) 
1.20 
(1.06-1.35) 
314.9+ 
315.4 
585 1.13 
(0.96-1.33) 
4–5.5 years 273.5+ 
7996.3 
6116 1.45 
(1.28-1.63) 
1.09 
(0.96-1.24) 
267.3+ 
231.5 
504 1.09 
(0.92-1.31) 
Supplementary Tab5. Results of the association of statin initiation and incident GOA overall and in subgroups 
*Observation-time in 1000 person-years 
†Adjusted for / PS-matched with all covariates (table1), except for hip fracture. 
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Supp11. Results of the association of statin initiation and incident negative control 
outcomes overall and in subgroups 
 Before PS-matching PS-matched 
 Obs.-time* in 
statin init. +   
non-init. 
Cataract 
events  
HR  
crude  
(95% CI) 
HR  
adjusted† 
(95% CI) 
Obs.-time* in 
statin init. +   
non-init. 
Cataract 
events  
HR 
matched† 
(95% CI) 
Overall 1104.7+ 
27,859.1 
75,129 2.30 
(2.24-2.36) 
1.17 
(1.14-1.20) 
1079.9+ 
1042.1 
11,590 1.02 
(0.98-1.06) 
Sex 
Men 551.0+ 
11,474.4 
25,563 2.30 
(2.21-2.39) 
1.22 
(1.17-1.28) 
541.1+ 
507.7 
4576 1.06 
(1.00-1.13) 
Women 553.6+ 
16,384.7 
49,566 2.41 
(2.33-2.49) 
1.14 
(1.10-1.18) 
536.7+ 
533.2 
6981 1.00 
(0.95-1.04) 
Age in years 
45-64 621.4+ 
20,579.3 
19,083 2.63 
(2.49-2.78) 
1.09 
(1.03-1.16) 
602.0+ 
593.8 
2469 1.11 
(1.02-1.20) 
65-84 483.2+ 
7279.8 
56,046 1.42 
(1.38-1.47) 
1.17 
(1.13-1.21) 
472.2+ 
446.3 
8790 1.06 
(1.02-1.11) 
Daily dose in simvastatin equivalents 
≤20mg 664.9+ 
27,859.1 
72,780 2.36 
(2.29-2.44) 
1.16 
(1.12-1.20) 
661.7+ 
623.1 
7266 1.04 
(1.00-1.09) 
>20mg 439.8+ 
27,859.1 
71,247 2.20 
(2.11-2.29) 
1.17 
(1.13-1.23) 
439.7+ 
433.4 
4740 0.96 
(0.91-1.02) 
Agent        
Atorvastatin 256.0+ 
27,859.1 
70,317 2.25 
(2.14-2.37) 
1.18 
(1.12-1.24) 
255.9+ 
234.7 
2593 1.08 
(1.00-1.16) 
Simvastatin 760.0+ 
27,859.1 
73,289 2.36 
(2.28-2.43) 
1.18 
(1.15-1.22) 
757.7+ 
737.3 
8479 1.02 
(0.98-1.07) 
Other statins 88.6+ 
27,859.1 
69,319 1.92 
(1.74-2.11) 
1.00 
(0.91-1.10) 
88.6+ 
84.5 
830 0.96 
(0.84-1.10) 
Indication for statin initiation 
Present dyslip. 809.0+ 
4942.8 
22,437 1.54 
(1.49-1.59) 
1.16 
(1.12-1.20) 
779.8+ 
738.1 
8098 1.07 
(1.02-1.12) 
Absent dyslip. 295.7+ 
22,916.4 
52,692 2.54 
(2.42-2.66) 
1.27 
(1.21-1.34) 
295.5+ 
295.2 
3402 0.94 
(0.88-1.00) 
Duration of follow-up   
0–1 years 292.0+ 
6943.6 
15,112 2.26 
(2.14-2.39) 
1.18 
(1.11-1.25) 
286.1+ 
295.8 
2640 0.98 
(0.90-1.05) 
2–3 years 440.2+ 
11,192.7 
28,659 2.23 
(2.14-2.33) 
1.14 
(1.09-1.19) 
430.4+ 
430.9 
4439 0.99 
(0.93-1.05) 
4–5.5 years 372.5+ 
9722.8 
31,358 2.37 
(2.28-2.47) 
1.21 
(1.15-1.26) 
363.3+ 
315.4 
4511 1.08 
(1.02-1.15) 
Supplementary Tab6. Results of the association of statin initiation and incident cataract overall and in subgroups 
*Obs.-time in 1000 person-years 
†Adjusted for / PS-matched with all covariates (table1), except for hip fracture and fluoroquinolone antibiotics. Additionally 
adjusted for non-steroidal anti-inflammatory drugs, non-melanoma skin cancer, and family history of cataract 
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 Before PS-matching PS-matched 
 Obs.-time* in 
statin init. +   
non-init. 
Peptic 
ulcer 
events  
HR  
crude  
(95% CI) 
HR  
adjusted† 
(95% CI) 
Obs.-time* in 
statin init. +   
non-init. 
Peptic 
ulcer 
events  
HR 
matched† 
(95% CI) 
Overall 1179.6+ 
28,871.6 
38,633 1.62 
(1.56-1.69) 
1.03 
(0.98-1.08) 
1154.8+ 
1111.6 
4562 1.00 
(0.94-1.06) 
Sex 
Men 570.9+ 
11,628.0 
17,485 1.46 
(1.38-1.55) 
0.99 
(0.93-1.05) 
561.0+ 
526.5 
2271 0.95 
(0.88-1.03) 
Women 608.8+ 
17,243.6 
21,148 1.75 
(1.65-1.85) 
1.07 
(1.01-1.14) 
591.4+ 
583.1 
2220 1.10 
(1.01-1.19) 
Age in years 
45-64 632.8+ 
20,800.9 
17,812 1.72 
(1.61-1.84) 
1.02 
(0.94-1.10) 
613.2+ 
604.3 
1649 1.04 
(0.95-1.15) 
65-84 546.8+ 
8070.7 
20,821 1.16 
(1.10-1.22) 
1.02 
(0.97-1.08) 
535.2+ 
503.5 
2853 0.98 
(0.91-1.06) 
Daily dose in simvastatin equivalents 
≤20mg 714.4+ 
28,871.6 
37,782 1.73 
(1.64-1.82) 
1.05 
(1.00-1.11) 
711.7+ 
667.7 
3037 0.96 
(0.90-1.04) 
>20mg 465.2+ 
28,871.6 
37,085 1.46 
(1.36-1.56) 
0.98 
(0.92-1.05) 
465.1+ 
457.7 
1665 1.03 
(0.93-1.13) 
Agent        
Atorvastatin 273.0+ 
28,871.6 
36,846 1.79 
(1.65-1.93) 
1.11 
(1.02-1.20) 
272.9+ 
249.2 
1164 1.00 
(0.89-1.13) 
Simvastatin 812.6+ 
28,871.6 
37,816 1.55 
(1.48-1.63) 
1.00 
(0.95-1.05) 
810.9+ 
788.2 
3128 0.99 
(0.92-1.06) 
Other statins 94.0+ 
28,871.6 
36,439 1.74 
(1.51-1.99) 
1.01 
(0.88-1.17) 
94.0+ 
89.4 
450 0.80 
(0.66-0.96) 
Indication for statin initiation 
Present dyslip. 863.4+ 
5196.0 
7814 1.52 
(1.44-1.60) 
1.02 
(0.96-1.08) 
834.0+ 
788.7 
2949 0.96 
(0.90-1.04) 
Absent dyslip. 316.2+ 
23,675.6 
30,819 2.05 
(1.91-2.19) 
1.03 
(0.96-1.11) 
316.0+ 
315.5 
1599 1.04 
(0.95-1.15) 
Duration of follow-up   
0–1 years 305.9+ 
7134.8 
9448 1.73 
(1.60-1.88) 
1.17 
(1.08-1.28) 
300.1+ 
310.4 
1271 1.03 
(0.92-1.15) 
2–3 years 467.8+ 
11,575.2 
15,288 1.53 
(1.43-1.63) 
0.98 
(0.91-1.05) 
458.1+ 
458.1 
1798 0.93 
(0.85-1.02) 
4–5.5 years 405.9+ 
10,161.6 
13,897 1.65 
(1.54-1.77) 
0.98 
(0.91-1.06) 
396.5+ 
343.1 
1493 1.07 
(0.96-1.18) 
Supplementary Tab7. Results of the association of statin initiation and incident peptic ulcer overall and in subgroups 
*Obs.-time in 1000 person-years 
†Adjusted for / PS-matched with all covariates (table1), except for hip fracture and fluoroquinolone antibiotics. Additionally 
adjusted for non-steroidal anti-inflammatory drugs, and proton pump inhibitor initiation 
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 Before PS-matching PS-matched 
 Obs.-time* in 
statin init. +   
non-init. 
Psor. 
events  
HR  
crude  
(95% CI) 
HR  
adjusted† 
(95% CI) 
Obs.-time* in 
statin init. +   
non-init. 
Psor. 
events  
HR 
matched† 
(95% CI) 
Overall 1186.2+ 
28,856.4 
51,722 1.18 
(1.13-1.23) 
1.00 
(0.96-1.05) 
1113.4+ 
1076.5 
4450 0.96 
(0.90-1.02) 
Sex 
Men 580.0+ 
11,755.6 
21,402 1.15 
(1.09-1.22) 
1.02 
(0.95-1.09) 
570.7+ 
534.3 
2101 1.10 
(1.01-1.20) 
Women 606.2+ 
17,100.9 
30,320 1.20 
(1.14-1.27) 
0.99 
(0.93-1.06) 
588.6+ 
582.1 
2375 1.00 
(0.93-1.09) 
Age in years 
45-64 629.7+ 
20,626.3 
37,901 1.25 
(1.19-1.32) 
1.00 
(0.95-1.06) 
610.4+ 
601.2 
2598 1.06 
(0.98-1.15) 
65-84 556.5+ 
8230.1 
13,821 1.15 
(1.08-1.23) 
1.01 
(0.94-1.08) 
545.1+ 
511.2 
1866 1.04 
(0.95-1.13) 
Daily dose in simvastatin equivalents 
≤20mg 719.1+ 
28,856.4 
50,827 1.22 
(1.16-1.28) 
1.06 
(1.00-1.12) 
716.6+ 
671.7 
2863 1.03 
(0.96-1.11) 
>20mg 467.1+ 
28,856.4 
50,226 1.12 
(1.05-1.20) 
0.92 
(0.86-0.99) 
466.9+ 
458.6 
1802 0.97 
(0.89-1.07) 
Agent        
Atorvastatin 274.9+ 
28,856.4 
49,930 1.28 
(1.18-1.38) 
1.08 
(0.99-1.17) 
274.8+ 
250.2 
1110 1.08 
(0.96-1.21) 
Simvastatin 816.2+ 
28,856.4 
50,906 1.13 
(1.07-1.19) 
0.96 
(0.91-1.01) 
814.4+ 
789.7 
3153 0.97 
(0.91-1.04) 
other 95.1+ 
28,856.4 
49,548 1.34 
(1.17-1.53) 
1.14 
(1.00-1.31) 
95.0+ 
90.2 
410 1.07 
(0.88-1.30) 
Indication for statin initiation 
Present dyslip. 863.7+ 
5153.1 
11,672 1.09 
(1.04-1.14) 
1.03 
(0.98-1.09) 
834.2+ 
787.7 
3281 1.04 
(0.97-1.12) 
Absent dyslip. 322.4+ 
23,703.3 
40,050 1.12 
(1.03-1.21) 
0.99 
(0.91-1.07) 
322.3+ 
320.6 
1230 0.94 
(0.84-1.05) 
Duration of follow-up   
0–1 years 307.5+ 
7132.6 
12,877 1.25 
(1.15-1.35) 
1.01 
(0.93-1.10) 
290.6+ 
301.0 
1289 0.95 
(0.85-1.06) 
2–3 years 470.4+ 
11,569.1 
20,654 1.19 
(1.11-1.27) 
1.00 
(0.93-1.07) 
442.0+ 
444.4 
1796 0.94 
(0.86-1.03) 
4–5.5 years 408.3+ 
10,154.7 
18,191 1.12 
(1.04-1.21) 
1.02 
(0.94-1.11) 
380.9+ 
331.1 
1365 0.99 
(0.89-1.10) 
Supplementary Tab8. Results of the association of statin initiation and incident psoriasis overall and in subgroups 
*Obs.-time in 1000 person-years 
† Adjusted for / PS-matched with all covariates (table1), except for hip fracture and fluoroquinolone antibiotics. Additionally 
adjusted for non-steroidal anti-inflammatory drugs, family history of psoriasis and history of organ transplantation  
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 Before PS-matching PS-matched 
 Obs.-time* in 
statin init. +   
non-init. 
Tinnitus 
events  
HR  
crude  
(95% CI) 
HR  
adjusted† 
(95% CI) 
Obs.-time* in 
statin init. +   
non-init. 
Tinnitus 
events  
HR 
matched† 
(95% CI) 
Overall 1172.5+ 
28,608.2 
107,367 1.16 
(1.13-1.19) 
1.01 
(0.98-1.05) 
1147.8+ 
1102.6 
9361 1.00 
(0.96-1.04) 
Sex 
Men 572.3+ 
11,649.9 
47,132 1.14 
(1.10-1.19) 
1.04 
(1.00-1.08) 
562.7+ 
526.2 
4750 1.01 
(0.95-1.07) 
Women 600.2+ 
16,958.4 
60,235 1.16 
(1.11-1.21) 
0.99 
(0.95-1.03) 
582.6+ 
573.9 
4682 0.95 
(0.90-1.00) 
Age in years 
45-64 626.7+ 
20,542.8 
78,485 1.20 
(1.16-1.25) 
1.00 
(0.96-1.05) 
606.4+ 
596.7 
5361 0.99 
(0.94-1.04) 
65-84 545,8+ 
8065.4 
28,882 1.16 
(1.11-1.21) 
1.05 
(1.00-1.11) 
535.0+ 
502.2 
3953 1.02 
(0.96-1.08) 
Daily dose in simvastatin equivalents 
≤20mg 711.1+ 
28,608.2 
105,396 1.14 
(1.10-1.18) 
1.01 
(0.98-1.06) 
708.3+ 
662.5 
5575 1.01 
(0.96-1.06) 
>20mg 461.4+ 
28,608.2 
104,471 1.20 
(1.14-1.25) 
1.10 
(1.05-1.15) 
461.3+ 
461.2 
3839 1.06 
(0.99-1.13) 
Agent        
Atorvastatin 272.7+ 
28,608.2 
103,605 1.13 
(1.07-1.20) 
1.00 
(0.95-1.07) 
272.6+ 
249.0 
2040 1.08 
(0.99-1.18) 
Simvastatin 805.3+ 
28,608.2 
105,872 1.17 
(1.13-1.21) 
1.02 
(0.98-1.05) 
803.5+ 
778.5 
6607 1.01 
(0.96-1.06) 
other 94.5+ 
28,608.2 
102,890 1.15 
(1.04-1.27) 
1.01 
(0.92-1.12) 
94.5+ 
89.8 
770 0.97 
(0.85-1.12) 
Indication for statin initiation 
Present dyslip. 853.2+ 
5067.7 
25,630 1.00 
(0.97-1.04) 
1.04 
(1.00-1.07) 
823.3+ 
777.2 
6928 1.02 
(0.97-1.07) 
Absent dyslip. 319.3+ 
23,540.5 
81,737 1.07 
(1.01-1.13) 
1.01 
(0.95-1.07) 
319.1+ 
318.8 
2364 0.96 
(0.89-1.04) 
Duration of follow-up   
0–1 years 304.9+ 
7091.9 
25,781 1.22 
(1.16-1.29) 
1.01 
(0.96-1.08) 
299.2+ 
309.2 
2570 1.00 
(0.92-1.08) 
2–3 years 465.4+ 
11,478.6 
42,588 1.17 
(1.12-1.23) 
1.03 
(0.98-1.08) 
455.7+ 
455.2 
3809 0.99 
(0.93-1.05) 
4–5.5 years 402.2+ 
10,037.7 
38,998 1.10 
(1.05-1.16) 
1.01 
(0.96-1.07) 
392.9+ 
338.1 
2982 1.02 
(0.95-1.09) 
Supplementary Tab9. Results of the association of statin initiation and incident tinnitus overall and in subgroups 
*Obs.-time in 1000 person-years 
† Adjusted for / PS-matched with all covariates (table1), except for hip fracture, fluoroquinolone antibiotics, and selective 
serotonin re-uptake inhibitors. Additionally adjusted for non-steroidal anti-inflammatory drugs, and initiation anti-
depressant drugs 
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8.9 Appendix 9 
Supplementary Table6. Baseline characteristics of statin initiators and non-initiators (follow-up 
>180 days) with information on index of multiple deprivation only before and after propensity 
score-matching  
 Before PS-matching PS-matched 
 
Statin initiators 
(N=39,572) 
Non-initiators 
(N=1,707,695) 
Statin initiators 
(N=37,881) 
Non-initiators 
(N=37,881) 
Mean age in years (SD) 56.4 (5.3) 53.1 (5.6) 56.3 (5.4) 56.5 (5.3) 
Mean follow-up in years (SD) 3.2 (2.1) 3.8 (1.9) 3.2 (2.1) 3.3 (1.9) 
Mean number of GP contacts 
≤1 year before cohort entry* 
(SD) 
18.9 (11.8) 9.6 (9.4) 18.5 (11.5) 18.8 (13.3) 
Current smokers 9053 (22.9%) 330,572 (19.4%) 8648 (22.8%) 8548 (22.6%) 
Average alcohol intake       
(>14 units/week) 
1364 (3.5%) 55,369 (3.2%) 1332 (3.5%) 1357 (3.6%) 
IMD quintile 1 (least deprived) 8605 (21.8%) 469,821 (27.5%) 8353 (22.1%) 8202 (21.7%) 
IMD quintile 2 9184 (23.2%) 432,993 (25.4%) 8837 (23.3%) 8832 (23.3%) 
IMD quintile 3 7962 (20.1%) 355,278 (20.8%) 7593 (20.0%) 7969 (21.0%) 
IMD quintile 4 7799 (19.7%) 274,582 (16.1%) 7411 (19.6%) 7457 (19.7%) 
IMD quintile 5 6022 (15.2%) 175,021 (10.3%) 5687 (15.0%) 5421 (14.3%) 
Comorbidities before cohort entry:    
Obesity (BMI>30kg/m2) 14,992 (37.9%) 325,260 (19.1%) 13,964 (36.9%) 13,944 (36.8%) 
Osteoporosis† 994 (2.5%) 29,947 (1.8%) 963 (2.5%) 1032 (2.7%) 
Dyslipidemia‡ 30,640 (77.4%) 307,155 (18.0%) 28,981 (76.5%) 30,183 (79.7%) 
Angina pectoris 2006 (5.1%) 11,954 (0.7%) 1761 (4.7%) 1479 (3.9%) 
Type2 diabetes 7557 (19.1%) 15,916 (0.9%) 6194 (16.4%) 5273 (13.9%) 
Hypertension 18,617 (47.1%) 229,735 (13.5%) 17,556 (46.4%) 18,189 (48.0%) 
Ischemic heart disease 1427 (3.6%) 3976 (0.2%) 1215 (3.2%) 926 (2.4%) 
Congestive heart failure 233 (0.6%) 1532 (0.1%) 206 (0.5%) 169 (0.5%) 
Hypothyroidism 4298 (10.9%) 97,908 (5.7%) 4060 (10.7%) 4321 (11.4%) 
Vascular disease 969 (2.5%) 21,045 (1.2%) 910 (2.4%) 875 (2.3%) 
Chronic kidney disease 1044 (2.6%) 9247 (0.5%) 1009 (2.7%) 975 (2.6%) 
Hip fracture 107 (0.3%) 4493 (0.3%) 102 (0.3%) 107 (0.3%) 
Liver disease 275 (0.7%) 3973 (0.2%) 259 (0.7%) 249 (0.7%) 
COPD‡ 844 (2.1%) 15,488 (0.9%) 793 (2.1%) 796 (2.1%) 
Deep vein thrombosis 601 (1.5%) 16,456 (1.0%) 571 (1.5%) 592 (1.6%) 
Dysphagia 628 (1.6%) 17,779 (1.0%) 989 (1.7%) 1079 (1.8%) 
≥1 hospitalization ≤1 year 
before cohort entry (SD) 
6100 (15.4%) 150,766 (8.8%) 5797 (15.3%) 5955 (15.7%) 
Incontinence 1291 (3.3%) 34,656 (2.0%) 1214 (3.2%) 1284 (3.4%) 
Pneumonia 838 (2.1%) 33,597 (2.0%) 803 (2.1%) 801 (2.1%) 
Psychotherapy§ 2442 (6.2%) 79,361 (4.7%) 2335 (6.2%) 2442 (6.5%) 
Co-medication ≤180 days before cohort entry:    
Hormone replacement 
therapy 
7016 (17.7%) 300,738 (17.6%) 6766 (17.9%) 7069 (18.7%) 
Oral corticosteroids 1619 (4.1%) 41,219 (2.4%) 1538 (4.1%) 1579 (4.2%) 
Opioids 2472 (6.3%) 51,189 (3.0%) 2328 (6.2%) 2260 (6.0%) 
Benzodiazepines 2482 (6.3%) 70,956 (4.2%) 2368 (6.3%) 2456 (6.5%) 
COPD|| drugs 405 (1.0%) 7313 (0.4%) 380 (1.0%) 346 (0.9%) 
Coronary vasodilators 1846 (4.7%) 4360 (0.3%) 1550 (4.1%) 1176 (3.1%) 
Histamin-2 antagonists 960 (2.4%) 21,715 (1.3%) 898 (2.4%) 904 (2.4%) 
SSRIs 3701 (9.4%) 103,470 (6.1%) 3522 (9.3%) 3578 (9.5%) 
Other lipid lowering agents 658 (1.7%) 2946 (0.2%) 607 (1.6%) 546 (1.4%) 
Number of CV drugs¶: 0 14,399 (36.4%) 1,453,157 (85.1%) 14,392 (38.0%) 14,812 (39.1%) 
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Number of CV drugs¶: 1-3 21,448 (54.2%) 242,661 (14.2%) 20,430 (53.9%) 19,848 (52.4%) 
Number of CV drugs¶: 4-12 3725 (9.4%) 11,877 (0.7%) 3059 (8.1%) 3221 (8.5%) 
SD: standard deviation, GP: general practitioner, IMD: index of multiple deprivation, COPD: chronic obstructive pulmonary 
disease, SSRI: serotonin reuptake inhibitor, CV: cardiovascular PS: propensity score 
* only records on separate days  
† defined as an osteoporosis diagnose or intake of drugs affecting bone metabolism 
‡ defined as either an hyperlipidemia Read code, a laboratory value of low density lipoprotein ˃3 mmol/l, of high density 
lipoprotein ˂1 mmol/l, or of triglycerides ˃1.7 mmol/l 
§ as a proxy for psychiatric disease 
|| defined as xanthines, long-acting inhaled anticholinergics including combinations, indacaterol, or aclidinium including 
combinations 
¶ defined as ACE-inhibitors, ATII-inhibitors, beta-blockers, calcium-channel-blockers, diuretics, thrombocyte-aggregation-
inhibitors, vitamin K antagonists, acetylsalicylic acid, other lipid lowering agents, insulin, oral antidiabetics, or 
antiarrhythmics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
